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Abstract 
From February 2013 to November 2014 I undertook a field placement at the Kirby Institute for 
Infection and Immunity in Society (the Kirby Institute), as a part of a Master of Philosophy in 
Applied Epidemiology (MAE).  This bound volume is the product of projects undertaken while 
at the Kirby Institute in the Justice Health Research Program and the Public Health 
Interventions Research Group. Within are six chapters which demonstrate work undertaken, 
lessons learnt, knowledge gained and MAE requirements met.   
Due to my placement predominantly in the justice health research program, three out of four 
major projects have a focus on blood borne viruses and associated risk factors among offender 
populations. I evaluated the national prison entrant’s blood borne virus and risk behaviour 
survey (NPEBBVS), the only multi-jurisdictional prison BBV monitoring mechanism nationally. 
As a data analysis project I explored hepatitis B core antibody and hepatitis C antibody 
prevalence and associated risk factors among Indigenous and non-Indigenous prison entrants 
from the NPEBBVS. Findings from this chapter were presented at a number of conferences and 
events. As an acute public health problem, I had the opportunity to investigate hepatitis C 
(HCV) incidence cases in a prison facility. We developed a case series study using mixed 
methods to collect data on the unusual cluster of HCV cases. I conducted both quantitative and 
qualitative interviews with participating inmates to gather prisoner’s perspective of HCV 
incidence, understanding routes of transmission in the prison setting and possible strategies in 
decreasing exposure and risk. 
From the start of 2013 I was involved in the ‘vaccine impact in the Indigenous population’ (VIP-
I) study with a large group of investigators. The aim of VIP-I was to evaluate the effectiveness 
of the HPV vaccine among Indigenous women in Australia. My role in the study was as a field 
coordinator, chapter 5 demonstrates my involvement from the development stage onwards. 
This chapter is largely methodological, only preliminary results are presented as recruitment is 
still ongoing. 
Teaching experience during the MAE included; lessons from the field and a group teaching 
session with MAE peers. I worked individually on a project management module for the lesson 
from the field exercise, my fellow MAE cohort completed this module which touched on 
interdisciplinary collaboration in research. The group teaching experience was created and 
conducted with two fellow MAE scholars, we built a framework to distinguish real or artificial 
rate change when interpreting time series data. 
The projects within this thesis contribute to the Kirby Institutes area of work with marginalised 
at risk populations. I have been fortunate to be a part of a number of projects that have 
v 
potential to impact public health policy and programs for both Indigenous and offender 
populations. 
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1.1 Abbreviations list  
ANU  Australian National University  
BBV  Blood Borne Viruses  
HBV  Hepatitis B 
HCV  Hepatitis C 
HIV  Human Immunodeficiency Virus 
HPV  Human papillomavirus  
IOH-CBG Indigenous Offender Health - Capacity Building Group  
JHRP  Justice Health Research Program  
MAE  Masters in Applied Epidemiology 
NCEPH  National Centre for Epidemiology and Public Health  
NCHECR National Centre for HIV Epidemiology and Clinical Research  
NPEBBVS The national prison entrants blood borne virus survey  
PHIRG  Public Health Interventions Research Group 
STI  Sexually Transmissible Infections  
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1.2 Introduction  
Over the past 21 months at the Kirby Institute I have been based in the Justice Health Research 
Program (JHRP) in the Indigenous Offender Health Capacity Building Group (IOH-CBG) and the 
Public Health Interventions Research Group (PHIRG) with some overlap into the Aboriginal & 
Torres Strait Islander Health Program.   
During this time I have had the opportunity to undertake a variety of projects including; 
evaluating the national prison entrants blood borne virus survey (NPEBBVS); analysing 
Indigenous specific hepatitis C and B data from the NPEBBVS; participate in a prison outbreak 
investigation; and work with a group of experienced investigators on a larger epidemiological 
study to evaluate the impact of the human papillomavirus (HPV) vaccine on HPV genotypes 
among Indigenous women. 
1.3 Overview of field placement  
1.3.1 The Kirby Institute 
The Kirby Institute, formerly known as the National Centre for HIV Epidemiology and Clinical 
Research (NCHECR), was formed in response to the Human Immunodeficiency Virus (HIV) 
pandemic in Australia during the mid 1980’s. NCHECR had the purpose of providing research to 
improve epidemiological evidence, knowledge, prevention and treatment of HIV. HIV was 
causing increasing panic and fear in the communities experiencing the full impact of a disease, 
particularly the gay community in Sydney. From its inception, NCHECR worked in partnership 
with community organisations and still to this day understands the important input 
communities can offer on issues affecting them. 
In 2011, NCHECR was renamed the Kirby Institute for infection and immunity in society. The 
Kirby Institute is a leader in HIV research and continues to have a large focus on clinical and 
behavioural research based in Australia and the Asia Pacific region. The change in name 
encompasses the broadening scope of research taken on over the past 27 years. The Kirby 
Institute has applied the same principles used during the HIV pandemic to produce 
comprehensive knowledge around other Blood Borne Viruses (BBV) and Sexually Transmissible 
Infections (STIs).  
The Kirby Institute consists of eleven research programs: 
 Aboriginal and Torres Strait Islander Health Program 
 Biostatistics and Databases Program 
 HIV Epidemiology and Prevention Program 
 Immunovirology and Pathogenesis Program 
CHAPTER 1 | INTRODUCTION 
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 Justice Health Research Program 
 Public Health Interventions Research Group 
 Sexual Health Program 
 Surveillance and Evaluation Program for Public Health 
 Therapeutic and Vaccine Research Program 
 Viral Hepatitis Clinical Research Program 
 Viral Hepatitis Epidemiology and Prevention Program 
1.3.2 Justice health research program 
The Justice Health Research Program (JHRP) is the newest program at the Kirby. Core work can 
be divided into three categories (Figure 1). Research projects involve adult and juvenile prison 
populations, as well as those serving community based sentences, ex-prisoners and 
community. 
JHRP researchers have published copious papers within the three categories both collaborating 
across Kirby Institute programs and with external organisations. The JHRP coordinates a 
triennial national prison entrants’ blood borne virus and risk behaviour survey. The data from 
this survey are used to assess prevalence of hepatitis C, B and HIV and risk behaviours among 
Australian prison entrants. The JHRP is also involved in evaluating and informing national 
prisoner health indicators. The Sexual Health Attitudes of Australian Prisoners (SHAAP) is 
another large study the JHRP has coordinated and is currently working towards adapting for 
the juvenile justice setting.  The wide scope of work undertaken within each of the three 
categories by the JHRP is a reflection of the health of Australian prisoners and the broad range 
of social, cultural and economic issues affecting them.   
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Figure 1. Justice Health Research Program: categories of work with examples 
 
 
 
 
 
  
 
 
 
 
 
 
 
1.3.3 Indigenous Offender Health Capacity Building Group  
Within the JHRP is the Indigenous Offender Health Capacity Building Group (IOH-CBG). 
Established in 2004, the IOH-CBG collaboration consists of Indigenous and non-Indigenous 
researchers, mentors and four collaborating centres from NSW, WA, ACT. Central coordination 
is conducted by the JHRP at the Kirby Institute.   
The aims of IOH-CBG are to foster knowledge and skills of Indigenous and non-Indigenous 
researchers in key areas affecting Indigenous offenders and to develop a national health and 
criminal justice network.   
The key areas affecting Indigenous offenders are: 
 Mental health 
 Substance use 
 Blood borne viruses 
 Impact of incarceration on  communities 
BEHAVIOURAL INDIGENOUS 
Triennial National 
Prison Entrant Blood 
Borne Virus and risk 
behaviour survey  
Impulsive violence 
COMMUNICABLE 
Indigenous Offender 
Health Research 
Capacity Building Group 
 
 
 
 
 
Sexual health & 
Attitudes of Australian 
Prisoners  
Traumatic Brain Injury 
 Justice 
Reinvestment 
 Alcohol 
 Juvenile Offender 
Pathways 
 Role of Elders in 
reintegration 
 
Tobacco Smoking 
Hepatitis C Prisons and 
Treatment 
Opportunities  
 
TB/HIV in Labour 
camps in China 
Prison and 
Transition Health 
Study 
Papua New Guinea 
Prison Health Study 
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 Models of care for offenders 
The majority of projects I have undertaken have an offender health focus reflecting my 
placement primarily with in the JHRP.  Chapter 2, 3 and 4 have an offender and blood borne 
virus focus. I have fulfilled core MAE requirement. Below is a list of MAE requirements met 
while placed at the Kirby Institute (Table 1, page 10).   
1.4 Summary of MAE requirements 
Field projects  
Chapter 2:    Analysis of a public health dataset: Blood borne virus prevalence and risk 
behaviours among Indigenous and non-Indigenous prison entrants in four 
Australian states  
 
Chapter 3:  Evaluate a surveillance system or other health information system: Evaluation 
of the National Prison Entrants Blood Borne Virus and Risk Behaviour Survey 
(NPEBBVS) 
 
Chapter 4:  Outbreak: Incident Hepatitis C cases detected through a custodial HCV 
treatment program  
 
Chapter 5:  Design and conduct an epidemiological study: Impact of Australia's HPV 
vaccination program on prevalence of HPV genotypes in Aboriginal and Torres 
Strait Islander women attending for Pap testing 
1.4.1 Teaching requirements 
Chapter 6: Lessons from the field - Project management  
  Interpretation of rate change in time series data 
1.4.2 Advanced draft peer review publication 
Chapter 2 Appendix 1: “Hepatitis C and hepatitis B prevalence and associated risk factors 
among Indigenous and non-Indigenous prison entrants in Australia” 
1.4.3 Communication for a non-scientific audience 
Chapter 1:  Appendix 1: Highlighting Aboriginal and Torres Strait Islander Research at the 
Kirby institute 2013 booklet 
Chapter 5 Appendix 2: Patient information sheet – VIP-I study 
Chapter 4  Appendix 5: Patient information sheet – Hep C incidence in prison study 
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1.5 Conference presentations 
1. UNSW fifth annual symposium 2013 – Dreaming up the future of Aboriginal 
and Torres Strait Islander Public Health, UNSW medical faculty, October 2013. 
Presentation Title: ‘Development and evaluation of a sexual and reproductive 
health program for young Aboriginal people in NSW’ 
 
2. The Australasian sexual health conference, Darwin Convention Centre, 
October 2013. Presentation title: ‘A funded Sexual and Reproductive Health 
Worker position at an Aboriginal Community Controlled Health Service 
improves health service access and sexually transmissible infection testing in 
Aboriginal youth’ Co-presented with Jackie Milsom from Bulgarr Ngaru Medical 
Aboriginal Corporation, Grafton 
 
3. Indigenous health conference, November Cairns, 2013  
Presentation title: ‘Blood Borne Virus prevalence among Aboriginal and 
Torres Strait Islander Prison Entrants in four Australian States’  
 
4. Royal Australian and New Zealand College of Obstetricians and 
Gynaecologists 2014 Indigenous Women’s Health Meeting Adelaide 
Convention Centre, South Australia, May 2014. Presentation title: ‘The VIP-I 
Project: HPV Vaccine Impact in the Australian Indigenous Population’ 
 
5. Kirby Institute NAIDOC seminar July 2014. Presentation title: ‘Blood borne 
viruses in the prison setting’ 
 
6. 2014 International Indigenous pre-conference on HIV & AIDS, Sydney, NSW, 
July 2014. Presentation title:  ‘Understanding “what’s going on with our mob” 
– knowledge, health service access and risk behaviour of young Aboriginal and 
Torres Strait Islander people in the Goanna survey’ 
 
7. 2014 International Indigenous pre-conference on HIV & AIDS, Sydney, NSW, 
July 2014. Presentation title: ‘Testing for blood borne viruses among 
Indigenous prison entrants’       
 
CHAPTER 1 | INTRODUCTION 
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8. 29th International HPV conference, Washington state convention centre, 
Seattle, August 2014. Satellite Symposium: Controversies-Barriers and 
facilitators for Indigenous people and HPV related diseases  
Presentation title:  ‘Evaluating the effectiveness of the HPV vaccine among 
Indigenous women in Australia’ (Appendix, chapter 5) 
 
9. UNSW sixth annual research symposium 2014, Public health aspects of 
infectious disease control, September 2014. Presentation title: ‘Blood borne 
viruses among Indigenous prison entrants in Australia’ 
1.6 Course Work  
I attended all three Course block sessions at ANU and attended online lectures. I presented 
field reports as required at course blocks, ran a problem solving session titled; ethical 
considerations when interviewing prisoners: confidentiality and incriminating evidence. As 
required, I obtained a distinction average across core subjects (first four course work subjects 
listed below). 
Course subjects: 
POPH8316  Outbreak Investigation – Semester 1 2013 
POPH8317  Public Health Surveillance – Semester 1 2013 
POPH8313  Analysis of Public Health Data – Semester 2 2013 
POPH8315  Methods in Applied Epidemiological Research – Semester 2 2013 
POPH8950F Issues in Applied Epidemiology – Semester 1 2014  
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2 Data analysis 
Bood borne virus prevalence and risk behaviours among Indigenous and Non-Indigenous 
Prison Entrants in four Australian States 
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2.1 Abbreviation list 
ACT   Australian Capital Territory 
Anti-HBc Anti-hepatitis B core antibody 
aOR  Adjusted odds ratio 
ARIA  Accessibility/remoteness index of Australia  
BBV  Blood borne virus 
CI  Confidence Interval  
HB  Hepatitis B virus 
HCV  Hepatitis C virus 
HCVAb   Anti-hepatitis C antibody 
HIV  Human Immunodeficiency Virus  
IDU  Injecting drug use 
IOH-CBG  Indigenous offender health capacity building group  
JHRP   Justice Health Research Program  
MAE  Masters of Applied Epidemiology  
NT   Northern Territory  
NPEBBVS National prison entrant blood borne virus and risk behaviour survey   
NSP  Needle and Syringe Programs 
NSW   New South Wales 
OR  Odds ratio 
QLD   Queensland  
SA   South Australia  
STI  Sexually transmissible infections  
TAS  Tasmania 
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WA   Western Australia  
2.2 Prologue 
2.2.1 My role  
The Justice Health Research Program (JHRP) at the Kirby Institute coordinates a number of 
large cross-sectional surveys in adult prisons. Data analysis of a public health data set is a core 
requirement the Masters of Applied Epidemiology (MAE). I undertook an analysis with the 
national prison entrant blood borne virus and risk behaviour survey (NPEBBVS) based on 
Indigenous status to understand the factors associated with blood borne viruses (BBVs) among 
Indigenous and non-Indigenous prison entrants. As my MAE has been partly funded by the 
Indigenous Offender Health Capacity Building Group (IOH-CBG) it is a priority of mine to add to 
Aboriginal and Torres Strait Islander offender health research. Originally, I set out to analyse an 
Indigenous only prison entrant sample. I developed a data analysis plan and completed 
analysis based on the original idea and later altered this to include an Indigenous/ non-
Indigenous comparison after meeting with supervisors to discuss the analysis and findings.  
On 4 October 2013, I attended the annual IOH-CBG meeting in Perth where I presented 
preliminary demographic and prevalence data to IOH-CBG investigators and field researchers. 
Attending this meeting gave me an opportunity to see the diversity of projects currently 
underway in the Indigenous offender health sphere. On 27 November 2013, I presented 
findings at the national Indigenous health conference in Cairns.  
As a requirement of the MAE I also developed this chapter along with colleagues from the 
JHRP into an advanced draft publication (we are currently waiting for further information on 
response rates for 2013/2014 survey collection. This was done later during the MAE and has 
the addition of 2013/2014 NPEBBVS data which this chapter does not include (Appendix 1)). 
2.2.2 Lessons learnt  
Given this is one of the only projects I have worked on during the MAE with existing data, a 
major learning I have taken from the analysis is to have a good understanding of the original 
purpose for the collection of the data. Understanding the aims and objectives of the NPEBBVS 
provided context to the way in which data were analysed and interpreted. This project has 
pushed me to examine data with a critical eye, particularly understanding and unpacking how 
stratification affects data and interpretation of findings.  
Because this study focused on a minority population within a larger sample I was challenged 
with interpreting the validity of smaller sample sizes when exploring trends over time. I was 
able to understand internal and external validity of findings taking into consideration the 
prison context and the methodological constraints to working in a rigid system.  
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Prior to starting the MAE I had no experience using analytical tools such as Stata. In 
preparation for this project from August - November I organised Stata sessions fortnightly with 
Kirby Institute based MAE alumni Amalie Dyda. I quickly grasped some of the basic concepts of 
the program and was able to conduct analysis and build a clear well-ordered Stata do file. A 
Stata do file is an optional file which allows one to write and save code for running analysis. A 
clear file allow for code to be run at the press of a button, particularly useful for doing same 
analysis of subset data.  
2.2.3 Acknowledgments 
I would like to acknowledge my supervisors Tony Butler, John Kaldor, Stephanie Davis, Phyll 
Dance and Emily Fearnley in assisting me to develop this chapter. Tony Butler established the 
NPEBBVS in 2004 and has coordinated the project every survey year since. Logistically this 
survey is complex to run due to jurisdictional negotiations and the ever changing funding 
environment; I appreciate the ability to use the NPEBBVS databases. I would also like to thank 
Amalie Dyda, who gave her time to tutor me on Stata to build up my skills and confidence to 
eventually use the program as described in this chapter.  
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2.3 Abstract 
2.3.1 Introduction  
The justice system is diverse comprising of juvenile and adult, female, male and transgender 
offenders serving different types and lengths of sentences in a number of settings. Indigenous 
prison entrants are over represented within this population making up 27% of the national 
prisoner population but only 3% of the general population. Prisons are recognised as a high 
risk setting for BBV acquisition. Indigenous people are recognised as a priority population in 
regards to BBVs. This data analysis aims to determine the prevalence of the hepatitis C virus 
(HCV), hepatitis B virus (HBV) and associated risk factors among Indigenous and non-
Indigenous prison entrants.  
2.3.2 Methods 
This study utilises data from the NPEBBVS in 2004, 2007 and 2010. Prison entrants were 
recruited at participating prison reception centres over a set two week period in four states; 
New South Wales (NSW), Queensland (QLD), Western Australia (WA) and Tasmania (TAS). 
Participants undertook a demographic and risk behaviour survey and provided blood and urine 
samples. Disease prevalence was determined by serological markers hepatitis C antibody 
(HCVAb) and hepatitis B core antibody (anti-HBc). Risk factors and demographics were 
analysed for associations to disease outcomes of interest. Data were stratified by Indigenous 
and non-Indigenous status and injecting status. Stata 12 was used to analyse data.  
2.3.3 Results 
There were 1,752 prison entrants from NSW, QLD, WA and TAS across all survey years. 
Indigenous prison entrants represented 22% (n=382) of the sample. Both Indigenous (83-88%) 
and non-Indigenous (90-92%) prison entrants were predominantly male. HCVAb prevalence 
among Indigenous prison entrants was 37% in 2004, 42% in 2007 and 24% in 2010 and 33%, 
30% and 23% respectively in non-Indigenous prison entrants. A history of injecting drug use 
was significantly associated with HCVAb positivity among both Indigenous (odds ratio (OR) = 
29.0, confidence interval (CI) = 9.85-85.20) and non-Indigenous (OR = 48.9, CI = 24.26-97.53) 
prison entrants. Indigenous prison entrants had a higher burden of disease; anti-HBc 
prevalence 40% (2004), 29% (2007) and 21% (2010), compared to their non-Indigenous 
counterparts 17% (2004), 15% (2007) and 16% (2010). Being over 30 years of age was 
significantly associated to anti-HBc positivity.  
2.3.4 Conclusion 
To best target resources, public health interventions should take into consideration the 
similarities and differences between Indigenous and non-Indigenous offenders when 
developing public health programs, policy and allocating funding.  
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2.4 Background  
Prisons are a focus of blood borne virus (BBV) risk because of the injecting drug use (IDU) 
histories of many offenders, and lack of harm-reduction strategies available to this population 
while in prison(1, 2). Sharing needles and other injecting equipment has been identified as 
presenting a higher risk of transmission of BBVs, particularly HCV, but community based  harm-
reduction initiatives are yet to be introduced into prisons(3).   
In 2011, Aboriginal and Torres Strait Islander (referred to in the remainder of the chapter as 
Indigenous) people were 3% of the Australian population, yet accounted for 27% of the 
Australian prison population(4). Indigenous people are over-represented in this high risk 
setting, therefore,  Indigenous  people in touch with the justice system are recognised as a 
high priority population within the Commonwealth government’s Third National Aboriginal 
and Torres Strait Islander Blood Borne Viruses and Sexually Transmissible Infections Strategy 
2010-2013(5). This strategy highlights the need to strengthen evidence-based harm reduction 
approaches to BBVs in the custodial setting. The translation of this strategy into practical and 
meaningful application within the Australian prison health context requires the support of 
research, including monitoring and surveillance, to determine resource allocation to establish 
and evaluate sustainable approaches to infectious disease transmission and harm reduction.  
2.4.1 The National Prison Entrants Blood Borne Virus Survey  
The NPEBBVS is a triennial cross-sectional survey established in 2004 by Tony Butler at the 
Centre for Health Research in Criminal Justice (Justice Health NSW) in partnership with the 
Kirby Institute (formerly known as the National Centre in HIV Epidemiology and Clinical 
Research). The aim of the NPEBBVS is to monitor prevalence of Human Immunodeficiency 
Virus (HIV), HCV, HBV, sexually transmissible infections (STIs) and risk behaviours among 
Australian prison entrants. The NPEBBVS is the only repeated multijurisdictional 
monitoring/surveillance mechanism across the Australian justice system. In 2004, the survey 
included four states, NSW, QLD, WA and TAS. Subsequent surveys have included all states and 
territories.  
Each survey year, data are collected over a two week period at centres where prison entrants 
are received before transfer into the general prison population. The Justice Health Research 
Program (JHRP) publishes a report after every survey round.  In addition, there have been two 
peer-reviewed publications describing the population and BBV prevalence of prison entrants 
including 2004-2010 survey data(6, 7). There has been no previous analysis of the survey 
according to Indigenous status.  
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Cross-sectional surveys like the NPEBBVS provide a snap-shot of disease and risk factors 
among the most disadvantaged and health poor people in society today. This marginalised 
group is often overlooked by national BBV surveillance despite carrying a large burden of 
disease. 
2.4.2 Hepatitis B and C 
In 2012, the overall Australian population prevalence of HCV was 1.4% and for HBV 0.97%. In 
Australia, there have been six HBV and/or HCV prison based prevalence studies providing an 
Indigenous and non-Indigenous breakdown(6, 8-12), these studies span the period from 1996 to 
2010. Variations in methodological approaches, sample size and source population have led to 
diverse BBV prevalence estimates of offender populations (Table 1). Although diverse 
estimates, these studies and other prison based cross-sectional surveys demonstrate the high 
burden of HCV and HBV among offenders compared to the general population(7, 13).  HIV is of 
low prevalence among the Australian prison population, therefore HCV and HBV are the focus 
of this chapter(7, 13). 
 
HCV and HBV both have a significant public health impact causing morbidity and mortality 
related to liver disease(14, 15). HBV is a vaccine preventable disease; the vaccine has been 
available in Australia since 1985 but initially administered adhoc and through antenatal  
screening  programs(16). In 2000, the Australia government funded a  universal HBV vaccination 
program targeting infants and school-based adolescents(16).  There is no vaccine available for 
HCV; however treatment for cure is available, unlike HBV which cannot be cured and requires 
monitoring and in some case lifelong antiviral medication if treatment is necessary(15, 17). 
 
As described above, only six studies were found to provide a breakdown of BBVs by Indigenous 
status. This is despite the overrepresentation of Indigenous people in prison which makes 
Indigenous status possible to report in-prison based studies. Providing such a breakdown in 
epidemiological studies acknowledges the differences between Indigenous and non-
Indigenous populations and provides further understanding of infectious diseases among 
marginalised groups within the offender population. This is important information to assist in 
effectively planning programs and other preventative activities.   
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Table 1. Prevalence of Hepatitis B and C among Indigenous and non-Indigenous offenders 
according to past prevalence studies in Australia 
 HCV antibody positive Anti-HBc positive 
Study and study 
type 
Study 
year 
Prison/s 
location 
Indigenous 
%(+/tested*) 
non-
Indigenous 
%(+/tested) 
Indigenous 
%(+/tested) 
non-
Indigenous 
%(+/tested) 
Butler et al, 1999
7
 
Cross-sectional 
survey 
1996 NSW 36 (82/228) 41 (209/510) 54 (124/229) 27 (139/514) 
Butler et al , 1997
4
 
Cross-sectional 
survey 
1994 NSW 37 (15/41) 37 (135/367) 29 (12/41) 31 (113/367) 
Miller et al, 2006
5 
Medical record 
audit 
2005 
SA 
metropolit
an prisons 
56 (n/a) 41 (n/a) − − 
 
 
SA 
northern 
regional 
prison 
19 (n/a) 37 (n/a) − − 
Butler et al, 2007
9
 
Cross-sectional 
survey 
2004 
and 
2007 
NSW, QLD, 
WA, TAS 
37 (29/102) 34 (125/435) 29 (22/102) 18 (64/435) 
Watkins et al 
2009
8
 
Retrospective 
medical record 
audit 
2005-
2006 
Western 
Australia 
15(n/a) 38 (n/a) − − 
 
 NSW 
    
Indig et al, 2010
6
 1996 Men 30 (61/204) 35 (158/453) 53 (108/204) 24 (108/453) 
Cross-sectional 
survey 
 Women 72 (22/31) 64 (64/101) 59 (18/31) 42 (42/101) 
 
2001 Men 42 (95/227) 39 (202/520) 31 (70/227) 24 (124/520) 
 
 Women 76 (22/29) 61 (84/138) 45 (13/29) 28 (38/138) 
 2009 Men 36 (93/259) 24 (129/538) 37 (95/259) 17 (91/538) 
   Women 54 (28/53) 43 (62/146) 35 (18/53) 33 (48/146) 
*(+/tested) = number of participants positive/number of participants tested.  n/a= data not available  
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2.5 Aims 
This data analysis aims to determine the prevalence of HCV and HBV among Indigenous and 
non-Indigenous prison entrants, identify risk factors for HCV and HBV, identify differences 
between populations and recommend where public health action could be directed.  
2.6 Methods 
NPEBBVS data from survey years 2004, 2007 and 2010 were obtained from the databases 
maintained by the JHRP at the Kirby Institute. NPEBBVS methods have been described in detail 
in a number of national reports, papers and chapter 3(6, 7, 13, 18). Only states and territories 
participating in all three survey years were included in the analysis: New South Wales (NSW), 
Western Australia (WA), Queensland (QLD) and Tasmania (TAS). Twenty survey participants 
with missing Indigenous status were also excluded from this analysis. NPEBBVS data are 
collected over a two week period every three years; therefore it was assumed prison entrants 
across the three time periods are separate individuals.   
During survey collection, nurses based at participating prison reception centres were 
responsible for survey procedures. Procedures included; recruitment of prison entrants, 
administration of questionnaires and collection of blood and urine samples. Blood and urine 
samples collected from consenting participants were tested for HCV, HBV, HIV and selected 
sexually transmitted infections (STIs), namely syphilis, chlamydia and gonorrhoea.  
There are a number of serological, virological, biochemical and histological markers to 
determine HBV status.  In this analysis hepatitis B core antibody (Anti-HBc) was used to 
determine current disease or past exposure and this is present among people who have acute 
HBV (where it is usually elevated during acute HBV and declines 3-6 months after onset) or 
patients who have previously been infected with HBV (it is a life-long marker of exposure)(15). 
Additional markers were used to determine immune status including; Hepatitis B surface 
antigen (HBsAg) for HBV carrier status; HBV surface antibody (Anti-HBs) levels ≥10 mlU/ml to 
signify vaccine conferred immunity, positive Anti-HBs and Anti-HBc to determine immunity 
through past exposure and no antibodies present representing no evidence of immunity.  
HCV prevalence was determined using the serological   marker HCVAb. HCVAb positivity 
indicates exposure to HCV and can indicate either past or current infection (HCV PCR which 
indicates current infection is not currently collected as a part of the NPEBBVS).  
2.6.1 Data analysis methods 
Descriptive analysis involved the calculation by year of the proportion of prison entrants 
according to Indigenous status, state of origin, gender, age group, sexuality, location of 
residence before entering prison, number of times incarcerated and risk behaviors such as 
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tattooing, history of injecting drug use, IDU status in the last month and risk factors associated 
with injecting including sharing of needles and injecting equipment.  
The Accessibility/Remoteness Index of Australia (ARIA), a remoteness measurement tool 
developed by the Department of Health and Ageing, is used by government in Australia to 
provide a quantifiable index of remoteness in relation to service provision(19).  ARIA scores are 
based on population density by postcode in relation to distance of service provision 
(Kilometres (km). Classifications used for this analysis are provided in table 2. 
Table 2. ARIA remoteness classification and definitions 
Classification ARIA score (km) Definition 
Highly Accessible 0 - 1.84 
Relatively unrestricted accessibility to 
a wide range of goods and services and 
opportunities for social interaction. 
Accessible >1.84 - 3.51 
Some restrictions to accessibility of 
some goods, services and 
opportunities for social interaction. 
Moderately 
Accessible 
>3.51 -5.80 
Significantly restricted accessibility of 
goods, services and opportunities for 
social interaction. 
Remote >5.80 - 9.08 
Very restricted accessibility of goods, 
services and opportunities for social 
interaction. 
Very Remote >9.08 - 12 
Very little accessibility of goods, 
services and opportunities for social 
interaction. 
Source: Information and Research Branch Depatrment of Health and Aged Care. Measuring Remoteness : 
Accessibility / Remoteness Index of Australia ( ARIA ), 2001 
(18) 
ARIA calculations were based on the prison entrant’s postcode of last residence, to classify 
participants into the two categories of highly accessible (highly accessible) and non-highly 
accessible (accessible, moderately accessible, remote, very remote).   
Overall HCVAb and anti-HBc prevalence were calculated for each survey year and by 
Indigenous status. A subgroup analysis of HCVAb and HBcAb prevalence by injecting and 
Indigenous status was also conducted.  The calculations used for these were: 
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Overall prevalence of  
HCVAb or HBcAb by survey year   
and Indigenous status  
 
Prevalence of HCVAb or HBcAb  
among prison entrants who  
have ever injected drugs  
 
Prevalence HCVAb or HBcAb  
among prison entrants who  
have never injected drugs   
 
Chi squared test for trends were used to detect significant changes in exposure variables, by 
Indigenous status, across survey years for all prison entrant participants. Logistic regression 
was conducted to determine overall risk factors associated with the outcomes of HCV and HBV 
prevalence, and associated risk factors by Indigenous status. The multivariate models included 
variables identified in previous prevalence studies as significantly associated with exposure to 
HCV and HBV. P values <0.05 were considered significant. Statistical analysis was carried out in 
Stata 12. Graphs and tables were created in Microsoft Excel. 
2.7 Results  
Overall, 1752 prison entrants from NSW, QLD, WA and TAS participated in the 2004, 2007 and 
2010 NPEBBVS. Over the two week survey period prison entrant participation rate in the 
analysed states was 83% (2004), 74% (2007) and 80% (2010). Indigenous prison entrants 
represented 22% (n=382) of the overall sample. Table 3 summarises demographic 
characteristics of Indigenous and non-Indigenous prison entrants by year of survey.  Of note, 
both Indigenous and non-Indigenous entrants were predominantly male and identified as 
heterosexual.   
Of Indigenous prison entrants, 54% were under 30 years of age compared to 47% of non-
Indigenous entrants. Indigenous prison entrants had higher representation from areas 
classified as “non-highly accessible”. There was a significant increase in the proportion of 
Indigenous people entering prison from non-highly accessible areas , 25% in 2004 and 2007 to 
47% in 2010 (p<0.001) (Table 3). Non-Indigenous participants had no significant ARIA change 
over survey years consistently coming from highly accessible locations (Table 3). 
On average, across survey years, those entering prison for the first time accounted for 26% of 
Indigenous and 34% of non-Indigenous prison entrants. Entrance of first time offenders 
No. Prison entrants tested  
No. of positive results  
No. IDU tested  
No. of positive IDU 
X 100 
X 100 
No. Non-IDU tested  
No. of positive Non-IDU 
X 100 
= 
= 
= 
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significantly increased across survey year among both Indigenous (p 0.004) and non-
Indigenous (p<0.001) (Table 3).  
Table 3. Characteristics of Indigenous and Non-Indigenous prison entrants by survey 
year 
    2004 2007 2010 *chi
2 
    No. % No. % No.  % p-
values 
Gender                 
Indigenous Male 82 80 96 85 147 88 0.234 
 Female 20 20 17 15 20 12 
Non-Indigenous Male 446 90 385 91 419 93 0.485 
 Female  47 10 39 9 33 7 
Age                 
Indigenous  ≤ 29 years 49 48 59 52 98 59 0.215 
  ≥ 30 years 53 52 54 48 69 41   
Non-Indigenous ≤ 29 years 234 47 203 48 213 47 0.975 
  ≥ 30 years  260 53 221 52 239 53   
Sexuality                 
Indigenous Heterosexual 97 97 106 96 160 97 0.772 
 Non-heterosexual 3 3 5 4 5 3 
Non-Indigenous Heterosexual 471 96 412 98 439 98 0.073 
 Non-heterosexual 19 4 7 2 9 2 
ARIA (by post code of last residency)               
Indigenous Highly accessible 73 75 76 75 85 53 <0.001 
  Not Highly 
accessible 
24 25 25 25 75 47   
Non-Indigenous Highly accessible 428 91 354 88 385 88 0.440 
  Not Highly 
accessible 
45 10 47 12 52 12   
Number of times in prison                
Indigenous First time 18 19 23 22 59 36 0.004 
  2+ 78 81 81 78 105 57   
Non-Indigenous First time 131 27 140 35 256 40 <0.001 
  2+ 347 73 264 65 191 43   
*chi2 calculation represents proportional change across survey year       
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Table 4. Risk behaviours of prison entrants by Indigenous status and survey year 
    2004 2007 2010 *chi2 
    n % n % n % p-values 
Ever injected drugs               
Indigenous Yes 64 64 68 60 75 45 0.004 
Non-Indigenous Yes 281 57 224 53 206 46 0.001 
Injecting behaviour of those who have ever injected 
Indigenous Injected , in 
last month 
41 64 44 66 45 61 0.829 
Non-Indigenous Injected , in 
last month 
181 65 125 57 113 55 0.061 
Shared needles in last month 
Indigenous Yes 11 28 15 34 12 28 0.756 
Non-Indigenous Yes 57 31 47 39 25 24 0.053 
Shared injecting equipment in last month 
Indigenous Yes 12 30 19 46 15 62 0.331 
Non-Indigenous Yes 49 27 50 44 31 28 0.007 
Tattoos 
Indigenous Yes 62 62 77 68 98 63 0.576 
Non-Indigenous Yes 298 61 268 63 304 68 0.076 
 
2.7.1 Injecting drug use and risk behaviours 
Table 4 shows risk behaviours of prison entrants. From 2004-2010 there was a decrease in the 
proportion of prison entrants who had ever injected illicit drugs, 19% (p= 0.004) among 
Indigenous and 11% (p=0.001) among non-Indigenous prison entrants (Table 4). ). Ever 
acquiring a tattoo remained constant across survey year among both Indigenous and non-
Indigenous prison entrants with60-70% of both groups ever having a tattoo (Table 4).  
2.7.2 Hepatitis C prevalence and risk factors 
HCVAb prevalence among Indigenous prison entrants was similar to that seen among non-
Indigenous prison entrants (Table 5). When stratified by injecting status, both Indigenous and 
non-Indigenous prison entrants with a history of IDU had consistently high HCVAb prevalence 
of above 50% across survey years compared to less than 7% among prison entrants with no 
history of IDU (Figure 1). Risk factor associated with HCVAb positivity among Indigenous and 
non-Indigenous prison entrants are shown in tables 6 and 7 respectively. Prison entrants who 
had ever injected were substantially more likely to be HCVAb positive compared to those who 
had never injected  on univariate analysis, and this relationship remained in multivariate 
analysis (adjusted odds ratio aOR=29, p<0.001 for Indigenous prison entrants and aOR=49, 
p<0.001 for non-Indigenous entrants). Other factors significantly associated with HCVAb 
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positivity in both Indigenous and non-Indigenous prison entrants included being female, aged 
30 years plus and incarceration for a second or subsequent time. 
Table 5. Overall hepatitis C antibody prevalence by Indigenous status and survey year 
  Indigenous prison entrants Non-Indigenous prison entrants 
Number  Number  Overall prevalence Number  Number  Overall prevalence 
tested positive Prevalence 95%CI tested positive Prevalence 95%CI 
2004 79 29 37% 28 - 51% 368 243 33% 30  - 40% 
2007 96 40 42%  33 - 54% 345 105 30% 27  - 37% 
2010 149 35 24% 18 - 32% 368 84 23% 19  - 27% 
Total  324 104 32% 27 - 37% 1081 432 39%  37 - 43% 
 
Entering prison from a less accessible geographical location was associated with a lower 
prevalence of HCVAb in both Indigenous and non-Indigenous entrants but the relationship was 
only statistically significant among Indigenous entrants (aOR=0.14, p<0.001). In univariate 
analysis, having ever acquired a tattoo was associated with HCVAb positivity among both 
Indigenous (OR=2.89, p <0.001) and non-Indigenous (OR=2.40, p <0.001) prison entrants. 
However, having ever acquired a tattoo was only significantly associated with HCVAb among 
non-Indigenous prison entrants when adjusted in the multivariate model (aOR= 1.53, p= 
0.038).  
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Figure 1. Hepatitis C antibody (HCVAb) 
prevalance among Indigenous and non-
Indigenous prison entrants by year 
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Table 6. Factors associated with HCVAb positivity among Indigenous prison entrants 
  
Unadjusted Adjusted* 
OR 95% CI P value OR 95% CI P value 
Gender         
Male 1     1     
Female 3.03 1.55-5.90 0.001 3.4 1.20-9.62 0.021 
Year         
2004 1 
  
1 
  
2007 1.22 0.66-2.34 0.526 1.92 0.77-4.79 0.161 
2010 0.52 0.29 - 0.94 0.030 1.61 0.66-3.91 0.296 
Age 
 
 ≤29 1 
  
1 
  
≥30 2.5 1.56 - 4.01 <0.001 5.37 2.47-11.66 <0.001 
Ever injected drugs 
 
 No 1 
  
1 
  Yes 40.8 15.92-104.58 <0.000 28.98 9.85-85.20 <0.001 
Tattoos 
 
 No 1 
  
1 
  
Yes 2.89 1.67 - 4.96 <0.000 0.92 0.40-2.12 0.838 
ARIA 
 
 Highly accessible 1 
  
1 
  Not Highly accessible 0.13 0.07 - 0.26 <0.001 0.14 0.05-0.35 <0.001 
Number of times in 
prison   
 First time 1 
  
1 
  
2+ time 6.7 3.09- 14.53 <0.000 9.96 3.11-31.90 <0.001 
*Adjusted for gender, year, age, IDU, tattoos, ARIA and number of times in prison  
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Table 7. Factors associated with HCVAb positivity among non-Indigenous prison 
entrants 
  
Unadjusted Adjusted* 
OR 95% CI P value OR 95% CI P value 
Gender         
Male 1     1     
Female 3.03 1.29-3.33 0.002 2.71 1.34-5.35 0.005 
Year     
2004 1     1     
2007 0.87 0.64-1.20 0.4 0.8 0.52-1.23 0.305 
2010 0.57 0.42-0.80 0.001 0.83 0.53-1.29 0.402 
Age     
≤29 1     1     
≥30 2.03 1.55- 2.55 <0.000 2.41 1.68-3.45 <0.001 
Ever injected drugs     
no 1     1     
Yes 57.05 30.68 - 106.08 <0.000 48.65 24.26-97.53 <0.001 
Tattoos     
No 1     1     
Yes 2.4 1.78-3.22 <0.000 1.53 1.02- 2.30 0.038 
ARIA     
Highly accessible 1     1     
Not Highly accessible 0.61 0.38- 0.99 0.043 0.59 0.32-1.08 0.087 
Number of times in 
prison  
  
  
First time 1     1     
2+ time 6.05 4.29 - 8.54 <0.000 3.16 2.02-4.90 <0.001 
*Adjusted for gender, year, age, IDU, tattoos, ARIA and number of times in prison 
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2.7.3 Hepatitis B prevalence and risk factors 
Across all survey years Indigenous prison entrants had higher Anti-HBc positive prevalence 
than their non-Indigenous counterparts (Table 8).  
Figure 2 shows anti-HBc positivity prevalence among prison entrants by Indigenous status and 
year, tables 9 and 10 show factors associated with anti-HBc positivity among Indigenous and 
non-Indigenous prison entrants respectively.  For both groups in the univariate analysis, a 
history of IDU was not significantly associated with anti-HBc positivity (Indigenous OR=1.58, 
p=0.087, non-Indigenous OR=2.71, p=0.087). However in the multivariate model injecting drug 
use was significantly associated with anti-HBc positivity among non-Indigenous prison entrants 
(aOR=2.18, p<0.001).  
Age was a common factor associated with anti-HBC positivity among both groups, those prison 
entrants 30 years and over were more likely to be anti-HBc positive then entrants under 30 
years of age. Interestingly, but not significant in either univariate or multivariate analysis, 
being male was associated with anti-HBc positivity among Indigenous prisoners , but  this was 
reversed among non-Indigenous prison entrants with women twice as likely to be anti-HBc 
positive than their Indigenous counterparts.  
In line with higher prevalence findings, 4% of Indigenous prison entrants were HBV carriers 
(chronic HBV infection) compared to 2% non-Indigenous (Table 11). Although a high 
percentage of both non-Indigenous (53%) and Indigenous (30%) prison entrants were not 
vaccinated, a higher proportion of Indigenous prison entrants were immune through previous 
exposure to HBV (Table 11). 
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Table 8. Hepatitis B core antibody prevalence among Indigenous and non-Indigenous 
prison entrants in NSW, QLD, TAS and WA, by survey year 
  
Indigenous prison entrants Non-Indigenous prison entrants 
Number  Number  Overall prevalence Number  Number  Overall prevalence 
tested positive 
Prevalence 
(%) 
95% CI tested positive 
Prevalence 
(%) 
95% CI 
2004 77 22 29 18 - 39 363 63 17 15 - 23 
2007 96 38 40 30 - 50 346 53 15 12 - 20 
2010 113 24 21 12 - 29 298 49 16 12 - 21 
Total 286 84 29 24 -35  1007 165 16 14 -19  
 
Table 9. Factors associated with hepatitis B core antibody positivity among 
Indigenous prison entrants 
  Unadjusted Adjusted* 
  OR 95% CI P value OR 95% CI P value 
Gender         
Male 1     1     
Female 0.93 0.43-2.11 0.87 0.59 0.21 - 1.65 0.317 
Year         
2004 1     1     
2007 1.64 0.86-3.11 0.132 1.69 0.82-3.50 0.157 
2010 0.67 0.35-1.32 0.248 0.76 0.35-1.63 0.478 
Age   
  
  
<29 1     1     
>30 3.02 1.78 - 5.12 <0.000 2.69 1.46-4.94 0.001 
Ever injected drugs   
 
    
No 1     1     
Yes 1.58 0.94- 2.67 0.087 1.29 0.66-2.52 0.464 
Tattoos   
 
    
No 1     1     
Yes 1.65 0.93 - 2.91 0.086 1.27 0.64-2.51 0.500 
ARIA         
Highly accessible 1     1     
Not Highly accessible 1.69 0.97 - 2.96 0.063 1.87 0.96-3.62 0.064 
Number of times in prison    
 
    
First time 1     1     
2+ time 2.88 1.39-5.98 0.005 1.74 0.76-3.97 0.188 
*Adjusted for gender, year, age, IDU, tattoos, ARIA and number of times in prison 
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Table 10. Factors associated with hepatitis B core antibody positivity among non-
Indigenous prison entrants 
  
Unadjusted Adjusted* 
OR 95% CI P value OR 95% CI P value 
Gender     
Male 1     1     
Female 1.59 0.83-3.03 0.158 1.51 0.75-3.05 0.252 
Year         
2004 1     1     
2007 0.81 0.55-1.21 0.308 0.81 0.52-1.25 0.333 
2010 0.89 0.59-1.33 0.557 1.14 0.72-1.79 0.576 
Age     
<29 1     1     
>30 4.1 1.78 - 5.12 <0.000 2.96 2.02-4.35 <0.001 
Ever injected drugs     
No 1     1     
Yes 2.71 1.89- 3.89 0.087 2.18 1.45-3.29 <0.001 
Tattoos   
 
    
No 1     1     
Yes 1.22 0.86 - 1.73 0.265 0.92 0.62-1.37 0.683 
ARIA         
Highly accessible 1     1     
Not Highly accessible 0.69 0.37-1.29 0.241 0.71 0.36-1.39 0.313 
Number of times in 
prison    
 
    
First time 1     1     
2+ time 2.01 1.39-2.94 <0.000 1.49 0.96-2.29 0.073 
*Adjusted for gender, year, age, IDU, tattoos, ARIA and number of times in prison 
 
Table 11. Immunity status of prison entrants tested for hepatitis B serology 
HBV immunity status 
Indigenous  non-Indigenous 
n % n % 
No evidence of immunity 90 30 542 53 
Vaccination conferred 121 41 297 30 
Immune by exposure 75 25 149 15 
Carrier 12 4 18 2 
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2.8 Discussion 
This study shows the high rates of HBV and HCV exposure amongst Australian prisoners and 
likelihood of higher disease. It also shows an increase over time of prison entrants who are 
entering prison for their first time. Those being incarcerated for a first or subsequent time are 
entering an environment of higher HCV and HBV prevalence compared to the general 
community with reduced harm minimisation options.  
2.8.1 Hepatitis C 
The prison entrant population has a higher HCVAb prevalence compared to the general 
Australian population (1.4% in 2013) (20). The  overall decrease in HCVAb prevalence from 2004 
to 2010 shown in this study,  may reflect the overall decline of hepatitis C diagnosis per capita 
in Australia(20) including reduced HCVAb prevalence among people accessing needle and 
syringe programs (NSPs) in the general community(21). However as this decrease was not 
significant this finding should be interpreted with caution.     
The major risk factor associated with HCVAb positivity among prison entrant is a history of IDU. 
The high prevalence of IDU seen in this study is consistent with rates of IDU among people in 
touch with the justice system found in other studies, this coupled with lack of harm 
minimisation available in-prison confirms IDU as a particularly important risk factor in the 
prison context(1, 10). Community based interventions such at the needle and syringe program, 
known to reduce HCV transmission in the general community are currently not available in any 
Australian prison(2, 22). Of people entering prison 17% will inject while incarcerated(12). Inmates 
(both injecting and non-injecting) will have potential exposure to blood through activities such 
as tattooing, piercing, fights and sport during incarceration put them  at risk of acquiring HCV.  
There were similar risk factors associated with HCVAb positivity among both Indigenous and 
non-Indigenous prison entrants including age, gender, injecting status and numbers of times 
incarcerated. It would appear similarities in social disadvantage and drug use across 
Indigenous and non-Indigenous offenders could be a common factor in HCVAb positivity. 
However this does not imply there should not be a focus on the Indigenous population with 
regards to service provision, education and harm minimisation. In fact, tailoring public health 
programs based on Indigenous status and place of residence would allow a more targeted 
approach to HCV health promotion, education and harm minimisation among Indigenous and 
non-Indigenous people in both the prison setting and the wider community.  
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2.8.2 Hepatitis B 
Both Indigenous and non-Indigenous prison entrants had a higher HBV prevalence than the 
general Australian population (less than 1%)(20). Overall anti-HBc prevalence was higher in 
Indigenous prison entrants, this probably reflects higher rates of vertical transmission from 
mother to child among the Indigenous population(23). Additionally, accessibility to antenatal 
screening and vaccination due to complex lives of people in touch with the justice system may 
contribute to lower vaccination rates in both Indigenous and non-Indigenous prison entrants.  
Although national notifications of newly acquired HBV have declined over time(24) there was a 
slight increase in anti-HBc positivity among prison entrants with no history of IDU. The reasons 
for continued HBV infections despite a national universal vaccination program (introduced in 
Australian in 2000) may relate to the high number of Indigenous and non-Indigenous prison 
entrants missing vaccination through main stream programs. In Australia national notification 
of newly acquired HBV among people under 30 years of age from 2003 - 2012 declined, 
demonstrating the impact of the HBV vaccine program(24, 25). There is some evidence from this 
study to suggest the universal HBV vaccination program has had some impact among younger 
prison entrants However, there are still a large number of Indigenous and non-Indigenous 
prison entrants who display no HBV immunity through vaccination or previous exposure. 
Therefore the prison setting provides an opportunity for vaccination of those who have missed 
mainstream vaccine programs. An accelerated HBV vaccine course would be ideal to provide 
some coverage while in-prison and when entering back into the community(26). An accelerated 
HBV vaccine course consists of 4 doses at 0, 1, 2 and 12 months or 0, 7 days, 21 days and 12 
months. Accelerated doses result in recipients attaining seroprotectve antibodies in earlier 
month compared to those receiving normal schedule at  0, 6 and 12 months(16). 
2.8.3 Strengths and limitations  
More than 50,000 people are processed through Australian prisons each year(4). The offender 
population is age, gender and security classification diverse. Offender populations have 
complex health needs which further marginalise and categorise them. The NPEBBVS is the only 
repeated multijurisdictional survey providing point prevalence of BBVs, STIs and risk 
behaviours among prison entrants. While the NPEBBVS participants represent a small 
proportion of the overall yearly prison entrant population, data from the NPEBBVS study are 
comparable to data from other prevalence prison studies(22) providing evidence for 
generalisability to prison entrant populations nationally. Additionally the recruitment of men, 
women, Indigenous, non-Indigenous entrants into the NPEBBVS is representative of the overall 
proportions of these populations within the justice system(8). The proportion of men to woman 
in the NPEBBVS is similar to that of the prison population; however the small female sample 
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size in the NPEBBVS creates difficulties in interpreting the findings from this group as 
proportions of various demographic and other factors are unstable by virtue of small numbers. 
However there is some evidence of the reliability of our findings with regards to female 
prisoners; female prevalence data from the NPEBBVS is comparable to another large cross 
sectional survey of prisoners(27). 
There maybe limitations with the generalisability of these findings to specific populations.  The 
Indigenous prison population varies between states and territories. The NPEBBVS findings 
from NSW, QLD, WA and TAS (current study population) in which Indigenous people make up 
22% of the prison population should be generalised only with caution to other jurisdictions 
who have different prison entrant demographic characteristics. For example, the NT has larger 
representation of Indigenous people in prison (86% in 2013(28)) and large cultural diversity 
among Indigenous people with many different language groups.  A separate analysis for the 
NT, WA and SA data would be beneficial for these populations. Alternatively, analysis by area 
remoteness of the overall NPEBBVS sample without looking at trends over time would allow 
sufficient data for analysis.  
HCVAb is an indicator of exposure; this serological marker cannot be used to directly 
determine level of acute or chronic HCV infection. As a result it is challenging to determine the 
actual burden of disease. Future surveys should consider testing for HCV PCR to provide a true 
indication of disease burden, although the test is expensive ($180). 
The strength of the NPEBBVS is in the purpose and uniqueness of the survey and the important 
contribution the NPEBBVS data provides for understanding BBV and risk factors among this 
marginalised population. In the absence of a national BBV monitoring mechanism or national 
screening policy for prison entrants, the NPEBBVS gives the only national BBV prevalence 
estimates among prison entrants.  
2.9 Conclusion 
The NPEBBVS is a unique mechanism for monitoring BBVs and risk factors among prison 
entrants. This study shows the high burden of HCV and HBV experienced by offender 
populations compared to the general community. It indicates a need for tailored and targeted 
health programs and policy to decrease the prevalence within the offender population.  
Factors associated with HCV and HBV are varied, therefore approaches to developing policy, 
initiatives and programs should be streamlined to take into consideration similarities while 
targeted to address differences identified between the Indigenous and non-Indigenous 
populations.   
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Likewise, when reporting on Indigenous BBV prevalence a break down by location (urban 
versus, regional and remote) and injecting status can provide context and inform program and 
policy development.  
2.10 Implications and recommendations  
 The findings of this study provide further evidence the need for harm minimisation in 
prisons. For a long time, there have been calls to implement  NSP’s in Australian 
prisons without success(3). Dialogue since the 1980’s is in a state of stalemate, new and 
innovative approaches to advocating for the implementation of NSP’s and other harm 
minimisation initiatives in this setting could lead to progression.   
 
 Prisons have been identified as high risk settings for HCV and HBV transmission due to 
both high prevalence among prison entrants and risk behaviours. Access to harm 
minimisation in the form of vaccination, condoms for those engaged in sexual activity 
while in-prison, bleach for cleaning injecting equipment, and other surfaces and 
equipment in contact with blood, opiate management programs and appropriate 
educational materials for individuals in the justice system could reduce risk of prison 
transmission.   
 
 HBV is higher among Indigenous prison entrants and vaccination coverage is poor.  
Prisons may provide a good setting to monitor coverage of the HBV vaccination 
program or provide a catch up program for those offenders missed in mainstream 
vaccination programs. 
 
 For a comprehensive understanding of HCV epidemiology, collection of HCV PCR in 
addition to HCVAb would be ideal to differentiate acute, past and current infection in 
prison entrants and assist prison medical services to manage cases appropriately. 
 
 The NPEBBVS is the only national prison surveillance system. Further discussion is 
required regarding the implementation of a passive national surveillance system to 
monitor infectious disease in prison to understand the epidemiology of infectious 
disease and provide adequate infection control measures and harm minimisation 
strategies where necessary.  
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 Future research, other than the NPEBBVS, should look to undertake targeted 
recruitment of women within the justice system to improve knowledge and 
understanding of BBV prevalence and associated risk factors among this population. 
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Hepatitis C and hepatitis B prevalence and associated risk factors among Indigenous and 
non-Indigenous prison entrants in Australia 
Intended Journal: Australian and New Zealand Journal of Public Health 
Authors:  Dina Saulo1, Paul Simpson1, Mary Ellen Harrod1, Tony Butler1 
1. The Kirby Institute  
 
Background: Prisoners and Indigenous people are priority populations. Yet, there remains little 
Indigenous-specific research on hepatitis C virus (HCV) and hepatitis B virus (HBV) among 
prisoners. This study aims to compare HCV and HBV antibody prevalence and associated risk 
factors by Indigenous status.  
Methods: Data was extracted from a national cross-sectional prison entrant survey collected in 
2004, 2007, 2010 and 2013. Descriptive analysis of demographic data and prevalence of HCV 
and HBV were determined. Logistic regression was used to examine factors associated with 
HCV and HBV by Indigenous status.  
Results: Indigenous people accounted for 25.4%(547/2230) of prison entrants. HCV antibody 
(HCVAb) prevalence in Indigenous entrants was 37%(2004), 42%(2007), 24%(2010), and 
42%(2013). Prevalence among non-Indigenous was 33%, 30%, 23%, and 37% respectively. Risk 
factors associated to HCVAb positivity were similar between groups, injecting drug use (IDU) is 
the predominate risk factor. HBV core-antibody (anti-HBc) prevalence among Indigenous 
entrants was higher in 2004, 2007 and 2010. In 2013, anti-HBc prevalence was similar (13-
14%). Age was significantly associated with anti-HBc status, injecting was only associated with 
anti-HBc among non-indigenous entrants. 
Conclusion: In developing public health programs and policies on HCV and HBV, consideration 
of the similarities and differences between Indigenous and non-Indigenous offenders is 
required. 
Background  
Aboriginal and Torres Strait Islander (hereafter Indigenous) people comprise 3.0% of the 
Australian population but a staggering 27% of the Australian prisoner population(30). 
Indigenous people in contact with the justice system are recognised as a high priority 
population within the government’s Fourth National Aboriginal and Torres Strait Islander 
Blood Borne Viruses and Sexually Transmissible Infections Strategy 2014-2017(31). This strategy 
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prioritises strengthening evidence-based approaches to harm reduction and increased 
surveillance and monitoring research for blood borne viruses (BBVs) in the custodial setting. 
Prisons are a priority setting for BBV risk due to the IDU history of many offenders, the high 
risk of transmission of BBVs, particularly HCV through sharing equipment, and the limited 
access to effective harm reduction measures such as needle and syringe program (NSP) (30, 31).  
From 1996-2010, six prison-based HBV and/or HCV prevalence studies have been conducted 
that provide an Indigenous non-Indigenous breakdown(6, 8-10, 28, 32). Breakdown by Indigenous 
status acknowledges that these populations are not homogenous and assist in effectively plan 
screening, prevention and treatment activities in a culturally appropriate manner.  Prevalence 
estimates provided by these studies indicate that Indigenous prison entrants have a higher 
level of HCV and HBV than non-Indigenous prison entrants. However, these studies do not 
provide an in-depth understanding of these differences. 
The aim of this study was to explore prevalence and identify factors associated with HCV and 
HBV exposure among Indigenous and non-Indigenous prison entrants across a ten-year period.  
Methods 
Survey 
The National Prison Entrants Blood Borne Virus Survey (NPEBBVS) is a triennial cross-sectional 
survey established in 2004. It monitors the prevalence of (Human Immunodeficiency Virus) 
HIV, HCV, HBV, sexually transmissible infections (STIs) and risk behaviours among Australian 
prison entrants. The NPEBBVS is funded by corrective/justice health from all jurisdictions. 
NPEBBVS methods are described in detail elsewhere(6, 13, 33). Briefly, data are collected over a 
two week period by identified Public Health Nurses at participating reception prisons. Survey 
procedures include obtaining informed participant consent, questionnaire administration and 
collection of a blood and urine sample. Samples are tested for sexually transmissible and blood 
borne viral infections. Hepatitis B core antibody (anti-HBc) was used in this analysis as a 
marker for exposure to HBV, and hepatitis C antibody (HCVAb) as a marker for exposure to 
HCV(34). 
This analysis includes 2004, 2007, 2010 and 2013 NPEBBVS data from states which participated 
in all four survey years: New South Wales (NSW), Western Australia (WA), Queensland (QLD) 
and Tasmania (TAS). Survey participants with Indigenous status not recorded were excluded 
from analysis.  
Data analysis 
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Chi-squared test for trends were used to detect significant changes in descriptive variables by 
Indigenous status, IDU status and survey year. HCVAb and anti-HBc prevalence were calculated 
separately for each survey year, and by Indigenous status. Logistic regression was conducted 
to determine those risk factors associated with HCV and HBV prevalence by Indigenous status. 
The Accessibility/Remoteness Index of Australia (ARIA) was included as an independent 
variable(35). ARIA calculations were based on the prison entrant’s postcode of last residence 
before prison with entrants classified into the two categories of highly accessible (locations 
with higher service provision) and non-highly accessible (locations with less service provision). 
Data analysis was carried out in Stata 12(35). 
Results  
Participants  
Overall, 2,230 prison entrants from NSW, QLD, WA and TAS participated in the 2004, 2007, 
2010 and 2013 NPEBBVS. Participation rate by prison entrants at reception centres over the 
two week survey period in the four states combined was 83% (2004), 74% (2007), 80% (2010). 
Indigenous prison entrants accounted for 24.5% of the total sample across all survey years 
(n=547). The overall sample was primarily male (89%) reflecting the composition of the overall 
prisoner population in Australia. Indigenous women made up 33% of the overall female prison 
entrants population and were incarcerated at a higher rate than non-Indigenous women from 
2004 – 2010. In 2013, both Indigenous and non-Indigenous woman were incarcerated at a 
similar rate. There was a high rate of recidivism among Indigenous and non-Indigenous prison 
entrants where the majority of prison entrants were returning to prison for a subsequent 
episode. However, from 2004 to 2013 there was an increase in first time offenders among 
both Indigenous (18.0% (2004) – 22.6% (2013), p 0.844) and non-Indigenous (26.7% (2004) – 
36.9% (2010), p 0.001) prison entrants. 
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*chi2
No. % No. % No. % No. % p-values
Gender
Indigenous Male 82 83.0% 96 85.0% 147 88.0% 142 86.1% 0.385
Non-Indigenous Male 446 90.3% 385 90.8% 419 92.7% 266 85.0% 0.018
Age
<29 47 46.5% 59 52.2% 95 57.2% 84 52.2%
>30 54 53.5% 54 47.8% 71 42.8% 77 47.8%
<29 222 45.0% 199 47.0% 207 45.8% 120 38.5%
>30 271 55.0% 224 53.0% 245 54.2% 192 61.5%
ARIA (by post code of last residency)
Highly accessible 73 75.3% 76 75.3% 85 53.1% 95 60.1% <0.001
Not Highly accessible 24 24.7% 25 24.8% 75 46.9% 63 39.9%
Highly accessible 428 90.5% 354 88.3% 385 88.1% 251 83.7% 0.043
Not Highly accessible 45 9.5% 47 11.7% 52 11.9% 49 16.3%
Number of times in prison 
First time 18 18.0% 23 20.4% 35 21.3% 37 22.6% 0.844
2+ 82 82.0% 90 79.7% 129 78.7% 127 77.4%
First time 131 26.7% 140 33.3% 169 37.8% 113 36.9% 0.001
2+ 360 73.3% 281 66.8% 278 62.2% 193 63.1%
Ever injected drugs
No 36 36.0% 45 39.8% 92 55.1% 75 45.7%
Yes 64 64.0% 68 60.2% 75 44.9% 89 54.3%
No 209 42.7% 200 47.2% 246 54.4% 153 49.8%
Yes 281 57.4% 224 52.8% 206 45.6% 154 50.2%
Injecting behaviour 
Injected, not in last month23 36.0% 23 34.3% 29 39.6% 26 29.6%
Injected , in last month 41 64.1% 44 65.7% 45 60.8% 62 70.5%
Injected, not in last month97 34.9% 94 42.9% 91 44.6% 45 29.4%
Injected , in last month 181 65.1% 125 57.1% 113 55.4% 108 70.6%
shared needles in last month
No 29 72.5 29 65.9 31 72.1 47 77.05 0.662
Yes 11 27.5% 15 34.1% 12 27.9% 14 23.0%
No 125 68.7% 74 61.2% 80 76.2% 75 70.1%
Yes 57 31.3% 47 38.8% 25 23.8% 32 29.9%
shared injecting equipment in last month
No 28 70.0% 22 53.7% 26 37.7% 48 80.0%
Yes 12 30.0% 19 46.3% 15 62.3% 12 20.0%
No 133 73.1% 65 56.5% 79 68.1% 88 83.8%
Yes 49 26.9% 50 43.5% 31 28.2% 17 16.2%
Tattoos
No 38 38.0% 36 31.9% 58 37.2% 35 21.5% 0.018
Yes 62 62.0% 77 68.1% 98 62.8% 128 78.5%
No 192 39.2% 156 36.8% 144 32.1% 80 25.9%
Yes 298 60.8% 268 63.2% 304 67.9% 229 74.1%
*chi2 calculation represent proportional change across survey year
Non-Indigenous 0.001
Indigenous 0.04
Non-Indigenous <0.001
Indigenous
Non-Indigenous 0.008
Indigenous
Non-Indigenous 0.11
Indigenous 0.01
Non-Indigenous 0.004
Indigenous 0.629
0.402
Non-Indigenous 0.108
Indigenous
Table 1. Demographics and risk behaviour of Indigenous and Non-Indigenous prison entrants by survey 
2004 2007 2010 2013
Non-Indigenous
Indigenous
Non-Indigenous
Indigenous
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Chi-squared analysis revealed a significant increase in the proportion of Indigenous people 
entering prison from non-highly accessible areas across survey years (from 25% in 2004 and 
2007 to 47% in 2010 and 40% in 2013 (p<0.001)). P-values for ARIA changed over survey years 
for non-Indigenous participants (p<0.043). 
Hepatitis C prevalence and risk factors 
From 2004 -2013 the proportion of people who had ever injected illicit drugs decreased from 
58.5% to 51.6%, this decrease was significant for both Indigenous (from 64% (2004), 60% 
(2007), 45% (2010) and 54% in 2013, p= 0.010) and non-Indigenous entrants (p= 0.004) (Table 
1). The majority of both Indigenous and non-Indigenous entrants who had ever injected did so 
in the month prior to incarceration. There was no significant change across survey years 
among prison entrants who had shared needles in the month prior to incarceration but there 
was a significant decrease in sharing injecting equipment in the month prior to incarceration 
among both Indigenous and non-Indigenous entrants (Table 1) From 2004 – 2013 there was a 
significant increase in prison entrants ever having a tattoo for both Indigenous (p =0.018) and 
non-Indigenous entrants (p= 0.001) (Table 1). 
 
HCVAb prevalence among Indigenous prison entrants was 37% in 2004, 42% in 2007, 24% in 
2010, and 42% in 2013; and 33%, 30%, 23%, and 37% respectively in non-Indigenous prison 
entrants (Table 2). When stratified by injecting status, both Indigenous and non-Indigenous 
prison entrants had a similar HCVAb prevalence. Indigenous people with a history of IDU had 
an HCVAb prevalence of 56% (2004), 63% (2007), 53% (2010), and 54% (2013). Non-Indigenous 
prison entrants with a history of IDU had an HCVAb prevalence of 56%, 55%, 51%, and 62%, 
(Table 2). 
 
Number Number Number Number 
tested positive Prevalence 95% CI tested positive Prevalence 95% CI
2004 79 29 36.7% 0.28 - 0.51 368 243 33.4% 0.30-0.40
2007 96 40 41.7%  0.33 - 0.54 345 105 30.4% 0.27-0.37
2010 149 35 23.5% 0.18- 0.32 368 84 22.8% 0.19-0.27
2013 88 37 42.1% 0.32-0.53 197 72 36.6% 0.30-0.43
Non-IDU prevalence
Prevalence 95% CI Prevalence 95% CI Prevalence 95% CI Prevalence 95% CI
2004 3.57% 0.0009 - 0.18 56.0% 0.41 - 0.70 3.21% 0.01-0.07 56.0% 0.49-0.63
2007 5.56% 0.006 - 0.19 63.3%  0.50 - 0.75 3.07% 0.01 - 0.07 55.0% 0.47-0.62
2010 1.18%  0.0003 - 0.06 53.1% 0.40 - 0.66 0.49% 0.0001-0.03 51.2% 0.43-0.60
2013 4.55% 0.001- 0.23 53.9% 0.41-0.66 4.76% 0.01 - 0.12 62.0% 0.52-0.71
HCVAb prevalence  among Indigenous and Non-Indigenous prison entrants 
By injecting  status and survey year 
Indigenous prison entrants Non-Indigenous prison entrants
IDU prevalence Non-IDU prevalence IDU prevalence
Table 2. HCVAb prevalence among Indigenous and Non-Indigenous prison entrants 
in NSW, QLD, Tas and WA,  by survey year 
Indigenous prison entrants Non-Indigenous prison entrants
Overall prevalence Overall prevalence
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Indigenous prison entrants who had ever injected were more likely to be HCVAb positive than 
those who had not injected drugs (adjusted odds ratio [aOR]=31.0, CI 11.64-82.67, p<0.001) as 
were non-Indigenous prisoner entrants who had ever injected drugs (aOR=42.5, CI 23.65-
76.36, p<0.001) (Table 3).  
Other factors significantly associated with HCVAb in both Indigenous and non-Indigenous 
prison entrants were age, subsequent imprisonment and residing in a highly accessible 
location before prison. Indigenous and non-Indigenous prison entrants aged over 30 were 
more likely to be HCVAb positive compared to those aged 29 and under (Indigenous aOR=3.57, 
CI 1.99-6.38, p<0.001 and non-Indigenous aOR=2.67, CI 1.89-3.65, p<0.001). Bei g incarcerated 
for the second or subsequent time was associated with HCVAb in both Indigenous prison 
entrants (aOR=4.30, CI 1.71-10.76, p<0.002) and non-Indigenous prison entrants (aOR=3.92,CI 
2.52-6.10, p<0.001). Entering prison from a less accessible geographical location was 
associated with a lower prevalence of HCVAb in both Indigenous and non-Indigenous entrants. 
Having ever acquired a tattoo was not significantly associated with HCVAb among either 
Indigenous or non-Indigenous prison entrants.
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Table 3. Factors associated with HVC antibody (HCVAb) positivity among Indigenous and 
non-Indigenous prison entrant  
  Indigenous Non-Indigenous  
  aOR 95% CI P value aOR 95% CI P value 
Gender     
Male 1     1     
Female 1.57 0.72-3.45 0.258 2.27 1.25-4.12 0.007 
Year         
2004 1     1     
2007 1.6 0.97-8.58 0.271 0.87 0.57-1.33 0.527 
2010 1.07 0.47-2.39 0.877 0.69 0.45-1.06 0.0.092 
2013 1.06 0.47-2.41 0.88 1.09 0.65-1.81 0.748 
Age     
<30 1     1     
≥30 3.57 1.99-6.38 <0.001 2.67 1.89-3.65 <0.001 
Ever injected drugs     
No 1     1     
Yes 31.02 11.64-82.67 <0.001 42.5 23.65-76.36 <0.001 
Tattoos     
No 1     1     
Yes 1.2 0.61-2.39 0.598 1.45 0.99- 2.11 0.055 
ARIA     
Highly accessible 1     1     
Not Highly accessible 0.29 0.15-0.59 0.001 0.56 0.32-0.97 0.04 
Number of times in prison    
First time 1     1     
2+ time 4.3 1.71-10.76 0.002 3.92 2.52-6.10 <0.001 
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Hepatitis B prevalence and risk factors 
From 2004-2010, anti-HBc prevalence among Indigenous prison entrants was 40% (2004), 29% 
(2007), 21% (2010), higher than their non-Indigenous counterparts 17% (2004), 15% (2007), 
and 16% (2010). In 2013, the prevalence was similar in Indigenous (13.3%) and non-Indigenous 
(14.4%) entrants (Table 4). Overall, from 2004-2010 anti-HBc has decreased among Indigenous 
prisoners and remained stable among non-Indigenous prison entrants. 
 
When stratified by injecting status, anti-HBc prevalence among Indigenous prison entrants 
who had ever injected drugs was 38% (2004), 45% (2007), 16% (2010) and 13% (2013) 
compared to 24% (2004), 23% (2007), 19.4% (2010) and 18% (2013) among non-Indigenous 
prison entrants who had never injected.  IDU was significantly associated with anti-HBc in non-
Indigenous prison entrants only (aOR=2.2, CI 1.52-3.25, p <0.001).  
Being 30 years of age or older was the only factor to be significantly associated with anti-HBc 
positivity in both Indigenous (aOR= 2.81, CI 1.61-4.91, p<0.001) and non-Indigenous (aOR= 
2.90, CI 2.02-4.17, p <0.001) (Table 5). Unlike HCVAb among Indigenous entrants, anti-HB is 
more likely to be of higher prevalence among those prison entrants not from a highly 
assessable area prior to prison (aOR=2.00, CI 1.05-4.91, p0.034). 
 
 
 
Number Number Number Number 
tested positive Prevalence 95% CI tested positive Prevalence 95% CI
2004 77 22 28.6% 18 - 39 363 63 17.4% 15-23
2007 96 38 39.6% 30 - 50 346 53 15.3% 0.12-0.19
2010 113 24 21.2% 0.14 - 0.29 298 49 16.4% 0.12-0.21
2013 75 10 13.3% 0.05-0.21 167 24 14.4% 0.08-0.20
Prevalence 95% CI Prevalence 95% CI Prevalence 95% CI Prevalence 95% CI
2004 11.54% 0.24 - 0.53 38.0% 0.25 - 0.53 9.03% 0.05-0.15 23.9% 0.18-0.30
2007 30.56%  0.16 - 0.48 45.0%  0.32 - 0.58 6.10% 0.03-0.11 23.4% 0.18-0.34
2010 25.80% 0.16 - 0.38 15.7% 0.07  - 0.28 14.02% 0.09-0.20 19.4% 0.13-0.27
2013 14.29% 0.03 - 0.36 13.21% 0.05- 0.25 11.11% 0.05-0.20 17.28% 0.09-0.27
Hepatitis B core antibody (BHcAB) prevalence among Indigenous and Non-Indigenous prison entrants 
By injecting  status and survey year 
Indigenous prison entrants Non-Indigenous prison entrants
Non-IDU prevalence IDU prevalence Non-IDU prevalence IDU prevalence
Indigenous prison entrants Non-Indigenous prison entrants
Overall prevalence Overall prevalence
Table 4. Hepatitis B core antibody (HBcAB) prevalence among Indigenous and Non-Indigenous prison 
entrants in NSW, QLD, Tas and WA,  by survey year 
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Table 5. Factors associated with HBV core antibody (HBcAb) positivity among 
Indigenous and non-Indigenous prison entrants  
  
Indigenous Non-Indigenous 
aOR 95% CI 
P 
value aOR 95% CI 
P 
value 
Gender   
Male 1     1     
Female 0.56 0.22- 1.44 0.227 1.34 0.72-2.51 0.351 
 Year       
2004 1     1     
2007 1.77 0.87-3.64 0.116 0.83 0.55-1.27 0.398 
2010 0.73 0.34-1.56 0.411 1.03 0.67-1.60 0.881 
2013 0.38 0.15-0.94 0.037 0.71 0.40-1.25 0.236 
 Age   
<30 1     1     
≥30 2.81 1.61-4.91 <0.001 2.9 2.02-4.17 <0.001 
Ever injected drugs   
No 1     1     
Yes 1.42 0.76-2.64 0.274 2.22 1.52-3.25 <0.001 
Tattoos     
No 1     1     
Yes 1.2 0.63-2.26 0.580 0.88 0.61-1.27 0.49 
ARIA   
Highly accessible 1     1     
Not Highly accessible 2.00 1.05-4.91 0.034 0.59 0.31-1.12 0.108 
Number of times in prison          
First time 1     1     
2+ time 2.19 1.04-15.98 0.082 1.37 0.91-2.08 0.129 
 
Discussion 
This study showed that the prison entrant population has a much higher HCVAb and anti-HBc 
prevalence compared to the general community which in 2013 was 1.4% for HCV and 0.97% 
for HBV(15). Findings revealed equally high HCVAb prevalence among Indigenous and non-
Indigenous prison entrants. Although anti-HBc prevalence rates were high in both Indigenous 
and non-Indigenous groups, the former exhibited higher and more variable rates that non-
Indigenous entrants across survey years.  
Despite the high prevalence of HCVAb there was a declining trend among prison entrants 
across survey years. Decreases in HCVAb prevalence among prison entrants may be due to a 
number of factors such as a decrease in those inmates who have ever injected. However, 
during this time period there was an overall decline of hepatitis C diagnosis per capita in 
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Australia(24) reflected in a reduced HCVAb prevalence among people accessing NSPs in the 
community(36). 
The high burden of HCVAb among prison entrants in this study was significantly associated 
with a history of IDU which is consistent with previous studies. The prevalence of having ever 
injected drugs was 44-65% among prison entrants, consistent with  the prevalence of IDU 
among those in contact with the justice system in other studies indicating IDU as an important 
risk factor in the prison context(1, 10). Non-Indigenous female prison entrants were more likely 
to be HCVAb positive than their male counterparts. Higher HCVAb prevalence has been noted 
among female (including Indigenous female) offenders in previous studies as well as 
community based IDU studies(27, 37). This could be attributed to gender roles and power 
dynamics between female and male injecting partners and groups(27), leading to women being 
more likely to be exposed to sharing behaviours. However, a limitation to understanding 
prevalence among women in the NPEBBVS is the relatively small female sample. 
Overall, Indigenous and non-Indigenous prison entrants had similar risk factors for HCVAb. This 
suggests that Indigenous status is not a predominant factor associated with HCV. Rather, 
findings indicate that age (being over 30 years), gender (female), injecting status and number 
of times incarcerated (2+ times) were risk factors associated with HCVAb. It would appear 
similarities in social disadvantage and drug use across Indigenous and non-Indigenous 
offenders could be a common factor in HCVAb positivity.  
This does not imply there should not be a focus on the Indigenous population in regards to 
service provision, education and harm-minimisation. Tailoring public health programs based on 
both Indigenous status and ARIA would allow a more targeted approach to HCV health 
promotion, education and harm-minimisation. Indigenous prison entrants were significantly 
more likely to be HCV antibody positive if they resided in a more highly serviced area, whereas 
coming from a non-highly accessible area was associated with lower risk, largely reflecting the 
differences in patterns of drug use between metropolitan and non-metropolitan areas(38). Little 
is known about Indigenous injectors from remote communities, further research is required.  
Overall, anti-HBc prevalence was higher in Indigenous prison entrants compared to non-
Indigenous prison entrants. Anti-HBc prevalence was related to age in both populations and 
injecting drug use in non-Indigenous prisoners only. Hepatitis B risk factors include: household 
contacts and vertical transmission with the higher prevalence in Indigenous entrants reflecting 
high exposure to hepatitis B in the general Indigenous population(23, 25, 39). Although national 
notifications of newly acquired hepatitis B have declined over time(24) there was a slight 
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increase in anti-HBc among prison entrants with no history of injecting. Like hepatitis C, there 
is a cumulative lifetime risk of HBV acquisition and being aged 30 years or older was associated 
with anti-HBc positivity in both Indigenous and non-Indigenous prison entrants. People aged 
over 30 years have not participated in either the universal infant HBV vaccination program 
introduced in 2000 or the adolescent catch-up program that commenced in 1997. These 
programs have demonstrated  decline in newly acquired HBV notifications in people aged 
under 30 as well as evidence of decreased prevalence(25) and increased immunity in younger 
people(24, 39). The prison setting provides an ideal opportunity to prevent HBV acquisition 
through vaccination to this at-risk population through either standard or accelerated HBV 
vaccine schedules(26). 
Further research on HBV among offenders and the wider Indigenous population is needed to 
understand hepatitis B vaccine coverage rates. Additionally, in-prison initiatives to ensure 
prison entrants have adequate immunity including incentives to be vaccinated and rapid 
vaccination schedules could be explored. 
The interpretation of the findings should be qualified by study limitations. The Indigenous 
sample from the NPEBBVS for each state and territory is relatively small, and data were only 
collected over a two week window period. The proportion of men to woman is similar to that 
of the prison population; low representation of women in the sample makes it difficult for the 
overall findings to be transferable to the wider female offender population. However, 
prevalence data from the NPEBBVS is comparable to other studies of female prisoners(12, 28). 
Further, the Indigenous population varies between states and territories and so does the 
Indigenous population in each prison. This difference means the analysis of each individual 
state or territory data would be beneficial but sample sizes would need to be larger to draw 
more reliable conclusions.  
HCVAb and HBcAb are both indicators of exposure, but these serological markers cannot be 
used to directly determine levels of acute or chronic infection with HCV or HBV. As current 
national strategies prioritise this population, there is justification to resource the NPEBBVS to 
provide an ongoing consecutive snapshot of BBV and risk behaviour among Indigenous and 
non-Indigenous prison entrants. 
The NPEBBVS is the only repeated multi-jurisdictional survey among prison entrants, and 
provides a snapshot of BBVs, STIs and risk behaviours in this population. The NPEBBVS 
prevalence data are comparable to other prevalence studies(27, 28, 36). In the absence of a 
national prison BBV monitoring mechanism or a national screening policy for prison entrants, 
the NPEBBVS provides the only national BBV prevalence among prison entrants.  
      INFECTIOUS DISEASES AMONG MARGINALISED POPULATIONS  
 
50 
Conclusion 
The NPEBBVS is a unique mechanism for monitoring BBVs and risk factors among prison 
entrants in Australia. Indigenous people are over-represented among this group and, 
therefore, this dataset provides understanding of disease burden among a marginalised 
population absent from national reporting. This study shows the high burden of HCV and HBV 
experienced by offender populations compared to the general community as well as 
similarities and disparities in associated HCV and HBV risk factors between Indigenous and 
non-Indigenous entrants. Factors associated with HCV and HBV acquisition vary, and 
approaches to developing policy, initiatives and programs should consider this. These could be 
streamlined to take into consideration similarities among both Indigenous and non Indigenous 
populations while targeted to address differences among these populations.   
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3  Evaluation of a surveillance system 
The National Prison Entrant Blood Borne Virus Survey  
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3.1 Abbreviations list  
ACT  Australian Capital Territory  
AIHW  Australian Institute of Health and Welfare  
BBV  Blood borne virus 
CDC  Centre for Disease Control and Prevention  
HBV  Hepatitis B 
HCV  Hepatitis C 
HIV  Human Immunodeficiency virus 
IDU  Injecting drug use  
JHRP  Justice Health Research Program 
NPEBBVS   National prison entrant blood borne virus survey  
NPHDC  National Prisoner Health Data Collection  
NPHIC  National Prisoner Health Information Committee  
NSW  New South Wales  
NT  Northern Territory 
QLD  Queensland  
SA  South Australia  
STI    Sexually Transmissible Infection 
TAS  Tasmania 
VIC  Victoria  
WA  Western Australia  
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3.2 Prologue 
Being placed in the Justice Health Research Program (JHRP) for the majority of my time at the 
Kirby Institute has given me a new understanding of the issues affecting offender populations. 
During my field placement I had an opportunity to analyse national prison entrant blood borne 
virus survey (NPEBBVS) data (Chapter 2). I looked at hepatitis B (HBV) and hepatitis C (HCV) 
prevalence and associated risk factors among Indigenous and non-Indigenous prison entrants. 
A requirement of the Masters of Philosophy in Applied Epidemiology is to evaluate a 
surveillance system so it was fitting to conduct the evaluation on the NPEBBVS. The survey 
runs every three years, and 2013 was a survey year (some jurisdictions were only able to 
participant in early 2014 for reasons discussed within) so it was a good opportunity to consult 
stakeholders on the operation and processes of the survey while it was fresh in their mind. 
My role in the evaluation included: 
 Assessing the NPEBBV surveillance system attributes as outlined in the Centre for 
Disease Control and Prevention (CDC) “Updated Guidelines for Evaluating Public 
Health Surveillance Systems”(1) via an interview guide for stakeholder consultation that 
I developed (Appendix 2).   
 
 Obtaining ethics approval from both University of New South Wales (NSW) and 
Australian National University human ethics committees (Appendix 1: participant 
information sheet and consent form). 
 
 Conducting phone interviews with stakeholders. I obtained consent to audio record 
interviews then transcribed them for analysis.  
 
 Analysing NPEBBVS data to examine survey variables for data quality and     
representativeness.  
 
 Feedback of findings to stakeholders in a condensed report, currently in development 
to be distributed to stakeholders, December 2014. 
 
I also had the opportunity to be exposed to other surveillance systems throughout my field 
placement. This included a two week secondment to the NSW Department of Health, Health 
Protection Branch to assist in chasing up missing data fields from the previous quarter’s HIV 
notifications. The epidemiological project I have worked on during the MAE (chapter 5) has 
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now moved into a surveillance phase. A pilot study has been developed to assess surveillance 
methodology and sampling techniques to ensure a targeted sample of Indigenous women and 
men for ongoing national HPV surveillance, and to test the acceptability and feasibility of self 
collected sampling.  
3.2.1 Lessons learnt  
During stakeholder interviews I listened to people talk about the complex needs of prison 
populations, the transmission of blood borne viruses (BBV) and prison setting aspects to 
disease among this population. An active surveillance system, like the NPEBBVS that also 
collects risk behaviour and demographic data, is valuable for understanding disease in context 
over time. A passive surveillance system that electronically captures disease notifications from 
prisons nationally would be beneficial, but there would still need to be an active system to 
monitor risk behaviours. Through using the CDC surveillance evaluation framework attributes, I 
have developed and gained more knowledge not only on how to evaluate a surveillance 
system, but I have a better understanding of how surveillance systems work and how the 
environment that they operate in influences performance.  
3.2.2 Public health implications 
The NPEBBVS produces influential data, which are used within national strategies, policy, 
planning and have cross disciplinary application. Stakeholders involved with this evaluation did 
not know the extent to which the NPEBBVS has influenced national or jurisdictional strategies 
and actions. From this evaluation, I will prepare a condensed report for stakeholders before 
the end of 2014. This report will share the achievements of the NPEBBVS nationally, and will 
demonstrate how jurisdictional collaboration through the NPEBBVS has benefited prison 
health. It would be ideal to have a communication channel for the ongoing dissemination of 
NPEBBVS work and to encourage more cross jurisdictional collaboration. It was evident that 
each state and territory justice or corrective health service was fragmented from others. There 
are some recommendations within this document that are based around resourcing and 
communication that could improve the operation of future NPEBBVSs. 
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3.3 Abstract  
The NPEBBVS was established in 2004 to monitor the prevalence of blood borne viruses and 
risk behaviours among prison entrants and to build national research capacity in the prison 
health sector. The survey has been undertaken every three years for the last decade and 
provides a valuable insight into a priority population. The NPEBBVS has not been formally 
evaluated. The aim of this evaluation is to assess whether the NPEBBVS is meeting its 
objectives effectively. 
3.3.1 Methods 
The Centre for Disease Control and Prevention (CDC) “Updated Guidelines for Evaluating Public 
Health Surveillance Systems” was used to systematically assess key attributes of the NPEBBVS. 
Information for the evaluation has been gathered through stakeholder interviews, document 
review and NPEBBVS data analysis. 
3.3.2 Results 
The NPEBBVS effectively gathers a unique dataset to enhance understanding of the prison 
population. It has been successful in raising the profile and advocating for prisoner health 
nationally, as demonstrated through its use at local and national levels. The NPEBBVS 
represents a small proportion of the overall prisoner population, however the longitudinal 
prevalence of prison entrant blood borne viruses (BBV), sexually transmissible infections (STIs) 
and risk behaviours are similar to other published studies. During interviews, stakeholders 
identified operational systems, resources and the complex needs of the prison entrant 
population as barriers to the simplicity and acceptability of the NPEBBVS. The NPEBBVS 
demonstrated flexibility to adapt in a sometimes unpredictable environment to meet the 
system objectives. NPEBBVS stability and longevity is reliant on external funding sources and 
resourcing.  
3.3.3 Conclusions 
The NPEBBVS is effective in influencing practice, policy and resources nationally and within 
jurisdictions. Whilst the effectiveness of the NPEBBVS to meet its objectives has produced 
great results from a data gathering perspective, it faces significant challenges in terms of 
stability. In the absence of other national data sets of BBVs and STIs for prison populations, the 
NPEBBVS monitors and provides context and input into national surveillance systems, and the 
data collected informs national prison health indicators. Ongoing collection with adequate 
funding to operate is recommended. 
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3.4 Introduction 
In 2013, the Australian prisoner population was 30,775, including sentenced and un-sentenced 
inmates in 123 prison facilities across the country(2). Men accounted for 92% and women 8% of 
the prison population. Overall the Australian imprisonment rate increased from 157 per 
100,000 in 2003 to 170 per 100,000 in 2013 (2). Recidivism was common, where 58% of the 
prison population had been incarcerated before their current episode(2).  
Most prisoners come from a low socioeconomic background, drawn from the most 
disadvantaged and marginalised groups in the community who are health poor, with 34% 
having education levels below year 10(3). The four predominant health issues among prisoners 
are mental health(4), chronic illness, communicable diseases and substance use(3).  Mental 
health has emerged as a key issue for this population. A large mental health study conducted 
in New South Wales (NSW) found a 12-month prevalence of any psychiatric disorder among 
prisoners was 74% compared to 22% in the general population, this burden could not be 
attributed only to alcohol and other drug use(4).  
Reported among prisoners in Australia or internationally are high rates of STIs such as syphilis, 
human immunodeficiency virus (HIV), hepatitis B (HBV), and herpes simplex virus type-2(5). 
Around 44%  of prisoners will use an illicit drug while incarcerated(16).  People who inject drugs 
while in prison are at risk of BBV infections  such as HIV, hepatitis C (HCV) and HBV, largely due 
to sharing contaminated injecting equipment(6). Even though possession of needles is illegal in 
prison, inmates do continue to inject during incarceration, albeit less frequently than in the 
community, and sharing equipment among inmates is common(7). When they do inject they 
are at an increased risk of acquiring infection(7, 8). Tattooing, sharing razors, and other blood 
contact (e.g. during fights or sport) also put prisoners at risk of exposure to BBVs(8). 
Nationally there are no surveillance mechanisms that identify BBV notifications from prisons, 
and no monitoring of STIs such as chlamydia, gonorrhoea, herpes and syphilis among this 
population. Previously, routine HIV testing among prison entrants occurred and was included 
in national monitoring for HIV infection(9). Nationally, the proportion of inmates tested at entry 
to prison decreased between 1997 and 2009, and testing varied across jurisdictions(9). For 
example, some states had a blanket test policy while others had a test at risk policy(10). Due to 
inconsistencies across jurisdictions and low prevalence, the collection of these data has 
ceased. Currently HIV, HBV, HCV and STI  notifications from the prison population are not 
identifiable in the national notifiable disease surveillance system . National epidemiology of 
these infections in this high risk population is still unclear. Several ad hoc prevalence studies 
have been conducted in some states and territories to bridge this knowledge gap(11-14) 
including the NSW prisoner health survey,  a large comprehensive cross-sectional inmate study 
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conducted every five years(15, 16). However, there is a lack of a national effort and co-ordination 
to monitor this at risk population. 
Each state and territory prison system operates differently and this is the case for prisoner 
health also. For example, Western Australian (WA) prison health is operated by corrective 
services with no direct reporting to WA Health (the state health department), compared to 
other jurisdictions which are connected to state or territory health departments(17). There are 
also private prisons in some jurisdictions, including privately run health services(17). This 
diversity may indicate why a national effort for monitoring disease notifications from prisons 
has not been established. In lieu of national government based monitoring, the NPEBBVS aims 
to monitor the prevalence of HCV, HBV, HIV and risk behaviour information among a 
consecutive sample of prison entrants. The NPEBBVS has not been formally evaluated 
previously. Evaluation of surveillance systems is important to ensure capturing and monitoring 
of conditions of public health importance are effective and meet surveillance system 
objectives.    
3.5 Purpose of Evaluation 
 Describe the systems and processes of the NPEBBVS  
 Identify  the extent to which the NPEBBVS meets its objectives 
 Provide recommendations for future NPEBBVS  
3.6 Evaluation methods  
To assess the effectiveness of the NPEBBVS in meeting its objectives the United States 
Department of Health, Centre for Disease Control and Prevention (CDC) “Updated Guidelines 
for Evaluating Public Health Surveillance Systems”(1) was utilised to provide a framework to 
systematically evaluate the NPEBBVS. The CDC guidelines identify ten attributes to evaluate. 
For the purpose of this evaluation, the following eight system attributes were assessed: 
1) Usefulness 
2) Simplicity 
3) Flexibility 
4) Data Quality 
5) Acceptability 
6) Representativeness 
7) Timeliness 
8) Stability  
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Sensitivity and predictive value positive are attributes of the CDC evaluation framework, but 
due to the type of diagnostic data collected for the NPEBBVS these calculations were not 
possible. Three data collection activities were undertaken to assess the selected system 
attributes: 1) Literature review, 2) Analysis of NPEBBVS data and 3) Stakeholder interviews 
(Table 1 outlines which method informed each attribute). 
3.6.1 Literature review  
Medline, Web of Science and Google Scholar (for grey literature) were used to search for 
NPEBBVS citations and mentions in publications, reports and policy documents.  
3.6.2 NPEBBVS data analysis  
NPEBBVS data from survey years 2004, 2007, 2010 and 2013 were analysed to assess data 
quality with a focus on variables relating to system objectives, representativeness and possible 
application of NPEBBVS data.  
3.6.3 Stakeholder interviews 
To assess the effectiveness of the NPEBBVS to meet its objectives, NPEBBVS stakeholders from 
all jurisdictions were invited to participate in 30 minute phone interviews (Appendix 1. 
Participant information and consent form). Stakeholders were invited by email from the 
central coordinator of the NPEBBVS to participate in the evaluation. Invitations were sent to: 
prison public health and medical service staff (directors, managers, doctors and public health 
nurses), staff that administered surveys, policy makers, NPEBBVS national and jurisdictional 
coordinators. All stakeholders invited were involved in the NPEBBVS at some level and gave 
feedback based on their own involvement and experience whether that was from a 
coordination, management, survey and sample collection or policy perspective. All attributes 
were explored through stakeholder interviews (see Table 1 for attributes explored and 
Appendix 2. Stakeholder interview guide).  
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Table 1. Data collection methods used to inform system attributes 
System Attribute 
Literature 
review 
Descriptive 
data 
analysis 
Stakeholder 
consultation 
Usefulness    
Simplicity -  
Flexibility - - 
Data quality   
Acceptability -  
Representativeness   
Timeliness   
Stability -  
  = yes   - = no 
3.6.4 Ethics 
Ethics approval was granted by the University of New South Wales Human Research Ethics 
Committee and the Australian National University Human Research Ethics Committee. 
3.7 Results 
Six stakeholders each participated in 30 minute interviews and represented five different 
states and territories. Stakeholders who participated included a prison medical director (1), 
public health nurses (2), people that administered the surveys (2) and a state government BBV 
program coordinator (1).  
3.8 System and processes of the NPEBBVS 
In early 2000 there was a notable gap in prison health data nationally(18). At this time, two 
national prison health related data sources existed: (i) the HIV notification system and (ii) 
deaths in custody(19). By 2009 the prison HIV notification system ceased operation due to ad 
hoc testing by jurisdictions and low prevalence leading to poor data quality(20, 21). There was a 
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noticeable absence of prison populations from national disease surveillance. Without a 
national effort to monitor BBVs, STIs and risk behaviours among offender populations, 
Professor Tony Butler (Kirby Institute) established the NPEBBVS in 2004 whilst at Justice Health 
NSW. The NPEBBVS was modelled on the consecutive community  national needle and syringe 
program (NSP) survey which commenced in 1995 and continues to provide a rich consecutive 
dataset collected over a two week period every year at NSPs around Australia(22).  
3.8.1 NPEBBVS aims and objectives 
The NPEBBVS aims to collect BBV, STI and risk behaviour prevalence among a consecutive 
sample of prisoner entrants. NPEBBVS objectives are to: 
1) Monitor HBV, HCV, HIV, and STI (syphilis, chlamydia and gonorrhoea) prevalence 
among prison entrants. 
2) Collect ongoing information on risk behaviours such as drug use, high risk injecting 
practices, sexual risk behaviours, tattooing, and tobacco smoking among prison 
entrants. 
3) Monitor BBVs, STIs and associated risk behaviours in Indigenous and non-Indigenous 
prison entrants. 
4) Examine trends in BBVs, STIs, and risk behaviours among prison entrants. 
5) Monitor HBV vaccination coverage in an at-risk (prisoners) population. 
6) Provide a snapshot of BBVs and risk behaviours in a national sample of non-injectors 
who are at risk of exposure to BBVs. 
3.8.2 NPEBBVS Study design 
The NPEBBVS is a cross sectional survey of consecutive prison entrants collected every three 
years over a two week period at selected prison reception centres (selected by jurisdictions). 
Data collection has occurred in 2004, 2007, 2010 and 2013/2014. In 2004, four jurisdictions 
participated, successive surveys have increased participation and in 2010 and 2013/2014 all 
jurisdictions participated (Table 2. NPEBBVS jurisdictions and prison entrants response rate at 
reception by survey year).  
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Table 2. NPEBBVS jurisdictions and prison entrants response rate at reception by survey year 
Survey year Participating states and 
territories 
Response rate 
2004 1.       NSW 612/739 (83%) 
2.       WA 
3.       TAS 
4.       QLD 
2007 1.       NSW 740/992 (75%) 
2.       WA 
3.       TAS 
4.       QLD 
5.       ACT 
6.       SA 
7.       VIC 
2010 1.       NSW 873/1154 (76%) 
2.       WA 
3.       TAS 
4.       QLD 
5.       ACT 
6.       SA 
7.       VIC 
8.       NT 
2013/2014 1.       NSW Response rate not currently 
available 2.       WA 
3.  TAS 
4.       QLD 
5.       ACT 
6.       SA 
7.       VIC 
8.       NT 
       NSW = New South Wales, WA = Western Australia, TAS = Tasmania, QLD = Queensland, ACT = 
Australian Capital Territory, SA = South Australia, VIC = Victoria & NT = Northern Territory 
 
3.8.3 NPEBBVS Study Population and recruitment  
There are around 20 prison reception centres across Australia; these centres process all prison 
entrants prior to transfer into the general prison population. Processing of prisoners includes 
screening and assessment by reception nurses, psychologists and welfare. During assessment 
prison entrants are asked to participate in the NPEBBVS. Written consent is obtained by 
identified public health nurses at participating prison reception centres.  
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All adult prison entrants (male and female) processed through reception centres during the 
two week survey period are eligible to participate in the NPEBBVS. Those prison entrants 
moving between prisons or court are excluded.  
3.8.4 Conditions under surveillance 
Conditions under surveillance include HBV, HCV, HIV, syphilis, chlamydia and gonorrhoea. 
Table 3 includes diseases monitored, test type and disease markers used in the NPEBBVS.  
Blood and urine samples are collected at admission or within the first 72 hours of an inmates’ 
prison stay. Screening for sexually transmitted infections only began in 2010. 
Table 3. NPEBBVS sample type and disease markers 
Sample Disease Marker 
Blood  Hepatitis B Hepatitis B surface-antibody  
Hepatitis B surface-antigen 
Hepatitis B e-antigen and e-antibody 
Hepatitis B (IgM & IgG) core-antibody 
Hepatitis C Hepatitis C antibody 
HIV HIV antibody 
HIV antigen 
Syphilis Treponema pallidum (syphilis) antibody 
Urine  Chlamydia Chlamydiatrachomatis DNA 
Gonorrhoea Neisseria gonorrhoea DNA 
IgG=Immunoglobulin G  IgM=Immunoglobulin M DNA=Deoxyribonucleic Acid  
Risk behaviours associated with conditions under surveillance are collected via a paper-based 
questionnaire administered by a NPEBBVS nurse at reception. The questionnaire includes basic 
demographic and criminological information, risk behaviours associated with diseases under 
surveillance including drug use, risky injecting practices, sexual risk behaviours, tattooing, 
piercing and tobacco smoking (Appendix 3. NPEBBVS data collection tool). 
3.8.5 Sample collection and pathology 
The NPEBBVS offers an enhanced screening period at participating reception centres. 
Reception nurses are integral to the NPEBBVS process; as they recruit prison entrants, 
administer the questionnaires and collect biological samples. Public health nurses involved in 
the survey have venepuncture and pre and post-test counselling experience. Blood and urine 
samples are ideally collected on the same day at prison entry and survey completion (however 
due to time constraints and limited resources samples can be collected within the first 72 
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hours after entering prison). Samples are sent to the prison medical service’s usual local public 
health laboratory for testing. Results are fed back to participants according to prison medical 
service policy and procedures, providing appropriate post-test counselling, education and 
clinical management. If participants have left prison before results are returned, public health 
nurses are required to follow up with the participant in the community. Laboratory and 
medical notifications of reportable diseases are provided to the appropriate jurisdictional 
health department as per usual notification procedures. For the NPEBBVS, test results are 
retrieved from medical records by a designated NPEBBVS public health nurse and compiled 
with their corresponding completed NPEBBVS questionnaires and sent to the Kirby Institute 
(paper based). The Kirby Institute receives positive, negative, equivocal and not tested 
information for each NPEBBVS participant who has been screened.   
3.8.6 Data management 
The NPEBBVS coordinator in each jurisdiction sends complete questionnaires and test results 
to the Kirby Institute. A data entry person is employed at the Kirby Institute to enter survey 
data from paper based surveys into a database. Data are cleaned and coded for analysis. 
Reports include comprehensive national, state and territory data and are distributed to 
stakeholders such as prison public health and medical staff, health departments, peak BBV and 
STI organisations and policy makers. Data for all survey years are stored at the Kirby Institute 
according to National Health and Medical Research Centre (NHMRC) guidelines. See Figure 1 
for system process and data flow. 
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Figure 1. NPEBBVS process and data flow chart 
 
 
 
 
 
 
 
 
1. Person enters prison at a reception centre 
2. Public health nurse recruits entrant at prison reception centre, and if participant consents will complete: 
a. Survey collection – NPEBBVS tool 
b. Sample collection – blood and urine sample 
3. Sample is sent to laboratory as per prison medical service usual procedure. Results are returned from the laboratory  to the prison medical service,  
4. The public health nurse documents laboratory results with corresponding surveys and follows up results with participants in prison and in the 
community if person has been released back to the community. Surveys are stored securely at the prison medical service. 
5. When complete, surveys with laboratory results are sent from the medical service to the Kirby Institute for: 
a. Data entry 
b. Data cleaning  
c. Analysis  
6. Reporting is conducted by the Kirby Institute
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3.9 Surveillance system performance  
NPEBBVS performance was measured by exploring surveillance system attributes. 
3.9.1 Usefulness  
Usefulness of a surveillance system is demonstrated through its contribution to prevent, 
control and improve understanding of health events and ability to influence(1).  
Document review 
The survey data have influenced clinical practice, program implementation and contributed to 
resourcing in a number of jurisdictions. NPEBBVS outputs include survey reports and 
publications; the following outputs were identified in this evaluation:  
 
1) National Prison Entrants Blood borne Virus Survey, 2004(23) 
2) National Prison Entrants Blood borne virus and risk behaviour survey report 2004 and  
2007(24)   
3) National Prison Entrants Blood borne Virus and Risk Behaviour Survey Report 2004, 
2007 and 2010(5) 
4) Current National Prison Entrants Blood borne Virus and Risk Behaviour Survey Report 
2013/2014 (to be completed by the end of 2014) 
5) The 2004 Australian prison entrants blood-borne virus and risk behaviour survey (25) 
6) Trends in HIV, hepatitis B and hepatitis C prevalence among Australian prisoners - 
2004, 2007, 2010(26) 
Two of the above mentioned peer-review publications (5 & 6) have collectively been cited 30 
times. Other publications planned include an Indigenous and non-Indigenous HBV and HCV 
prevalence comparison (see Chapter 2, Appendix 1), among others. Presentations of NPEBBVS 
data have been conducted by Tony Butler (Kirby Institute) to provide feedback to jurisdictions, 
national committees and various other groups with a prison health agenda.  
The first NPEBBVS and three other key prison based surveys collectively informed the 
establishment of the National Prisoner Health Information Committee (NPHIC) with the role of 
reporting national prisoner health indicators(27). In 2009, the NPHIC led the establishment of 
the National Prisoner Health Data Collection (NPHDC) in which data were also collected over a 
two week period at Australian prisons. The Australian Institute of Health and Welfare (AIHW) 
use NPHDC data  along with national and jurisdictional prison data sets to produce the “Health 
of Australian Prisoners” report(3). NPHDC is the only national prison data set to collect 
comprehensive health data, however, it is self-reported and not diagnostic. For this reason, 
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data for the reporting of communicable diseases in the AIHW ‘Health of Australian prisoners’ 
report are obtained directly from the NPEBBVS.  
People in custodial settings continue to be a priority population in all current National BBV and 
STI strategies(28-31). The incorporation of prisoners as a priority population is the result of a 
number of bodies of work and advocacy including the NPEBBVS. The first national hepatitis C 
strategy 2005-2008 identified no nationally standardised data on hepatitis C from prisons (32, 33). 
In the third strategy(32), the NPEBBVS provided the only national BBV and STI snapshot.. 
Providing the only diagnostic national dataset, the NPEBBVS could be a tool for measuring 
national indicators, particularly for the HCV strategy.  
In recent years the NPEBBVS has become more recognised for its drug related data collected 
as a part of risk behaviour section of the survey. The National Drug Strategy 2010-2015(34)  
identified the need to focus on prison drug supply and demand. The NPEBBVS has application 
in this area and could potentially be utilised in national drug related monitoring, particularly 
for understanding demographic and criminological factors ,and the use of drugs before 
entering prison. Another example of the NPEBBVS cross sectoral application is the use of 
smoking data. Prisoners smoke tobacco at extremely high rates (85%)(24). This finding from the 
NPEBBVS resulted in prisoners being identified as a key group in the National Preventative 
Health Taskforce Report and has resulted in the development of a national summit on tobacco 
smoking in prisons(35). 
Stakeholder Interviews 
NPEBBVS stakeholders discussed how the NPEBBVS was used in their jurisdiction. Responses 
included:  
 As an advocacy tool to raise the profile of prisoner health.  
 Providing evidence to obtain funding to increase or implement on site 
specialty health services.  
 To negotiate collaboration with external health providers. 
 As an advocacy tool for the development of BBV programs and educational 
resources. 
 As evidence to increase treatment provision within prisons. 
 
One of the larger jurisdictions (NSW) conducts a comprehensive inmate health survey(16, 36) 
every five years. The impact of the NPEBBVS is reduced for this jurisdiction as they often use 
their health survey data as an advocacy tool rather than the NPEBBVS. From interviews with 
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stakeholders, no other jurisdiction had a survey like the ongoing inmate health survey. 
Participation in the NPEBBVS for a majority of jurisdictions was seen as a chance to:  
1. Receive a snapshot of disease burden and risk factors in their jurisdictions.   
2. Raise the profile of prison health services at national and state level for both advocacy 
and public health practice purposes. 
3.9.2 Simplicity 
Simplicity is the ease at which a surveillance system operates(1).  
Stakeholder interviews 
There are around 126 prisons around the country and processing of persons through prison 
reception centres before entry to prisons is a common practice across all jurisdictions. By 
focusing on the prison entrant population, operation of the NPEBBVS is narrowed to about 20 
prison reception centres around the country creating a common collection point for all prison 
entrants over a two week period. . Data collection at prison entry is designed to minimise 
prison health service disruption. However, despite this process, difficulties to collect blood and 
urine samples at admission occur due to time constraints, workload and priority of high risk 
patients requiring health assessments on entry. While stakeholders recognised NPEBBVS 
collection at reception centres as the easiest, most systematic and consistent sampling 
method, there were a number of barriers complicating NPEBBVS collection identified, 
including: 
 Prison entrants in a state of withdrawal from substances. 
 Current lengthy jurisdictional entry assessments; another survey is a burden. 
 The high volume of prisoner movements (entry, release, transfer between 
prisons, court and external medical appointments) through the system 
increasing workload of already over stretched prison health service. 
 Competing priorities of high risk entrants (mental health or other health 
issues) requiring immediate attention. 
 Staffing issues – reduced number of staff, increasing imprisonment rate and 
reduced capacity to take on other work. 
One stakeholder reflected on difficulties of screening entrants as follows: 
“A lot of patients have mental health issues ... they are at risk of self-harm, or 
they are violent or they are detoxing so we can’t actually access them to 
conduct the survey. So that can be quite difficult, and I understand why it is 
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focused on new receptions, but it can be difficult in terms of actually being 
able to access those patients.” 
During interviews, stakeholders identified the need for a dedicated public health nurse with 
venepuncture and pre-/post-test counselling experience assigned during the NPEBBVS 
recruitment period. In the absence of ongoing funding to assist jurisdictions over the two week 
period, the issues related to simplicity have somewhat been relieved by the flexibility of the 
NPEBBVS to adapt to jurisdictional needs (see 3.8.3 flexibility). 
Within six months of survey collection, stakeholders receive the NPEBBVS report. Reports 
include overall data by survey year, a comparison to previous years and a breakdown by each 
jurisdiction.  There is no one place online where all NPEBBVS reports can be found, the most 
recent can be downloaded from the Kirby Institute’s website and only one of three NPEBBVS 
reports appeared during literature searches on Medline, PubMed and Web of Science. 
NPEBBVS reports are extensive, while all stakeholders found the reports useful, they also 
thought they could be simplified. During interviews three stakeholders suggested condensing 
the report. Stakeholders also suggested a two page document summarising key findings, such 
a document would be useful for jurisdictions to share with their stakeholders as an advocacy 
tool. 
3.9.3 Flexibility 
Flexibility is the ability of a surveillance system to accommodate change and adapt 
appropriately(1).  
Stakeholder interview and document review 
Survey tool flexibility 
Being a longitudinal cross sectional survey, a set methodology with core questions is 
necessary, and this has been achieved with the NPEBBVS. However, over time there has been 
additional survey questions included. Some jurisdictions have seen the NPEBBVS as an 
opportunity to add jurisdiction specific questions, and nationally a number of questions have 
been added or adjusted over time to collect relevant information. For example, a government 
funded National Human Papillomavirus (HPV) vaccine program was implemented in 2007 in 
schools and the community for women under the age of 28 years(37). An additional question 
about HPV vaccination was added to the NPEBBVS in 2010.  
In 2010, following consultation with sexual health researchers and clinicians, sexual risk 
behaviour questions were changed from risk behaviours in the last month to focus on risk 
behaviours in the last three months. The change aligned NPEBBVS sexual risk behaviour 
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questions to other general population risk behaviour surveys for future comparison purposes. 
Another change in 2010 saw the inclusion of a demographic question about homelessness. In 
2013, a question about willingness to undertake HCV treatment was included.  
In the future there is potential to include alcohol and mental health questions. Considering the 
existing constraints of time and staffing, broadening of questions and survey scope could 
impact timeliness and in turn acceptability. For consistency and focus, it will be important for 
the NPEBBVS not to move away from its original objectives.  
Operational flexibility 
The NPEBBVS is collected during the same two week period as the community based national 
NSP survey to decrease overlap of clients. However, overtime, particularly in 2013, some 
jurisdictions participating in the NPEBBVS were unable to participate during the set collection 
period. Jurisdictions negotiated a two week survey collection period to accommodate their 
reduced capacity. The inclusion of all jurisdictions in all NPEBBVS moving forward is far more 
valuable than ensuring strict collection periods and demonstrates the flexibility of the 
NPEBBVS to accommodate jurisdictional needs. From 2007-2013,  only 5-6% of NPEBBVS 
participants had reported ever having taken part in the NSP survey(5).  
One stakeholder described the flexibility of the NPEBBVS to accommodate jurisdictional 
capacity: 
 “The capacity for us to select our own two weeks was a God-send. We would 
just not be able to have done it on the planned days because our HR [human 
resource] capacity wouldn’t have allowed for it.” 
Due to lengthy jurisdictional entry assessments, substance use withdrawal and prison system 
operations, some jurisdictions have had difficulties collecting blood and urine samples at entry. 
To accommodate these identified issues jurisdictions can collect a sample within the first 72 
hours after entry. It is acknowledged that resources and jurisdictional operational issues 
provide challenges for the NPEBBVS. The NPEBBVS has proved to be flexible by adapting and 
modifying its content and timelines to accommodate national, state and territory needs 
without jeopardising the ability to meet its core objective.   
3.9.4 Data quality 
Data quality refers to completeness and validity of information gathered by the surveillance 
system(1).  
Data analysis and stakeholder interviews 
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Jurisdictionally, the quantity of data varies due to the overall population size and weekly 
offender intake (Table 4. Prison entrant participation per jurisdiction (% distribution) by survey 
year). The ACT and TAS have a smaller prison population size and therefore have a smaller 
NPEBBVS sample. However, the inclusion of these jurisdictions in the overall data provides 
completeness to national reporting. In stakeholder interviews, smaller jurisdictions saw the 
value in participating and the ability to use national data when advocating, planning and 
developing policy for prison health services. Past NPEBBVS have had a 70-80% response rate of 
entrants over the two week survey period. In stakeholder interviews, it was evident that public 
health nurses were trying to balance tensions between collecting survey data and duty of care. 
Public health nurses were dealing with patients with complex health needs. This affected the 
number of prison entrants they could recruit and the time spent with each individual entrant. 
Table 4. Prison entrant participation per jurisdiction (% distribution) by survey year 
 Survey Year 
Jurisdiction 2004 2007 2010 2013/2014 
NSW 308 (51%) 244 (33%) 254 (31%) 69(9%) 
QLD  140 (23%) 157 (21%) 211 (26%) 282 (36%) 
WA 117 (19%) 98 (13%) 122 (15%) 97(13%) 
Tas 43 (7%) 46 (6%) 32 (4%) 35(4%) 
NT  - -  75 (9%) 60 (8%) 
SA - 27 (4%) 56 (7%) 50 (6%) 
ACT  - 4 (1%) 13 (2%) 27 (3%) 
VIC - 161 (22%) 48 (6%) 173 (22%) 
Total  608 737 811 793 
-= Did not participate   
In states and territories where there are many prisons, movement of prisoners is common. 
Movements do not always coincide with health staff work hours, meaning some entrants will 
be lost to follow up in the NPEBBVS or they will have questionnaires collected but not blood 
and urine samples. One stakeholder explains: 
“... a lot of patients get received into the system, say in one afternoon, and then next 
morning before the nurses start work they are already on a truck to another centre or 
in a truck back to court. So it is difficult to get actual representative data because they 
are on the move so much.” 
Prisoner movements, time constraints and resource issues such as under staffing or absence of 
a dedicated public health nurse at reception centres in combination  cause potential selection 
biases and was leading to loss to follow up. This translates to less testing of participants who 
have completed questionnaires (20-30% of participants each survey year have no samples 
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collected), and missed opportunities to strengthen the NPEBBVS data set.  Systemic issues of 
increasing imprisonment rate, high prisoner movements and under resourcing at reception 
centres were common across jurisdictions. The NPEBBVS operates in a regimented and rigid 
environment, issues like the above stated are ongoing particularly for larger states and 
territories with a high number of prisoner movements daily. 
Data analysis and stakeholder interviews  
Data completion and quality were examined through analysis of NPEBBVS data in regards to 
the system objectives listed below.   
NPEBBVS objective 1:  Monitor BBV (HBV, HCV, HIV), and STI (syphilis, chlamydia and 
gonorrhoea) prevalence among prison entrants. 
NPEBBVS objective 4:  Examine trends in BBVs, STIs, and risk behaviours among prison 
entrants. 
Table 5 depicts BBV status and the number of survey participants not tested, ranging from 19% 
to 49% for different tests over the eleven year period of the surveys. This is a reflection of the 
prison system and the operational boundaries of the system, and not necessarily the ability for 
the surveillance mechanism to capture these data. Over the two weeks of collection, each 
jurisdiction is conducting enhanced screening of prison entrants; this is a stretch on the prison 
health system’s usual operation. In 2013, sample testing data were poor due to resourcing 
issues, and participants not tested ranged from 29% to 49% across different BBVs (Table 5. 
Number and percentage of NPEBBVS participants tested for BBVs).  
Key themes identified as putting pressure on resources within the prison system and therefore 
impacting the NPEBBVS function include: 
 Increasing prison population.   
 Poor health and complex needs of those entering prison needing immediate attention 
 Lack of public health nurses within the prison system. 
 Funding constraints. 
 Competing issues and political environment within and outside of prisons. 
STI testing was introduced in 2010. Testing rates were considerably different between 2010 
and 2013, with higher rates of participants ‘not tested’ in 2013 for all STIs (Table 6. Frequency 
of NPEBBV STI testing). Stakeholder interviews revealed some reluctance around sexual health 
questions by survey administrators and cultural issues when asking sexual health questions in 
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some jurisdictions. Risk factor questions are particularly affected by the survey administrators 
or the participants’ acceptability and comfort to ask and answer. 
Table 5. Number and percentage of NPEBBVS participants tested for BBVs 
 Survey year (n=number of surveys completed) 
 
2004 
n=608 (%) 
2007 
n=737 (%) 
2010 
n=811 (%) 
2013 
n=793 (%) 
Hepatitis C antibody 
Negative  299 (49) 380 (52) 510 (63) 393 (50) 
Positive 155 (26) 207 (28) 141 (17) 168 (21) 
Equivocal 3 (<1) 4 (<1) 1 (<1) 2 (<1) 
Not tested 151 (25) 146 (20) 159 (20) 226 (29) 
Hepatitis B core antibody 
Negative  360 (59) 445 (60) 426 (53) 374 (48) 
Positive 87 (14) 120 (16) 101 (13) 82 (10) 
Equivocal 3(<1) 2 (<1) 0 1 (<1) 
Not tested 158 (26) 170 (23) 284 (35) 329 (42) 
Hepatitis B surface antigen 
Negative  440 (72) 571 (78) 596 (74) 389 (49) 
Positive 13 (2) 14 (2) 13 (2) 13 (2) 
Equivocal 0 0 0 1 (<1) 
Not tested 155 (26) 152 (21) 202 (25) 384 (49) 
HIV         
Negative  447 (74) 580 (79) 661 (82) 501 (64) 
Positive 3 (1) 4 (1) 0 0 
Equivocal 0 2 (<1) 0 0 
Not tested 158 (26) 151 (21) 150 (19) 286 (36) 
 
There were good response rates for number of partners in the last three months, 14-18% of 
participants did not respond to condom use questions however it is not known if this is due to 
not being asked or the invasiveness nature of the question (Table 7. NPEBBVS sexual behaviour 
and risk). Condom use in the last three months with both female and male partners was 
introduced to the NPEBBVS in 2010. This question appeared to be causing confusion at a data 
collection and/or data cleaning point. Review of this question to better understand findings for 
both male and female participants would be beneficial, and may require specific training at 
point of collection or understanding at a data cleaning phase for conformity (Table 7. NPEBBVS 
sexual behaviour and risk). 
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Table 7. NPEBBVS sexual behaviour and risk 
 
Survey year (n=number of surveys completed) 
  
2004 
n=608 (%) 
2007 
n=737 (%) 
2010 
n=811 (%) 
2013 
n=793 (%) 
Number and gender  of sexual partners in the last 3 months   
No sex in last 3  months   121 (15) 108 (14%) 
1-5 partners     628 (77) 605 (79) 
6-10 partners     28 (5) 33 (4) 
10+ partners     19 (2) 11 (1) 
Missing     15 (2) 36 (5) 
1 or more female sexual partners in last 3 months 612 (76) 573 (76) 
Male entrants  104 (84) 536 (86) 
Female entrants   8 (57) 14 (17) 
1 or more male sexual partners in last 3 months 75 (9) 81 (11) 
Male entrants  
 
15 (54) 5 (1) 
Female entrants   
 
60 (83) 77 (75) 
Condom use at last sex       
Yes 155 (26) 169 (23)     
No 443 (73) 563 (76)     
Missing 10 (2) 5 (<1)     
Condom use with regular female sex partner     
Never      325 (40) 338 (43) 
Always      73 (9) 43 (6) 
Sometimes     73 (9) 82 (11) 
Not applicable     201 (25) 178 (23) 
Missing     139 (17) 140 (18) 
Condom use with casual female sex partner     
Never      96 (12) 110 (14) 
Always      66 (9) 44 (6) 
Sometimes     53 (7) 66 (9) 
Not applicable     488 (60) 447 (57) 
Missing     107 (14) 114 (14) 
Condom use with regular male sex partner     
Never      48 (6) 15 (2) 
Always      9 (1) 15 (2) 
Sometimes     9 (1) 37 (5) 
Not applicable     29 (4) 506 (65) 
Missing     716 (88) 182 (23) 
Condom use with casual male sex partner     
Never      12 (2) 7 (<1) 
Always      5 (<1) 9 (1) 
Sometimes     4 (<1) 7 (1) 
Not applicable     72 (9) 542 (69) 
Missing     718 (89) 216 (28) 
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Table 7 continued. NPEBBVS sexual behaviour and risk  
  
2004 
n=608 (%) 
2007 
n=737 (%) 
2010 
n=811 (%) 
2013 
n=793 (%) 
Ever paid  for sex in the last month 
Yes 8 (1) 14 (2)   20 (3) 
No 586 (96) 713 (97)   735 (93) 
missing 14 (2) 10 (1%)   38 (5) 
If yes, did you use a condom       
Yes  4 (50) 6 (43)   7 (35) 
no 3 (38) 5 (36)   5 (25) 
missing 1 (13) 3(21)   8 (40) 
 
Table 6. Frequency of NPEBBV STI testing 
 Survey year 
 
2010 
n=811 (%) 
2013 
n=793 (%) 
Chlamydia 
Negative 461 (75) 470 (59) 
Positive 26 (4) 23 (3) 
Equivocal 0 2 (<1) 
Not tested 132 (21) 228 (38) 
Gonorrhoea 
Negative 473 (76) 490 (62) 
Positive 3 (1) 1 (<1) 
Equivocal 0 2 (<1) 
Not tested 143 (23) 230 (38) 
Syphilis 
Negative 471 (76) 505 (64) 
Positive 23 (4) 7 (1) 
Equivocal 1 (<1) 1(<1) 
Not tested 124 (20) 280(35) 
 
NPEBBVS Objective 2: Collect ongoing information on risk behaviours such as drug use, high 
risk injecting practices, sexual risk behaviours, tattooing, and tobacco 
smoking among prison entrants. 
NPEBBVS Objective 6: Provide a snapshot of BBVs and risk behaviours in a national sample of 
non-injectors who are at risk of exposure to BBVs. 
Prison entrants who had history of injecting drug use (IDU) in the last month was consistent 
over time between 25-38% and data completeness for this variable was good. For this variable 
only 19 out of 2634 instances of incompleteness occurred over the four survey years, however 
we must consider the fact that illicit drug use particularly on entry to prison may not be 
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accurately reported (Table 8). Analysis of risk behaviours such as frequency of injecting, 
sharing of needles and syringes, and injecting equipment are only calculated among those who 
have injected in the last month. Completeness of variables corresponds with the number of 
people who injected in the last month. 
Table 8. NPEBBVS frequency of risk factors over survey year 
  
2004 
n=608 (%) 
2007 
n=737 (%) 
2010 
n=811 (%) 
2013 
n=793 (%) 
Frequency of injecting in the last month  
Never injected 247 (41) 333 (46) 458 (57) 398 (55) 
Injected in last month 225 (38) 247 (34) 199 (25) 215 (30) 
Did not inject in the last month 125 (21) 151 (21) 150 (19) 102 (14) 
Missing  11 (2) 6 (<1) 4 (<1) 3 (<1) 
Frequency of sharing needle and syringe in last month  
Did not share 157 (70) 162 (67) 137 (73) 174 (81) 
Shared  68 (30) 80 (33) 52 (28) 41 (19) 
Ever sharing injecting equipment in the last month 
Did not share 164 (73) 136 (59) 127 (67) 52 (25) 
Shared  61 (27) 96 (41) 62 (33) 158 (75) 
Any tattoos         
Yes 368 (61) 456 (62) 484 (60) 532 (67) 
No 232 (38) 280 (38) 310 (38) 232 (29) 
Missing 8 (1) 1 (<1) 17 (2) 29 (4) 
Any tattoo in the last month         
Yes  69 (19) 135 (30) 148 (31) 168 (32) 
No 295 (80) 319 (70) 329 (68) 360 (68) 
Missing 4 (<1) 2 (<1) 7(1) 4 (<1) 
Ever smoked cigarettes 
Yes   679 (92) 759 (94) 699 (88) 
No   58 (8) 51 (6) 67 (9) 
Missing   0 1 (<1) 27 (4) 
Current smoker         
Yes   626 (92) 690 (85) 629 (79) 
No   52 (8) 119 (15) 63 (8) 
Missing   1 (<1) 2 (<1) 7 (<1) 
 
NPEBBVS objective 3:  Monitor BBVs, STIs and associated risk behaviours in Indigenous and 
non-Indigenous prison entrants. 
Completeness of Indigenous status is very good. From 2004 to 2013 only 25 out of 2639 
records have not included Indigenous status (Table 9). Survey reports include Indigenous and 
non-Indigenous breakdown, and there is currently a BBV Indigenous, non-Indigenous 
comparison paper being prepared for publication (Chapter 2, Appendix 1).  
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Table 9. NPEBBVS Indigenous status completion by survey year 
Indigenous status 2004 
n=608 (%) 
2007 
n=737 (%) 
2010 
n=811 (%) 
2013 
n=793 (%) 
Indigenous  102 (17) 128 (17) 260 (32) 260 (33) 
Non-Indigenous 494 (81) 601 (82) 551 (68) 525 (66) 
Missing 12 (2) 8 (1) 0 8 (1) 
 
The Indigenous entrant numbers allow for analysis among complete variables like injecting 
drug use, but when looking at risk factors among people who inject by Indigenous status, these 
numbers are too small to compare by year. Women prison entrants account for a smaller 
percentage of survey participants, only up to 14% of the NPEBBVS survey sample each year, 
this creates difficulties in understanding BBVs, STIs and risk factors among female prison 
entrants (Table 10. NPEBBVS Gender frequency by survey year). 
Table 10. NPEBBVS Gender frequency by survey year 
Gender 
2004 
n=608 (%) 
2007 
n=737 (%) 
2010 
n=811 (%) 
2013 
n=793 (%) 
Male  538 (89) 666 (90) 734 (90) 684 (86) 
Female  69 (11) 71 (10) 77 (10) 109 (14) 
Transgender 1 (<1)  -  -  - 
 
Data completeness for variables relating directly to NPEBBVS objectives were relatively 
complete. Issues in data completeness were related to sample collection for diagnostic testing. 
A closer look at the process of sample collection (blood and urine) for future survey iterations 
may improve testing rates. Again, it comes back to resourcing, including having a dedicated 
public health nurse without other duties to focus on recruiting and collecting survey 
information. Sexual health questions are relatively complete, but not tests, and lower 
prevalence of STI infections makes drawing conclusions based on sexual risk behaviours 
difficult.   
3.9.5 Acceptability 
Acceptability includes both participant and the organisational willingness to be involved or 
contribute to the surveillance system(1). Stakeholder interviews 
Stakeholder interviews revealed that acceptability by jurisdictions was highly dependent on 
resources. Most jurisdictions discussed reduced capacity to take on other work and the impact 
of increasing imprisonment rates on health service staff, capacity and budget. 
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Allocating staff to dedicate time to NPEBBVS collection over the survey period put a burden on 
usual prison health service operations. Most jurisdictions noted the survey time frame of two 
weeks as acceptable, as longer time frames would create issues relating to rostering and 
health service operation.  
The NPEBBVS does not have ongoing funding. The national survey coordinator based at the 
Kirby Institute negotiates with state and territory health departments and corrective/justice 
health services to provide funding and resources during the survey period. Jurisdictions are 
asked to provide a core amount of money for the central coordinator based on the size of the 
prisoner population. In the current funding model jurisdictions pay for extra pathology costs 
and other in-kind expenses such as state coordinator, additional health services staff and 
public health nurses. This is a long negotiation process undertaken well in advance of each 
survey collection period. The willingness of state and territory health departments and prison 
health services to provide both funding and resources demonstrate jurisdictional support for 
the NPEBBVS and acceptability for the aims, objectives and outputs of the NPEBBVS. 
Reception is a relatively acceptable place to conduct the NPEBBVS although this varied across 
jurisdictions. Gaining access to patients at reception seemed the best vantage point in terms of 
information gathering as this operation is consistent across jurisdictions. Every prison entrant 
is processed through a reception centre regardless of jurisdiction, but exit surveys have found 
inconsistencies in the ability to monitor all prisoners exiting the system(3). During stakeholder 
interviews, nurses administering surveys said the survey was easy to navigate and most 
questions were acceptable to participants. Training was provided to public health nurses by 
the central coordinator based at the Kirby Institute or coordinator based at jurisdictions with 
NPEBBVS experience. People administering the survey may benefit from receiving educational 
material around asking sensitive questions. More buy-in from nurses at the stage of writing 
publications and analysing the data may also assist in gathering more complete data sets and 
promoting the usefulness of the survey outcomes to individual and organisational practice. 
Response rates of people entering participating prison reception centres have been consistent 
over survey years at 83% in 2004, 75% in 2007 and 76% in 2010. (Further information not yet 
available from reception centres is required to calculate 2013/2014 response rate). 
Stakeholders who have collected data for the NPEBBVS said prison entrants were relatively 
keen to participate; one stakeholder said the staff emphasize to entrants that the survey is 
national and entrants like the idea of being a part of a national survey. One stakeholder talked 
about environmental pressures and volatilities on both participants and survey administrators:  
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“they [prison entrants] have been bombarded with questions plus 
geographically dislocated from their life, the questions are invasive and 
environmentally you have to have somewhere they feel safe to answer the 
questions and that can’t always be afforded during a reception and particularly 
if we don’t know a client that is our highest risk, for any prison it’s the highest 
risk period of time, volatilities can present themselves” 
Due to logistical reasons, people entering prison and participating in the NPEBBVS were not 
interviewed for the purposes of this evaluation. Being able to understand acceptability from 
the prison entrant perspective would provide greater understanding of acceptability. 
3.9.6 Representativeness 
Representativeness encompasses accuracy to describe the population (person and place) over 
time(1).  
Stakeholder interviews, data analysis and document review 
In 2013, the Australian prison population reached over 30 000 people for the first time(2). The 
NPEBBVS sample represents 3% of the overall prison population. Never-the-less, both prison 
and community based prevalence studies from different jurisdictions are consistent with 
NPEBBVS findings,(12,16,38) externally validating NPEBBVS HCV, HBV and injecting prevalence 
results. The NPEBBVS has been collected four times over the last 12 years. With continuation, 
it has the potential to be much like the ongoing NSP survey which has provided a valuable 
longitudinal dataset of BBV prevalence, injecting drug use and risk behaviours in the general 
community(38).  
Two jurisdictions raised the issues of population, geographic and service provision variation 
within their state or territory. Both jurisdictions noted a two week period doesn’t allow for an 
adequate representation of the overall prison population. This included remote and non-
metropolitan comparisons which would be beneficial, but under the current methodology 
would be difficult to capture. Two stakeholders mentioned the value in targeted sampling for 
specific populations (women and remote entrants); however, increasing time of collection 
would have resource implications. One stakeholder discussed implications of the 
underrepresentation of women in their jurisdictional sample:  
“Female prison population is much smaller than the male population. The 
numbers for females ... was 9 or 10 and none of them came up with hep C 
positivity and that sort of gives a false representation when we know the 
numbers in female prisoners [with HCV] is generally higher” 
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Gathering a representative sample is a juggling act of epidemiological rigour, resources, prison 
setting constraints, prison population issues and meeting the objectives of the surveillance 
system. 
3.9.7 Timeliness 
Timeliness incorporates timeframes of all steps within the surveillance system(1).  
Interviews 
The NPEBBVS is collected over a two week period every three years but from start to finish, 
the survey takes around 18 months to plan, implement and conclude, leaving a 12 month 
downtime period before repeating the process. The central coordinator begins negotiation 
with jurisdictions regarding funding and ethics approval 12 months prior to survey collection. 
The coordinator provides one day of NPEBBVS training for prison medical staff in each 
jurisdiction before surveys are collected. Laboratory results are received by prison medical 
services as per usual practice. Once laboratory results are received by prison medical services, 
a public health nurse compiles results with corresponding surveys. All documents are then sent 
to the central coordinator at the Kirby Institute. Prison health services provide funding for 
survey pathology costs therefore timeframes related to laboratory aspects of the survey were 
out of the scope of this evaluation. Altogether, public health nurses could be engaged in study 
activities for up to a month depending on their availability to compile results with surveys. The 
time from data entry and cleaning to producing a printed report can take up to six months. The 
central coordinator of the NPEBBVS is not a funded role and therefore the NPEBBVS is not a 
primary focus of work, extending the timeline of some survey steps. Additionally lack of 
funding for a dedicated data manager delayed the time between survey collection and 
distribution of findings. 
  
NPEBBVS collection every three years was acceptable to all jurisdictions and related mainly to 
resource availability. The three year time period was adequate for allowing jurisdictions time 
to use the findings to generate outcomes for their service provision. One stakeholder reflected 
on the time frame: 
 
“I definitely wouldn’t recommend it sooner, particularly because of the stress that it 
does put on the public health nurses. I think the main focus in terms of time should be 
how long it takes for each organisation to absorb their information and timing to 
changing service planning appropriately.” 
At admission to prison, the interview process can take up to 25 minutes. This is additional time 
on top of other assessments required by prison protocols (protocols and entrant assessment 
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vary by jurisdiction). Multiple jurisdictions collect samples within the first 72 hours of entrants’ 
incarceration. One jurisdiction opted to do next day survey collection due to time constraints, 
entry protocols and its impact on entrants: 
 
“We have a forty-five minute health induction. I can’t tack a twenty-five minute BBV 
survey on the end of that, particularly when for our cohort, most of them have spent 
the night in custody, had a police questionnaire, been to court, come to prison, had 
the prison questionnaire then come to health and had the health questionnaire then 
fronting another questionnaire. It’s just not going to happen. It becomes problematic 
in a lot of ways, but that is our current practice. But they were all caught the following 
day if they were still in custody.” 
 
Timeliness and a number of the attributes ended up being discussions related to resourcing of 
prisons to cope with the increasing incarceration rate and the specific issues unique to the 
prison setting such as, prisoner’s complex needs, movement of prisoners in short timeframes 
and nursing roster hours.  
3.9.8 Stability 
Stability of a surveillance system assesses the reliability of the system to operate without 
failure(1).  
Stakeholder interviews  
It was evident from stakeholder interviews that the NPEBBVS was driven by champions in 
jurisdictions. Some identified the potential for the survey to lose momentum if champions 
were to leave prison health services. Stakeholders recognised the importance of gaining prison 
medical director’s support in conducting the survey. Currently the survey is housed at the Kirby 
Institute, however it has moved to different organisations with the originator of the survey and 
national coordinator, Tony Butler. Gaining ongoing funding for the NPEBBVS would allow for 
the survey to be based at one organisation and not be so reliant on an individual driver. 
Ongoing funding would allow for a dedicated central coordinator, leading to improved 
communication with stakeholders. Dedicated resources could assist with translation of the 
NPEBBVS into actionable state and territory strategies and cultivate ongoing collaboration 
across jurisdictions. One participant reflected on possibilities if properly funded: 
“The key to more sustainability is having more buy-in from jurisdictions, but it is really 
hard without a central budget to have ongoing teleconferences and having someone in 
the background writing papers and engaging people.” 
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Stability is very much reliant on funding and resources. The current model of funding is far 
from ideal. The outcomes and uses of the NPEBBVS warrant improved stability.  
3.10 Limitations of the evaluation  
There are a number of limitations to this evaluation. Inability to interview people (prison 
entrants) who have participated in the survey is an obvious limitation to understanding 
acceptability from all perspectives. It would have been beneficial to do a cost benefit analysis, 
but due to time constraints this was not possible, but this may be of benefit in the future to 
advocate for an ongoing funding source. A number of jurisdictions did not participate in the 
stakeholder interviews as part of the evaluation. As jurisdictions are diverse, full participation 
would provide more comprehensive evaluation findings. Operation and governance in each 
state and territory are different, and each has its own unique barriers and strengths. 
Jurisdictions’ practices influenced the process of collecting the NPEBBVS in each jurisdiction, so 
evaluating processes of the survey were sometimes difficult to compare between jurisdictions. 
3.11 Conclusions    
In the absence of a national prison BBV and STI surveillance scheme, the NPEBBVS provides the 
only national prison based BBV and STI snapshot and trend analysis over time.   
The data collected as a part of the NPEBBVS are used to describe BBVs, STIs and risk 
behaviours to meet the objectives of the NPEBBVS, which is demonstrated in a number of 
outputs(5, 23-26). 
The NPEBBVS achieves its purpose and objectives; from a data gathering perspective it has 
proven to be effective through its many applications in policies and guidelines. Despite being a 
smaller snapshot of the wider offender population, NPEBBVS data are consistent with other 
jurisdictional cross sectional BBV prevalence studies. Overall, the main issue affecting all 
attributes, jurisdictions and the operation of the NPEBBVS in general, is limited resources. 
Commonwealth funding (ongoing) would enable smoother operation and increase data quality 
by improving biological sample collection, by supporting jurisdictions to employ dedicated 
public health nurses during survey collection and a central coordinator position.  
At a national level it is evident that it has been challenging to get all jurisdictions involved, and 
long negotiation periods are required for participation in the NPEBBVS. Champions at each of 
the prisons need to be increasingly supported to advocate for the NPEBBVS. Ongoing 
commitment from jurisdictions could be formalised to ensure the continuation of the 
NPEBBVS, creating more stability and reducing the risk of the NPEBBVS losing momentum 
when champions leave.          
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3.12 Recommendations 
 The main recommendation from this evaluation is the absolute need for the ongoing 
collection of the NPEBBVS. There are areas that could improve, but overall the survey 
meets its objectives. 
 
 A central coordinator is needed to provide consistent communication between all 
stakeholders on an ongoing basis and facilitate research translation and collaboration. 
 
3.12.1 Report and data 
 Simplification of reporting jurisdictional data would be beneficial, particularly a two 
page summary report for jurisdictions to share with their stakeholders and 
management. 
 
 Targeting women’s prison reception centers for a longer duration (four weeks) would 
allow for a larger female sample, and ability to understand the female offender 
population would be beneficial in terms of planning and resourcing these centers.  
 
 Achieving more buy-in from prison nurses or other prison staff to be a part of the 
reporting phase of NPEBBVS, for example through publication, could increase prison 
sector research capacity. 
3.12.2 Funding 
The current funding model is not ideal and ongoing Commonwealth funding would allow 
for stability through: 
 All jurisdictional involvement in every survey year moving forward. 
 Dedicated public health nurses to focus on collecting surveys and samples over the 
two week collection period. 
 Cost coverage of pathology (currently paid by jurisdictions).  
 A dedicated person to coordinate from start to finish, stay in contact with stakeholders 
and develop output during the 12 months in between surveys.   
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Appendix 1. Participant Information and consent form 
HREC Approval No:  2014-7-30 
THE UNIVERSITY OF NEW SOUTH WALES AND THE KIRBY INSTITUTE  
PARTICIPANT INFORMATION STATEMENT AND CONSENT FORM 
Evaluation of the National Prison Entrant Blood Borne Virus Survey  
Investigator: Dina Saulo   
Introduction 
You are invited to take part in the Evaluation of the National Prison Entrant Blood Borne Virus Survey 
(NPEBBVS). You have been invited because of your involvement as a stakeholder of the NPEBBVS, your 
contact details were obtained as a result of your involvement. 
This Participant Information Sheet/Consent Form tells you about the research project. It explains the 
processes involved with taking part. Knowing what is involved will help you decide if you want to take 
part in the research. 
What is the purpose of this research? 
The purpose of this research project is to formally evaluate the NPEBBVS, an evaluation is important to 
ensure the capturing and monitoring of conditions of public health importance is effective, efficient and 
meeting the NPEBBVS objectives. The evaluation will consists of stakeholder interviews with people 
involved at all different levels of the NPEBBVS system.  
Why have I been invited to participate in this research? 
You have been invited to participate in a consultative interview because you are a stakeholder of the 
NPEBBVS. Your involvment in the NPEBBVS,wether it be at a managment or reception center level at 
participating prison facilities or policy, data and reporting level, your knowledge and insight into the 
NPEBBVS survey processes or data as a  stakeholders is grealty valued. 
Description of study procedures and risks 
If you decide to participate: 
Consent  
You will be asked to provide written consent to take part in a one-on-one interview with the 
investigator. This may be by phone or face to face depending on logistics. Consent to audio record will 
also be asked of participants, you may refuse to be audio recorded in which case the investigator will 
scribe notes during the interview process. 
Interview process 
You will be asked to participate in a semi-structured interview about the NPEBBVS in relation to the 
following attributes; Simplicity, flexibility, data quality, acceptability, representativeness, timeliness and 
stability. Interviews will take 30-60 minutes. 
The information you provide will be confidential. The interview will be recorded for the purpose of 
transcribing; after the interview is transcribed the audio recording will be erased. Only the investigator 
will have access to interview data. The investigator will ensure participants organisational association 
and individual identity are not identifiable in any research outputs. On obtaining consent from 
participants a number and involvement in the system will be assigned, for example; “Stakeholder 1, 
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survey collector”, “Stakeholder 2, medical director”. Jurisdiction of participant will be kept anonymous 
to further provide anonymity. 
What are the possible benefits of taking part? 
Your involvement could potentially inform improvements in the NPEBBVS system in the future. We 
cannot and do not guarantee or promise that you will receive any benefits from this study. 
What are the alternatives to participation? 
Participation in this research is voluntary. If you don’t wish to take part, you don’t have to. Your decision 
not to participate will not affect your future relations with the University of New South Wales or the 
Kirby Institute.  
Confidentiality and disclosure of information 
Any information that is obtained in connection with this study and that can be identified with you will 
remain confidential and will be disclosed only with your permission, except as required by law.  If you 
give us your permission by signing this document, we plan to publish the results in the form of a short 
report for NPEBBVS coordinators and stakeholders. Additionally; Dina Saulo will be publishing data on 
the evaluation of the NPEBBVS as in a surveillance evaluation chapter of her Master of Applied 
Epidemiology thesis as a part of an Australian National University degree. Information published will be 
in relation to the above stated attributes and recommendations for future survey rollout. In any 
publication, information will be provided in such a way that you cannot be identified. Information 
provided will be stored securely for 7 years after the interviews in compliance with ethics guidelines. 
Recompense to participants 
There will be no remuneration or additional cost attached to participating in this study and you may not 
directly benefit from participation in the study. 
Complaints 
Complaints may be directed to the relevant Ethics Secretariat, details of which are provided below. Any 
complaint you make will be investigated promptly and you will be informed of the outcome.  
University of New South Wales HREC  
02 9385 4234 or humanethics@unsw.edu.au 
 Application ID: 2014-7-30  
 
Australian National University HREC 
02 6125 3427 or human.ethics.officer@anu.edu.au 
Application ID: 2014/555 
 
Feedback to participants 
If you would like to recieve a summary report of the eveluation please indicate to the investigator 
during the interview process. 
Your consent 
If you decide to participate, you are free to withdraw your consent and to discontinue participation at 
any time; you can do this by filling out the revocation consent form below and returning to Dina Saulo. 
You do not need to provide a reason and will not prejudice future relations with the University of NSW 
or the Kirby Institute. Once withdrawn, information from interviews conducted with you will not be 
included in any publication. 
If you have any questions, please direct them to Dina Saulo: 
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Dina Saulo  
Master of Applied Epidemiology student, Kirby Institute  
P: 02 9385 9002 or 0447 003 090 
E: dsaulo@kirby.unsw.edu.au 
 
You will be given a copy of this form to keep.      
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THE UNIVERSITY OF NEW SOUTH WALES AND THE KIRBY INSTITUTE 
PARTICIPANT INFORMATION STATEMENT AND CONSENT FORM (continued) 
Evaluation of the National Prison Entrant Blood Borne Virus Survey  
Investigator: Dina Saulo  
Declaration by Participant 
 I have read the Participant Information Sheet or someone has read it to me in a language that I 
understand.  
 I understand the purposes, procedures and risks of the research described in the project. 
 I have had an opportunity to ask questions and I am satisfied with the answers I have received. 
 I freely agree to participate in this research project as described and understand that I am free to 
withdraw at any time during the project without affecting my future care. 
 I understand that I will be given a signed copy of this document to keep. 
 
……………………………………………………                                              .……………………………………………………. 
Signature of Research Participant                                                                        Signature of Witness   
……………………………………………………                                              .……………………………………………………. 
 (Please PRINT name)     (Please PRINT name) 
……………………………………………………                                              .……………………………………………………. 
Date       Nature of Witness 
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REVOCATION OF CONSENT 
Evaluation of the National Prison Entrant Blood Borne Virus Survey  
Investigator: Dina Saulo  
 
I hereby wish to WITHDRAW my consent to participate in the research proposal described above and 
understand that such withdrawal WILL NOT jeopardise any treatment or my relationship with The 
University of New South Wales, and the Kirby Institute 
……………………………………………………                                              .……………………………………………………. 
Signature                       Date 
……………………………………………………                                               
Please PRINT Name 
The section for Revocation of Consent should be forwarded to: 
Dina Saulo  
Master of Applied Epidemiology student, Kirby Institute  
Justice Health Research Program | The Kirby Institute 
Wallace Wurth Building, Sydney NSW 2052 
T: +61 (0)2 9385 9002 
E: dsaulo@kirby.unsw.edu.au 
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Appendix 2. Stakeholder interview guide 
 
Questions will be asked about usefulness, Simplicity, data quality, representativeness, 
flexibility, acceptability, timeliness and stability. All Questions are not relevant to every 
stakeholder, themes for direction of questioning are provided below along with sample 
questions that could be asked during interviews, dependant on stakeholder involvement in the 
NPEBBVS.  
 
 
Attributes and 
themes 
Questions 
Usefulness  
Outputs  
application 
 
 
 
Simplicity 
process 
impact 
 
 
 
 
 
 
 
 
Data quality  
completeness 
Validity 
Relevance 
 
How are you involved in the NPEBBVS? 
1. How useful is the NPEBBVS for you and your organisation?  
(Probe: use, application of findings, work or funding as a result 
of findings, how could you use it?)  
2. What outputs from the NPEBBVS are you aware of? 
3. The survey has a large focus on injecting, is this appropriate for 
this population; can you see other applications for the data?  
 
The system 
4. What is the process of maintaining the NPEBBVS system every 3 
years? 
(Probe: time and resources, running and maintaining, process of 
coordination, training required) 
The survey 
5. Explain the recruitment process  
6. Does the survey have an impact on the usual operation of the 
reception centre? If so, how 
7. Is the structure of the survey easy to follow? 
8. Are paper based surveys the best way of collecting in this 
setting  
The report  
9. How is the NPEBBVS reported?  
10. Is the report easy to understand and use? (probe: positive and 
negative aspects of the report) 
11. How would you improve reporting of the NPEBBVS? 
 
12. Do you consider the NPEBBVS a valid and necessary 
undertaking? (probe: why, why not, in terms of surveillance use) 
13. Validity of data (Probe: sample size, conclusions, trend over 
time survey collected over a two week period every three years) 
14. What are the ramifications of jurisdictions not participating in all 
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Representativeness 
Sample frame 
Sample size 
trends 
 
 
 
Flexibility 
Modification  
 
Acceptability 
Health staff 
Participant 
 
Timeliness 
System  
Survey  
Reporting  
 
Stability 
Funding  
Sustainability  
 
survey years? (probe: application of data, surveillance) 
15. Is it worth having a sexual health component? (in relation to 
data completeness of sexual health questions) 
16. Is the data from NPEBBVS relevance in the current environment 
and for organisations that might use the data? 
17. Do you think the NPEBBVS is representative of the wider prison 
entrant population? Or prison population 
18. Does a sample collected over two weeks reflect the wider prison 
entrant population? (probe: Can NPEBBVS data be used as a 
yearly prevalence for prison entrants)  
 
19. Is the NPEBBVS survey tool easy to modify (probe: ease of 
change, limitation and ability to modify in the future)  
 
20. Is the survey easy to collect? ( Probe: layout of survey, design, 
difficulty asking questions, workload, extra steps, dynamic of 
setting, retrieving lab results) 
21. On recruitment, what reactions do participants have to the 
NPEBBVS? (collection of specimens, survey questions, extra 
steps) 
22. Would there be a problem with running the survey longer at 
your reception centre?   
23. Are the timeframes of the system adequate (probe:  just the 
time frames on the aspects you are involved in, rollout of 
survey, collection, analysis and reporting)  
24. From enrolment to finish how long does it take to recruit, 
collect survey information and collect bloods and urines?  
25. After the survey how long until you receive the report? 
 
26. Do you know who funds the NPEBBVS? (probe: how funding is 
acquired) 
27. Do you think it is sustainable to run a national survey every 3 
years in prison reception centres?  
28. What do you think would be a more sustainable way or running 
the survey?  
29. What time, resources and organisational support are needed to 
maintain system? 
30. How do you see the survey working in the future 
Is there anything else you would like to tell me about the NPEBBVS? 
How would you improve the survey NPEBBVS? 
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Appendix 3: NPEBBVS data collection tool, 2010. 
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4  Outbreak 
Incident hepatitis C cases detected through a custodial HCV treatment 
program  
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4.1 Abbreviation list 
HCVAb  Hepatitis C antibody 
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ALT  Alanine transaminase 
BBV  Blood borne virus 
CDNA  Communicable Diseases Network of Australia  
HCC   Hepatocellular carcinoma  
HCV  Hepatitis C virus 
HREC   Human Research Ethics Committee  
HITS  Hepatitis Incidence and Transmission Study 
IDU  Injecting drug use 
JHRP  Justice Health Research Program 
NSP  Needle and Syringe Programs 
PCR  Polymerase chain reaction 
RNA   Ribonucleic acid 
SVR  Sustained viral response  
 
Common language used by participants 
Clean  Hepatitis C negative  
Fits  Needle and syringe (injecting equipment) 
Hep C  Hepatitis C virus  
 
 
 
 
4.2 Prologue  
In March of 2013, I was informed by a field supervisor of an in-prison hepatitis C virus (HCV) 
outbreak. I was aware this was a non-traditional outbreak; it was slow moving, where incident 
cases were identified over a two year period in a test and treatment in-prison program, a 
number of different HCV strains had been identified and there were potential constraints 
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including permission to conduct the study, implementation and recruitment restrictions. 
Nevertheless, this project would cover key competencies required to investigate an acute 
public health problem. Primary information about cases of HCV was obtained and a group of 
investigators came together to develop a plan of action.  
I was a part of a core team including Associate Professor Stuart Kinner, Melbourne University, 
the prison Medical Director, Ms Kathryn Snow, Melbourne University and Professor Tony 
Butler, Justice Health Research Program (JHRP), Program Head, Kirby Institute. Our first 
meeting took place in early 2013 to discuss possible approaches to investigate the outbreak 
and roles within the team. It was established that the emphasis of the investigation would be 
for the purposes of research to determine if identified cases were in-prison HCV incidence, to 
understand the extent to which HCV transmission was happening in the facility, and to provide 
recommendations to improve strategies, interventions and possibly lead to reduction in HCV 
exposure among participants. 
My role and participation in the team included: 
 Development of a patient information sheet (Appendix 1) 
 Adaption of a quantitative survey and development of a qualitative interview tool 
(Appendix 2) 
 Input into the ethics application on how I would be conducting interviews, obtaining 
consent and analysing data 
 Ethics was submitted to three Human Research Ethics Committees (HRECs). I prepared 
and submitted one of these ethics applications to a relevant jurisdiction HREC.  
 Attending prison security training  
 Recruiting participants and obtaining signed consent  
 Conducting quantitative and semi-structured qualitative interviews 
 Transcribing and coding semi-structured interviews 
 Entering quantitative data into an Epi Info database  
 Analysing quantitative and qualitative data  
4.2.1 Lessons Learned  
Investigating an acute public health problem or outbreak can take on many different forms 
depending on the context. I learnt that an outbreak investigation can have different aims, in 
this case an emphasis on investigation for the purpose of research to inform or improve 
control measures within a prison facility. Responses to the identified problem can be very 
different. The common steps in investigating an acute public health problem (outbreak 
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investigation ten steps) are transferable and flexible across different scenarios. Combining 
qualitative interviews with a case series study validated quantitative findings in this 
investigation. For me this highlighted the important skill of interviewing people as part of an 
outbreak investigation to truly understand the intricacies of the agent (HCV), host (study 
participant) and environment (impact and challenges presented by the prison setting).   
4.2.2 Public health impact 
This mixed methods approach using outbreak investigation principles had not been 
documented in the custodial setting before. The findings from this study have application to 
harm minimisation strategies in this prison facility. There is potential to generalise these 
findings across other prison facilities as risk factors identified among study participants have 
been documented in prison based studies in other jurisdictions(1). Prisons in other jurisdictions 
should be encouraged to adopt this facility’s approach by making available a range of harm 
minimisation strategies to reduce HCV incidence rates. The findings from this study strongly 
support the growing body of evidence for Needle and Syringe Program (NSP) introduction in 
this prison facility. 
Cases were identified as a result of an HCV treatment program, and it is clear that harm 
minimisation is a priority for the medical services at this facility. The findings of this study 
might assist in improving current strategies. Findings could assist in the improved screening for 
HCV treatment candidates and targeted education materials could be of benefit if targeted at a 
lower literacy level. Also at risk subgroups, such as younger non-injecting drug users, who 
might be more likely to use drugs while incarcerated or be influenced by older inmates, could 
benefit from targeted education.  
This study combined both quantitative and qualitative methods to give prisoners’ perspectives 
of HCV incidence. HCV is a prison issue and therefore prisoners should be given the 
opportunity to be directly involved in the decision making on issues that affect them. Mixed 
method approaches can assist in giving a voice and context to accompany quantitative data. 
4.2.3 Acknowledgments 
Firstly, I would like to acknowledge the men who participated in the study for sharing their 
experiences. Thanks to the prison medical director, Stuart Kinner and Tony Butler for 
identifying this study as a potential MAE outbreak project and allowing me to run with it. 
Special thanks to Emily Fearnley for designing the Epi Info database. Further thanks to Phyll 
Dance, Emily Fearnley, Tony Butler and John Kaldor for your attention and support during 
survey collection, analysis and write up.  
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4.3 Abstract  
4.3.1 Background 
As a result of increased testing through a prison HCV treatment program there was an increase 
of in-prison incident cases from March 2009 (when this prison opened) to May 2013. HCV test 
results and time of imprisonment provided suggestive evidence that 30 cases were possibly 
acquired in custody. The aim of study was to describe and assess the strength of evidence for 
in-prison HCV incidence among 22 people still in custody and better characterise HCV 
transmission in a prison setting to identify effective control measures.  
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4.3.2 Methods 
A mixed methods approach was taken, including both quantitative and qualitative interviews. 
Interviews were conducted at the prison facility with identified participants. Interviews were 
to determine risk behaviour and imprisonment timeframes related to blood exposure between 
time of last HCV negative blood test and HCV positive test during the 50 month period, March 
2009 to May 2013. Descriptive analysis of demographic and risk factor data from quantitative 
surveys were conducted and qualitative interviews were manually coded to extract key themes 
relating to participant experience of HCV. 
4.3.3 Results 
Seven out of 22 potential participants consented to take part in the study. Six of the seven 
participants were classified as HCV in-prison incident cases. It was determined that all in-prison 
incident cases were not notifiable to public health units under the current national newly 
acquired HCV case definition. All six identified cases had a common history of injecting drug 
use and one or more episodes of sharing injecting equipment while in prison. Other exposure 
to blood while in-prison included; hair clippers, tattoos, fights, sport and penile implant. 
Qualitative interviews shed light on prisoner perspectives of HCV; drug use while in prison; 
sharing of equipment and knowledge; and inmate perceptions of HCV results, treatment and 
health. 
4.3.4 Conclusion 
This was an unusual cluster of HCV infection in a prison and the study provides evidence of in 
prison HCV incidence. This finding would imply current harm minimisation and reduction 
strategies are not adequately meeting the needs of a subsection of high risk prisoners. The 
findings of this investigation add to a body of evidence pointing to the need to implement 
NSPs in Australian prisons to complement current strategies. 
4.4 Background 
4.4.1 Hepatitis C 
Estimated globally, 184 million people were living with HCV in 2005(2) and in Australia an 
estimated 210,000 people were living with HCV in 2001(3). HCV can cause liver cirrhosis, liver 
failure and Hepatocellular Carcinoma (HCC). Of those who acquire HCV (acute HCV is 
characterised as HCV within 6 months of infection) around 15-45% will spontaneously clear the 
virus, 55-85% will develop chronic HCV(4), 16% of whom will develop cirrhosis of the liver 
within 20 years of infection(5) and an estimated 1-3% will progress to HCC after 30 years(6). 
There are a number of HCV genotypes and subtypes which vary geographically. In Australia 
HCV genotype 1 (54%) and 3 (39%) are most common, the remaining 7% genotype prevalence 
can be attributed to genotype 2, 4, 5 and 6(7, 8). 
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HCV is a blood borne virus (BBV) transmitted through blood to blood contact with a HCV 
positive person. Risk factors have been identified in a number of studies, the most common 
being injecting drug use and sharing of injecting equipment; transmission routes also include 
unsterile tattooing or piercing equipment, sharing of toothbrushes, razors, and sexual contact 
(1, 9). People are often asymptomatic and may not know they have HCV due to slow disease 
progression.  
HCV antibodies are present in blood 8-12 weeks after acute HCV infection, elevated alanine 
transaminase (ALT) may also be indicative of acute HCV with jaundice and bilirubin in urine 
detectable in some patients(10). HCV antibody positivity is indicative of past or present 
infection. The Polymerase Chain Reaction (PCR) test detects presence of HCV ribonucleic acid 
(RNA), determining current or no infection. PCR RNA can be detected within two weeks of 
acute infection. Additional tests are required for genotype and viral load(11).  
Prisoners are at risk of blood borne viruses while incarcerated(12, 13) with evidence to support in 
prison transmission of HCV(14-16). In Australia, research on HCV in prisons is predominately 
through cross sectional surveys determining demographic characteristics, risk factors and 
behaviours associated with HCV prevalence among offenders. The Hepatitis C Incidence and 
Transmission Study (HITS), a large prospective cohort study has been conducted since 2005. 
HITS actively sought and reported on HCV incidence rates of inmates in 13 New South Wales 
prisons(17-19). Australia is at the forefront of understanding HCV incidence rates, associated 
demographic characteristics, risk factors and related treatment issues. Additionally, Australian 
researchers conducted early work on understanding HCV DNA and genotype effects within the 
prison setting.  
HCV treatment is available for individuals over 18 years of age who are HCV PCR positive. 
Treatment can clear (cure) the HCV virus but does not provide immunity against re-
infection(20). Treatment type and duration is based on HCV genotype, disease stage and 
response to treatment. Duration of treatment for genotypes 1 or 4  is 48 weeks(10).  The 
treatment course includes weekly pegylated interferon injections, twice daily ribaviron and 
daily Simeprevir tablets for 12 weeks. Then an additional 12-36 week course of dual therapy 
weekly pegylated interferon injection plus twice daily ribaviron tablets. HCV treatment for 
genotypes 2 or 3 has a shorter duration of about 24 weeks with interferon and ribaviron. 
Therapeutic drugs are not limited to the above mentioned; the world of HCV treatment is 
advancing with a new wave of superior drugs becoming available(21). 
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Greater than 20% of patients who commence HCV treatment will experience side effects such 
as, but not limited to: fatigue, headaches, fever, muscle pain and/or cramping, insomnia, hair 
loss, joint pain, irritability, anorexia, weight loss, depression and injection site 
inflammation/reaction(22). Side effects of earlier and continuing HCV treatment therapeutics 
are a particular obstacle for treatment up take and compliance. The prison setting provides a 
unique opportunity for treatment due to health care availability, however a number of 
barriers, both actual and perceived exist(23). The next wave of improved treatment and 
combination therapies promise fewer side effects and reduced course duration(24). 
4.4.2 Detecting incident cases 
Incidence is an important measure to describe the number of new cases of a disease. 
Incidence data can be translated into risk of disease, provide projections of disease outcomes, 
assist in cost effectiveness or mathematical modelling and impact on health policy focus and 
funding. HCV is a notifiable disease in Australia, if a patient’s blood tests HCV PCR positive this 
is reportable to jurisdictional public health units by the doctor or laboratory. Reporting a HCV 
case as “newly acquired” (i.e an incident case) requires a HCV PCR positive blood test result 
and clinical evidence  as defined by the current Australian national notifiable disease case 
definition, stated by the Department of Health, Communicable Diseases Network Australia 
(CDNA) (Table 1)(25). The definition does not identify new acquisition of a different HCV 
genotype as a newly acquired infection or an antibody positive, PCR negative individual who 
becomes PCR positive. The definition relies heavily on an antibody negative status before a 
PCR positive test result.  
 
 
 
Table 1. Australian national notifiable diseases case definitions - hepatitis C (newly acquired) 
Reporting - Only confirmed cases should be notified.  
 
Confirmed case 
A confirmed case requires either: 
1. Laboratory definitive evidence 
        OR 
2. Laboratory suggestive evidence AND clinical evidence. 
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Laboratory definitive evidence 
1. Detection of anti-hepatitis C antibody from a person who has had a negative anti-
hepatitis C antibody test recorded within the past 24 months 
               OR 
2. Detection of hepatitis C virus by nucleic acid testing from a person who has had a 
negative anti-hepatitis C antibody test result within the past 24 months 
               OR 
3. Detection of anti-hepatitis C antibody from a child aged 18 to 24 months 
               OR 
4. Detection of hepatitis C virus by nucleic acid testing in a child aged 1 to 24 months. 
Laboratory suggestive evidence 
       Detection of anti-hepatitis C antibody, or hepatitis C virus by nucleic acid testing. 
Clinical evidence 
Clinical hepatitis within the past 24 months (where other causes of acute hepatitis have 
been excluded) defined as 
1. Jaundice 
               OR 
2. Bilirubin in urine 
               OR 
3. Alanine transaminase (ALT) seven times the upper limit of normal.  
Source: Department of Health, CDNA, Australian National Notifiable disease case definitions
(25)
.    
Among a high risk group this definition fails to identify true incidence. People engaged in risk 
behaviour may be HCVAb positive due to the frequency of risk behaviours yet HCV PCR 
negative, and individuals who are PCR positive are at risk of dual infection with other HCV 
genotypes(18). Re-infection or infection by an alternate genotype could be considered as newly 
acquired HCV. The definition does not acknowledge the availability of therapeutic treatment 
options in which a patient may clear HCV and achieve Sustained Viral Response (SVR) (patients 
who achieve SVR will still be HCVAb positive but PCR negative). The Australian diagnostic 
strategy of the Hepatitis C testing guidelines state genotype testing is a predictor of treatment 
dose, therapy and response; but does not touch on genotype testing for diagnosis of re-
infection or co-infection(26). Currently this means patients clearing HCV while on treatment 
who become reinfected will only be considered newly acquired cases (notifiable) if there is 
 
CHAPTER 4 |OUTBREAK 
109 
clinical evidence accompanying, however, most cases of HCV are asymptomatic. Identification 
of serological ALT seven times the upper limit of normal is not possible in all acute HCV cases. 
Taking into consideration the limitations of the current case definition for newly acquired HCV, 
we developed incidence criteria for this study to determine in-prison incidence. In-prison HCV 
incidence was determined if patients met criteria one, two or three set out in Table 2. 
 
4.4.3 Study context, setting and preliminary observations  
Following the expansion of a HCV treatment program at a prison facility in an eastern state of 
Australia, there was an increase in uptake and frequency of HCV testing among people 
incarcerated. As a result of increased testing, 30 prisoners were identified as possible in-prison 
incident cases from March 2009 to May 2013. On further examination of HCV test results and 
time of imprisonment, of these 30 HCV infections there was suggestive evidence that 22 of the 
cases may have been acquired in custody. The preliminary laboratory evidence suggested that 
it was not a point source outbreak as cases in these prison residents were of different 
genotypes. 
The identification of 22 cases of HCV in a single prison facility provided an opportunity to 
better characterise HCV transmission in a prison setting, and to identify potential effective 
control measures. In order to do this we undertook a mixed methods approach including both 
quantitative data collection and qualitative interviews to provide inmate perspective, to 
determine and describe in-prison HCV transmission and incidence. 
4.5 Aims 
The aims of this study were to: 
1. Describe an in-prison case series of newly acquired HCV infection. 
Table 2. In-prison HCV incidence criteria  HCVAb PCR 
1 
On entry to prison −/+ − 
Up to 12 weeks in prison −/+ − 
More than 13 weeks in prison −/+ + 
2 
In-prison HCV treatment – Sustained Virological Response (SVR) −/+ − 
Re-infection while in prison (preferred different genotype) −/+ + 
3 
In-prison spontaneous HCV clearance  −/+ − 
Re-infection (preferred different genotype) −/+ + 
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2. Determine the strength of evidence for in-prison HCV transmission for each 
suspected incident case. 
3. Identify possible modes of transmission for each suspected incident case, in order to 
inform preventive efforts. 
4.6 Methods 
4.6.1 Study type 
This study is a mixed methods case series of HCV infection in a prison setting. Semi-structured 
interviews were undertaken to understand demographic and risk factors. For confidentiality 
reasons all participant and prison facility identifying data has been removed from this report. 
4.6.2 Study population 
At the agreed time of interviews, from the 21st to the 24th July 2014, 16 out of 22 potential 
participants were currently detained at the prison facility.  
4.6.3 Participant selection and recruitment 
The potential sixteen participants were placed in a line list created by the prison medical 
director. The line list was analysed by the medical director, medical service reception and 
correctional staff at the prison for non-associations (people not allowed to associate with each 
other), visiting time schedule and logistical issues (prison guard to prisoner ratio, ability to 
move prisoner from housed area to medical service, times of lock-in or muster and least 
disruption to medical services operation). A timetable of estimated day and time to move 
potential participants from housed areas to the prison medical service for interviews was 
established. Letters were sent to all 16 current detainees on the line list. Letters were 
personally addressed to potential participants from the prison medical director and sent via 
internal mail. The letter described the study and invited individuals to participate in a one-on-
one, survey and semi-structured interview regarding potential risk factors and exposures for 
infection. Included with the letter was a participant information and consent sheet (Appendix 
1). The letter reiterated confidentiality and individuals who chose not to take part in the study 
were asked to dispose of the letter and not discuss the study. The investigator interviewing 
only had a de-identified list of possible participants. During the interview week, possible 
participants whom letters were sent to were further contacted by medical service reception 
staff and asked if they would like to participate in the study. 
4.6.4 Consent process  
Once possible participants had expressed interest in participating they were moved at earliest 
mutual convenience to the medical service and introduced to the interviewer. The interviewer 
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went through study details as found on the participant information sheet and consent form 
(Appendix 1). Participants were asked to give written consent before interviews. 
4.6.5 Survey and Interview tools 
1. Demographic and risk factor survey 
The survey used in this study (Appendix 2) was an adaptation of the HITS interview 
tool(27). HITS is a large ongoing custodial incidence prospective cohort study including 
a survey tool for both pre and post HCV infection. For this study both HITS pre and 
post survey tools were adapted to develop one survey tool for an outbreak scenario. 
When adapting the survey the following were taken into consideration, time frame of 
outbreak, demographics and risk factors between time of last HCV negative blood 
test and HCV positive test during the time period March 2009 to May 2013. 
2. Semi-structured interview 
Semi-structured qualitative interview topics were established including perception 
and diagnosis of HCV, prison network and peer education, stigma, injecting, tattooing 
and treatment. A list of questions was designed as a guide (Appendix 2).  
4.6.6 Interview process 
Interviews were conducted in a prison medical service consult room to provide a level of 
confidentiality to the study. The interview room was in view of the medical service prison 
guard station and a duress alarm was worn by the interviewer for further safety precaution as 
per prison protocol. Each participant took part in an interview process consisting of both a 
demographic and risk factor quantitative and semi-structured qualitative interview. Audio 
recording of interviews was approved at an ethics committee level, but audio recording was 
ruled out at a service provision level. Confidentiality of the participant was of upmost 
importance, therefore interviews were conducted by one investigator and qualitative 
interviews were scribed during interviews by the investigator. The research team decided one 
investigator interviewing and scribing would be more appropriate for the participants due to 
the content of the interviews. For safety reasons a doctor not associated with the research was 
present in the interview room or other medical staff in an adjoining room.  
It was ideal to begin interviews with qualitative interviews to understand each participant’s 
personal experience of HCV testing, diagnosis and treatment within the prison setting before 
moving onto the quantitative survey. In some instances, due to time constraints such as 
muster or lock-in, interviews were conducted with quantitative collection first and the 
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remaining time was used to interview participants about personal perspectives through the 
qualitative component.     
4.6.7 Analysis  
Demographic, risk factor and exposure survey data were entered into an Epi Info database to 
conduct simple descriptive analysis. Qualitative semi-structured interview data were 
transcribed, thematic analysis of interviews was undertaken by first coding of key words. 
Secondly, key words were grouped into themes, and thirdly themes were allowed to emerge 
independently as key words were then analysed into major themes to shed light on the 
ethnographic concepts of HCV incidence among people while in prison. Triangulations of 
quantitative and qualitative findings were integrated to provide an in-depth understanding of 
HCV incidence in prison.  
4.6.8 Ethics   
Ethics approval was obtained from three relevant jurisdictional HRECs. 
4.7 Results 
Seven out of sixteen potential participants consented to take part in the study. The reason for 
refusal was not documented. One potential participant refused at the interview room door 
because he did not want to talk to someone he did not know. The full combined quantitative 
and qualitative interview process took around 60 minutes per participant, however due to the 
constraints of the setting, two interviews were cut short by 30 minutes.  
All seven participants were male, heterosexual, with a mean age of 30 years (range 23 to 40 
years). One participant had an education level above Year 10. All participants were born in 
Australia and one identified as Aboriginal. Four out of seven had been detained in juvenile 
detention centres more than once in their life (recall on number of times in juvenile detention 
was variable, therefore no range reported) and recidivism was high with all seven participants 
incarcerated in adult prisons three or more times in their lives (ranging from three to ten 
times).  
Six out of seven participants reported a history of mental illness, all of whom singled out a 
history of depression during the quantitative survey. However, during qualitative interview the 
individual who reported not having a history of mental illness talked about a state of 
depression when hearing about his HCV diagnosis. This was a common reaction for most 
participants when first diagnosed or when they received news of re-infection. Words used by 
participants to describe this feeling included “sad”, “depressed” and “upset.”   
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4.7.1 Risk factors 
Participants were asked to recall in-prison risk factors potentially leading to blood exposure 
between their last negative HCV test and positive HCV test. Risk factors identified included: 
injecting drug use, haircuts where the scalp or skin was cut, tattoos, undergoing a penile 
implant, sport and fights in which another inmate’s blood came into contact with their eyes, 
mouth or open wound (table 3). Six out of seven participants reported multiple in-prison risk 
factors (table 3). 
Table 3. Risk factors exposing participants to another inmates blood by incident case 
between last negative and positive HCV test while in prison 
Participant  Injecting Haircut Tattoos Fights Sports 
Penile 
implant 
Case 1      -  - 
Case 2    -   
Case 3     -  -  - 
Case 4     -   - 
Case 5    -    - 
Case 6   -  -  -  -  - 
Case 7   -   -  -  - 
Total 7 5 4 3 3 1 
 
4.7.2 Drug use   
All participants had a history of illicit drug use. Six participants reported injecting drugs and 
one participant reported only smoking or taking drugs orally prior to incarceration.  All six 
participants whom reported injecting prior to prison had access to and used clean injecting 
equipment from needle and syringe programs (NSPs). One participant who reported injecting 
on the outside noted primarily smoking heroin, rarely injecting and only if he had clean 
injecting equipment. Between the time of last negative and positive HCV test results, all seven 
participants reported injecting drugs while in prison (Table 3).  
Of those who injected on the outside, five reported injecting drug use decreasing during their 
sentence in which they became HCV positive (Table 4). One participant explained the decrease 
in injecting behaviour was due to availability and expense of drugs. Two participants discussed 
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the need to change the way drugs were taken to essentially get their money’s worth, one of 
whom said:  
 “Well you would have to be a millionaire in here to use the same as outside. 
You definitely wouldn’t smoke drugs it is too expensive.” 
The other person explained: 
 “Before coming inside I never injected drugs, I used to smoke them or eat 
them. I learnt different ways of taking drugs when I came in here.”  
Two participants reported an increase in injecting drug use while incarcerated (Table 4). When 
contextualised by qualitative data, only one participant had a real increase in injecting drug 
use. The other inmate who reported an increase was actually initiated to injecting drug use 
during his prison sentence and did not inject drugs on the outside. Initiation to injecting drugs, 
initiation to sharing injecting equipment and picking up a “habit” was something a number of 
participants made reference to during qualitative interviews.  
Six out of seven participants reported poly-drug use while in prison (table 4). One participant, 
who didn’t report poly-drug use, recalled only one incident of injecting at the start of 
imprisonment when withdrawing and an inability to access the methadone treatment program 
during this time. The participant did mention this was under older policies and he thought 
access to methadone treatment on entry had changed to take into consideration this 
transitional period. 
4.7.3 Sharing of injecting equipment in prison 
Injecting drug use, access to injecting equipment and sharing were predominant factors in HCV 
in-prison incidence. All seven participants believed they became HCV positive while in custody, 
six singled out injecting drug use combined with sharing as the reason for seroconversion in 
custody. 
 
 
 
 
Table 4. Prison injecting drug use by incident case between last negative and positive HCV test 
result 
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Participant Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 
Frequency of injecting 
drug use 
Monthly 
or more 
often 
Daily 
Monthly 
or more 
often 
Monthly 
or more 
often 
Less 
than 
monthly 
Less 
than 
monthly 
Less 
than 
monthly 
Injecting frequency 
during imprisonment 
compared to rest of 
life 
↓ ↑ ↓ ↑ ↓ ↓ ↓ 
Heroin      
 
Buprenorphine 
(Subutex)        
Ice (crystal 
meth/amphetamines)        
GHB/GBH/Liquid 
e/fantasy  
 
    
Cocaine/Coke   
    
Benzodiazepines/ 
Benzos  
  
   
Anabolic/ Steroids 
 
 
    
Other 
opiates/codeine/ 
pethidine/ 
opium/omnopon 
  
 

  
Hallucinogens/LSD/ 
acid/magic/Mushies/ 
Daitura  

    

Ecstasy/E/MDA/ 
MDMA  

 

   
Ketamine/special K 
       
Oxycodone eg. 
Oxycontin, Endone        
Methadone 
 
 
    
Morphine    
  

Speed/base or other 
methamphetamines  
  
   
4.7.4 Access to injecting equipment outside and inside prison 
Participants had access to clean and sterile injecting equipment on the outside and actively 
sought it. All participants, with the exception of one younger participant whose initiation to 
↓=decreasing ↑=increasing 
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injecting was during his current sentence, reported collecting clean injecting equipment to use 
from a NSP “every time I needed” and one participant reported “most times I needed.” One 
person said: 
“Anywhere you go you can get a clean fit or buy them for two dollars from a vending 
machine, so much on the outside [in] every satellite area fits are easy to get.” 
There was a sense of frustration and no control over the lack of access to clean sterile injecting 
equipment while in prison. All participants knew they were at risk of HCV through sharing 
injecting equipment, yet had felt they had no choice apart from cleaning injecting equipment 
with bleach. The quotes from four people below exemplify frustrations and the complications 
of moving from an environment with abundant access to clean injecting equipment to an in-
prison environment which provides no access to clean injecting equipment:  
  “It’s not by choice that I share.”  
“The whole fact that jail doesn’t have clean fits doesn’t change injecting, it 
does change the rate of infection. No clean fits doesn’t change how people 
use. It only changes the rate among clean people. “ 
 “I didn’t really inject much until custody in two thousand and five, I know there 
was a risk and what it does to you [HCV], I didn’t share outside. When I first 
used in prison, first time to use sharing was inside. I was fresh off the streets 
and withdrawing. Clean fits are really available in Sydney, everywhere, really 
available, so I wasn’t used to it.” 
 “I never shared needles before. I had no control over the situation, it was 
someone else’s fit and I was really sick so I just shared it. I have never shared 
on the outside and I had to share, I’ve seen lots of people do that. I was 
hanging out, I haven’t injected much and would smoke [heroin], usually I 
would only inject if the fit was clean.” 
Policy difference between inside and outside environments forced people who inject drugs 
while in prison to engage in high risk behaviour that put them at risk of BBVs. 
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4.7.5 How people are sharing and sourcing injecting equipment 
All seven participants had shared injecting equipment while incarcerated. The quotes below 
from three people shed some light on the circumstances where sharing injecting equipment 
might occur: 
 “Usually there is more than one, like one between two to three people. I only 
really shared since at the [current housed area]. I use with the same three to 
five people.” 
 “I have a fit I share between two to three people but if someone has drugs and 
asks for it I give it to them but only two to three regulars using the fit.” 
 “Every second person has their own equipment I’ve seen one fit used between 
forty blokes, no bleach, no nothing just a quick clean of water.” 
It would appear from interviews that needles and syringes were being made using any 
available material.  
  “I’ve seen people use chicken bones and pens.” 
There was some confusion around proper cleaning processes for injecting equipment and 
almost no talk about processes for cleaning other equipment such as hair clippers. The lack of 
access to clean injecting equipment meant people were resourceful and creative in making 
their own and sharing equipment. (Described in more detail under heading 4.7.12 
Resourcefulness and creativity attached to minimising harm) 
4.7.6 Hair clippers 
Five out of seven participants had a haircut while in prison where their scalp or skin was cut in 
the period between last negative HCV test and positive HCV test. Two participants identified 
the following concerns around use of hair clippers and exposure to blood in prison: 
 Sharing of hair clippers among many inmates; 
 Popularity of using clippers on closest possible cut setting (zero); 
 Lack of knowledge around blood clean up; 
 Lack of available cleaning products for clippers after haircuts. 
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One participant said: 
“All the time, clippers braise [participants own language] us all the time. We 
don’t have anything to clean them with. We just use little alcohol wipes 
sometimes but it’s not meant for that. With the clippers, I have hep C so I use a 
number one instead of a zero. A lot of inmates like to use zero.” 
The second participant provided similar information: 
 “One set of clippers is between about fifty to sixty people. Most people use 
zero to cut hair. Not long ago someone cut them self and there was blood all 
over it, to sterile equipment, to clean them up, if there is blood on the clippers 
just wipe off and rinse under water. He was hep C positive. There is no other 
way of cutting hair.” 
4.7.7 Tattooing 
Three participants indicated that tattooing in this particular facility was not too common. This 
was expressed by one person as “… not as much as other jails”. Yet four out of seven 
participants had in-prison tattoos between their last negative and positive HCV test. Tattooing 
equipment usually consisted of a motor, pen as a barrel and needle. Ink used by inmates 
consisted of charcoal, soot, mixture of soot and toothpaste, pen ink and, if available, tattoo 
ink. Two out of four people who acquired in-prison tattoos said they supplied clean equipment 
(new motor - a device that allows for the rotating motion needed to tattoo effectively, needle 
and/or pen). However, a participant who was both doing other inmates’ tattoos and his own 
said the process was “dirty”: 
 “Pretty much it’s dirty. Might use water and change other parts like the motor 
and needle ... I try to change parts between inmates but it was up to them to 
have clean parts.” 
Two inmates receiving tattoos sourced clean parts for their own tattoos, evidently aware of 
and trying to reduce their risk of acquiring HCV. 
 “You can’t really catch anything just hep C, just need a new needle and pen 
each time. I had a tattoo every time I’m in, always with clean equipment” 
 “I was just trying to get hold of my own gear and clean it. I clean just with 
water and bleach.” 
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4.7.8 Other blood to blood contact 
Additional behaviours exposing participants to blood while incarcerated included: fighting, 
sport and penile implants. Three out of seven participants reported a fight in which blood from 
another person came into contact with their mouth, eyes or an open wound. Three out of 
seven participants reported having another person’s blood on them while playing sport. Both 
football and fighting were identified as sports in which contact with someone else’s blood 
occurred. Fighting as a sport would imply inmates organising fights as opposed to a 
disagreement leading to a fight, but more information was not sought to differentiate these. 
One participant had a penile implant between his last negative and positive HCV test. He 
recalls there was “Only a little bit of blood involved” adding: 
 “Yeah I have had that twice. Usually like glass shaved down. Mine were 
smashed microwave plate. I ground it down on the concrete in the yard, where 
everyone walks. I bleached it and then boiled it, it’s not sterile. I’ve seen it go 
bad.” 
No participants reported sharing razors or toothbrushes, sexual contact with another inmate, 
needle stick injury or stabbing.  
4.8 Different concepts of shared and cleaned 
Participants had different ideas of what was clean and sterile. Each participant explained 
different ways of cleaning injecting equipment. Participants put a large emphasis on bleaching 
and cleaning injecting equipment. Yet blood in other situations was not thought of or treated 
in the same way by everyone. This was evident when discrepancies arose between 
quantitative and qualitative interviews. For example, one participant indicated always used 
clean and sterile equipment when injecting in the quantitative component of the data 
collection, yet discussed sharing equipment with more than 20 people during qualitative data 
collection. His idea of clean and sterile was bleaching and washing equipment before using. 
Another participant said he did not share with anyone but he used someone else’s equipment. 
It seemed sharing was a concept when physically in the presence of others using injecting 
equipment, but not when using an unsterile fit individually as indicated by one person in the 
following comment:  
 “What do you mean by sharing, like straight after someone or just having your 
own fit? I have a fit I share between two to three people but if someone has 
drugs and asks for it I give it to them but only two to three regulars using the 
fit.” 
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When participants were asked if they bleach or fincol (a hospital grade disinfectant used in 
some prisons) their injecting equipment properly, most participants immediately said “yes”. 
But when the recommended process was explained (two flushes of water, two flushes of 
bleach or fincol, and a 30 second soak of the equipment in bleach or fincol and then two 
flushes of water) participants went on to change their answers to “sometimes” or “never.” . 
Some participants explained different processes. One said: 
 “Sharing needles in here, I try to bleach out every time. You are meant to soak 
overnight it’s the best way. I bleach out six to eight times, suck in and out and 
rinse with water. I haven’t seen anyone soak overnight.” 
4.9 Normalisation and ignoring Hepatitis C 
When asked if there was stigma around HCV or if inmates with HCV were perceived differently 
in prison, six out of seven participants described a culture of HCV normalisation with little 
stigma attached to HCV infection, or injecting inside. Below five people discuss their view of 
HCV in prison: 
 “It’s just normal, no one really cares about it, so many people have it.”  
“Compared to the sentence I’m doing, it doesn’t really matter.” 
 “People don’t really talk about hep C or health, if someone is asked they admit 
it but no one just talks about it ... majority of people in here have it, if you are 
going to start treating people differently you will make it difficult for yourself.” 
 “Main worry isn’t hep C no one really cares about hep C same sort of thing, 
bleach every time, should be alright.” 
 “Hep C is pretty acceptable and normal. If people have AIDS then that is a thing 
but hep C not really.” 
One participant however described it in a different way: 
 “The culture is people try to ignore it, it’s easier to deal with, ignore it.” 
HCV was seen as acceptable and normal by participants, yet people inside didn’t really talk 
about it they “ignored it”. There was, however a culture of learning and teaching strategies to 
reduce risk, and in doing so, consciousness to protect self and others from becoming infected.  
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4.10 Ideas and behaviours observed, learnt and taught  
Inmates were getting input and piecing together a puzzle about hepatitis C transmission and 
infection control from a number of different sources: 1) themselves (learnt ideas and 
behaviours) 2) other inmates (taught and observed ideas and behaviours) and 3) prison 
medical staff and educational materials. Four participants talked about receiving HCV 
information from medical staff and material around the facility such as the bleach protocol or 
“hep C review” (a monthly magazine produced by Hepatitis Australia). 
For some participants preconceived ideas and behaviours surrounding HCV developed on the 
outside were continued even though they were inside, living in a high risk environment. Some 
participants changed the way they used inside, influenced by other inmates to use drugs, 
learning new techniques of taking drugs or learning how to clean equipment or strategies to 
reduce risk of blood to blood contact. One person who was initiated to injecting while in prison 
recalls older inmates teaching techniques: 
 “The older blokes taught me how to inject. I never experienced needles before 
here. They taught me how to shoot up.” 
Another person commented on the information received from medical staff at the prison 
facility but discussed a lack of conveying that learnt information to other inmates. There was a 
sense of trying to do this, but maybe not knowing quite how to convey the message in the way 
a peer educator would.  
“Had pretty good information from medical staff, inmates don’t really talk 
about it, some people tell others not to do things, I try to tell others not to do 
things but it’s up to them to do it or not.”  
Taught and learnt ideas and behaviours were evident through language and actions. Language 
used by participants demonstrated a level of understanding about HCV, transmission routes, 
risk of HCV, genotype, treatment options (current and future options), infection rate and 
statistics. Participants described actions of implementing their own harm reduction techniques 
and consciousness of protecting others in situations where risk arose.    
Medical staff provided education to participants; some participants understood discussions 
with medical staff but confusion about aspects of their diagnosis was evident. There were 
misunderstandings or misconceptions about HCV, transmission, risk, diagnosis and harm 
reduction. One person demonstrated misunderstanding of diagnosis:  
“When I had the test again my body had antibodies to beat it but must not had 
too much cos I had it again.” 
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A misunderstanding about ability to access treatment was demonstrated by a different 
participant: 
“I would like to do treatment again but not sure if I can, might only get one 
chance.” 
Participants had different processes for bleaching injecting equipment, not always in line with 
the recommended guidelines.  
4.11 Resourcefulness and creativity attached to minimising harm  
While there was an overpowering undertone among participants to not talk about health or 
HCV, there was a number of self-developed harm minimisation and reduction strategies that 
inmates tried to practice to decrease their risk of HCV infection while incarcerated. These 
included:  
 Bleaching, washing  and cleaning equipment 
 Using among the same small group of people to reduce the pool of infectivity 
 Having/making their own injecting equipment to reduce their need to share, and if 
sharing takes place, ability to dictate who uses it 
 Allowing those without HCV to use equipment first  
 Using the methadone program to reduce their need to inject more frequently. 
These were a number of taught and learnt strategies used by participants who reported always 
having access to and using clean safe injecting equipment on the outside. 
4.12 Chasing a high 
All participants knew the risk of contracting HCV; they identified behaviours that put them or 
others at risk of contracting HCV, but this was overridden by the high. Four out of seven 
participants described a mentality of chasing a high which lead to an increased level of risk 
related to injecting in prison. The ramifications of sharing equipment and HCV became 
secondary to the high as explained by the following three quotes from different participants: 
“The want to get high is higher than worry about hep C, it’s pretty sad really.” 
  “No not a care factor, just want to get high.” 
 “People that are getting high or stoned are not really concerned about 
anything else.” 
Two participants talked about coming into custody and being in a state of withdrawal and 
needing to use. One of these participants said  
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“It’s a bit hard when you are really sick. You don’t think about hep C you just 
think about getting high.” 
4.13 HCV diagnosis, treatment and re-infection 
Misunderstanding the risk of re-infection after HCV treatment was a reoccurring factor. Five 
out of seven participants had been on HCV treatment while in prison and all five had been 
reinfected with the same or different genotypes after clearing the virus or while on treatment. 
Attached to the initial diagnosis, treatment and re-infection, was a collective emotion of upset 
and anger which played out differently for each individual. Most felt depressed, some started 
using again. Five people provided some insight into their experience of HCV treatment in 
prison and related issues: 
 “I was on treatment in two thousand ten [in prison] when I left [when 
released] I stopped taking the ribavirin tablets, they made me feel like shit, 
depressed. I thought I was clean, I didn’t use on the outside because I thought I 
was clean.” 
 “This time I’ve been in since two thousand ten, at the start of this sentence in 
two thousand ten I started six months of treatment. I cleared it but then I was 
told I had it again, it’s pretty shit.” 
 “In two thousand seven I found out [I was HCV positive]. I had a blood check. 
At first I was really apprehensive; I didn’t want to hear the results, I felt guilty. 
[While in prison] I went on treatment  and cleared it in a month but started 
using again, next blood test I got a different genotype, treatment was 
extended for another six months. I retested in a month and was surprised to 
hear I had genotype one. When I had the test again my body had antibodies to 
beat it but must not had too much cos I had it again.”  
 “In two thousand and six in prison I did treatment for genotype one A and in 
two thousand and twelve in prison treatment for genotype three A.”  
Diagnosis or re-infection while in prison added another layer of complexity for inmates with 
already compound histories of mental illness, drug use, crime and institutionalisation. While all 
participants had an innate adaptability and survival mentality there were glimpses of a struggle 
to cope with aspects of their diagnosis, re-infection and treatment while in the prison 
environment.  
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4.14 Experience and perception of HCV treatment in-prison 
The notion of sickness as a weakness and vulnerability was highlighted, relating to the nature 
of the prison environment and the need to stay alert. Two participants who had not been on 
HCV treatment described treatment side effects observed while inside and their perception of 
treatment: 
  “I won’t do it, it makes you vulnerable, it makes you sick, your strength’s not 
there and you need that. If you look sick it makes you weak and vulnerable.”  
 “I really want to do treatment; it’s just shit how sick it makes you. I seen it 
make people lose weight, get really sick. They say they can give you stuff for it. 
But the last thing I want to be is curled up on the floor. I’ve got to be on the 
ball.” 
Five participants who had been on HCV treatment in-prison (treatment undertaken in current 
or previous sentences) experienced different emotional and physical side effects. Each 
individual was in a different mind frame about treatment when asked about their experience 
and if they thought treatment was an option in the future. Most said it would be an option but 
conditionally, if they were healthy, in the right mental state, while others recognised they 
would be using drugs and did not want to be reinfected. Below four different participants 
offered their insight into treatment and side effects in-prison: 
 “It’s not something I’m thinking about right now, I’m gonna get treatment 
again one day. The medicine put my body through a lot, it fucked me up and I 
would want to use.” 
“When I was doing interferon I lost ten to fifteen kilograms, it was mentally 
and physically draining. I would want to get myself to a place where I was 
healthy to do treatment; I’m waiting for new treatment to be available.” 
 “Not while I’m in here. Not the right time I need to be in the right mental 
thinking. I’m going to use again. I don’t want to get reinfected. I want to be 
healthy and be able to deal with it.” 
 “Treatment was Ribavirin and Pegasus for twelve months of treatment, nine 
months I did in segregation because I was losing it.” 
One participant mentioned if he could do treatment again he would have done it in the last six 
months of his sentence. Two participants with longer sentences talked about the want to 
progress through the system and the need to change behaviours at the later end of their 
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sentence with the motives of behaviour change and parole. For one participant it was a matter 
of using less and not letting the drugs affect him as much, “it’s a bit like roulette.” For another 
it was totally isolating himself from people and activities to stop using and progress through 
the system.  
4.15 Health is a priority 
While there was a culture of not talking about health or HCV (as discussed above), as being 
healthy and strong was important for participants. Even though most were long term drug 
users and injected while in prison. Five participants discussed their desire to be healthy in 
different contexts; to be healthy while inside prison to reduce vulnerability, health in general 
(eating and exercising), wanting to stop using drugs and wanting to protect family from illness 
on the outside. Four out of seven participants talked about changing their lifestyle to not take 
drugs. Of those four, one tried rehabilitation (not specified if in or out of prison) and three 
implemented their own strategies to try and stop taking drugs at different times during 
sentences, including isolation, going “cold turkey” and focusing on exercise and eating better.  
4.16 “We need safe equipment” 
Three out of seven participants specifically talked about a need for access to clean and safe 
injecting equipment in prison. These were unprompted discussions, two people when asked if 
they would like to say anything else at the end of the interview process and one person during 
a discussion about perception of people with HCV. Their want for clean injecting equipment 
was more a concern for other people coming into the prison system, particularly for people 
coming into prison “clean” (HCV negative) and leaving the prison system with “hep C” and a 
“habit”. One person explained: 
“I tell you what, we need a needle exchange here so we can exchange used fits. I 
know people who have come in clean and left with a JR and hep C.” 
When asked what the term JR meant the participant explained: 
“A jack rabbit is a habit, once you are down the burrow you are stuck in the hole.” 
In reflection of his own story of HCV acquisition and knowing others in the same situation 
another person expressed the need for an NSP: 
“We need safe equipment, stats show most people come in without and contract 
hep C. It’s disturbing the same situation happened to me, off the street feeling 
sick and withdrawing, not worried about using or hep C.” 
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One participant offered the following quote during the interview process in relation to a 
question about perception of people with hepatitis C.  
“A needle exchange would be good. If they could think about a needle exchange 
because there are heaps of guys I know who come in and have only smoked 
marijuana and other drugs and inject for the first time.” 
The following quote was expressed by a person who was frustrated by constant talk of 
possibilities of NSP’s in prison with no outcome. The language he used was a little different in 
that he spoke about an “injecting room” for safe use and disposal. 
“They worry about the safety of prison guards, inmates using needles as weapons 
things like that, it hasn’t happened though. If they had an injecting room, people 
could use safely dispose safely it wouldn’t be an issue.” 
4.17 In-prison incidence  
Using the study criteria developed to define in-prison incidence, six out of seven cases of HCV 
could be classified as in-prison newly acquired HCV cases. The exception was case six whose 
drug use outside prison was predominantly through smoking and who recalled sharing 
injecting equipment for the first time on entry into the prison system. This case is without a 
doubt a new incident case of HCV, but there is contention as to whether HCV acquisition was 
in or outside of prison. Due to the transition period into prison, testing results and study 
criteria, this case has been excluded as in-prison incidence. See Table 5 for each case’s 
incarceration periods, test and HCV status across the study timeline (Note: Table 5 includes 
primary data obtained for each case at the beginning of the investigation). 
All identified in-prison incident cases believe they had contracted HCV while in prison. All six 
identified their HCV in-prison diagnosis was as a result of injecting drugs in the context of 
sharing needles. Interestingly, recalled scenarios of how participants believe they contracted 
HCV collected during qualitative interviews, were consistent with timeline testing and 
diagnosis data. 
Of the six in-prison incident cases, four acquired HCV genotype 3a, one participant acquired 
HCV genotype 1 and one participant acquired genotype 1a. Cases one, two and three had 
genotype change and/or dual infections. Four participants had undergone HCV treatment 
during current or previous sentences. Three cases were re-infection after SVR to treatment 
and one case was either relapse or re-infection after SVR. 
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Only two participants (cases four and six) would be considered notifiable as newly acquired 
HCV cases according to the national case definition.  
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4.18 Discussion 
In line with findings from previous in-prison HCV incidence studies, participants in this case 
series were all born in Australia, predominantly had an education level equal to or less than 
year 10, had a history of recidivism, a history of injecting drug use and a history of injecting in 
prison(1, 17, 19). Exposure to blood while incarcerated and multiple risk factors placed study 
participants at high risk for HCV in-prison incidence and demonstrated the considerable risk of 
exposure to blood for people residing in the custodial setting. In this study multiple exposures 
to blood while in prison, between negative and positive HCV test, occurred through injecting 
drug use, hair clippers, tattooing, fights, sport and penile implants. 
Injecting drug use and sharing of injecting equipment while incarcerated was a common risk 
factor among all participants in this study. All in-prison incident cases said seroconversion was 
as a result of injecting or sharing of injecting equipment. Around 22% of people with a history 
of injecting drug use will inject drugs while in prison(28), although a national community based 
study of ex-prisoners reported 42% injected while incarcerated(29). This study reflects 
demographic and behavioural factors associated with HCV transmission among a high risk 
group of people who inject drugs while in prison.  
This prison facility is providing a number of harm minimisation strategies to reduce HCV 
incidence. These include bleach provision, condom availability, opioid substitution 
programmes, a HCV treatment program and educational materials. The prison facility in which 
all study cases resided provided all of the above mentioned strategies, however, in Australia 
these strategies are not consistently available across all jurisdictions and prisons(30). In addition 
to facility led initiatives, participants were employing their own harm minimisation tactics by 
reducing injecting drug intake, reducing sharing of equipment, reducing the pool of infectivity 
in which to share and implementing cleaning strategies. This study provides evidence of in-
prison incidence occurrence despite availability of harm reduction strategies. This finding 
would imply current harm minimisation strategies are not adequately meeting the needs of 
this subsection of high risk prisoners.  
There was a culture of invention/creativity, learning, teaching and taking on different practices 
and ideas. This was not always best practice, as notable misconceptions and myths about HCV, 
HCV treatment and harm reduction was demonstrated by participants. Peer education could 
be an angle of myth breaking and education in the future to decrease transmission, improve 
outcomes of disease, support treatment and also improve prison health services for people at 
risk of acquiring HCV(31, 32).  
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Despite best efforts to reduce risk by both participants and corrections, the predominant 
factor in HCV transmission in prison continues to be the sharing of injecting equipment. This 
study describes the ongoing sharing within prison facilities and resourcefulness of inmates in 
finding ways to use drugs while incarcerated. With no availability of clean injecting equipment 
inmates who use while incarcerated or inmates who are initiated to injecting while 
incarcerated will continually be at high risk of acquiring HCV.   
Five out of six incident cases had undergone HCV treatment during current or previous prison 
sentences. As demonstrated, this high risk group of people is likely to become reinfected by 
the same, different or multiple HCV genotypes while incarcerated due to risk factors. 
Treatment may decrease the presence of co-infection among this group but little is known 
about the effects of treatment on circulating HCV genotype immune response. A longitudinal 
study found the ability of a dominant HCV strain (in a co-infection situation) to suppress and 
clear a less virulent HCV co-infection(18). Little is known about the physiological outcomes of re-
infection after treatment in comparison to co-infection which suppress and clears less virulent 
strains. Further work is required to fully understand physiological and biological effects of the 
disease and its treatment on host immunity.   
The psychological effect of re-infection after treatment was evident among participants in this 
study. Coping skills observed among participants lead to the conclusion that prison based 
mental health services attached to HCV diagnosis and treatment would be beneficial. It is 
crucial for prison based HCV services to integrate mental health/support services into their 
clinical model, although it is acknowledged that resources to do so are limited. 
HITS had a lower mean age of incidence (25.7 years) compared to the current study mean age 
(30 years) (19), and it was noted in this study that younger inmates were being taught injecting 
behaviours by older inmates. A number of participants expressed worry about younger 
inmates and inmates who use drugs but do not inject being initiated into injecting while in 
prison. Power dynamics within the prison system are potential influences of HCV incidence, 
though little is known about pressures associated with user dynamics in the prison context. 
4.18.1 Limitations 
 This is a small descriptive case series. The constraints of the prison setting would require more 
time and resources to conduct a case-control or cohort study and may not yield different 
results, therefore the current study design was chosen taking into consideration the setting 
and ensuring confidentiality of participants. The strength of the mixed methods approach 
included providing a unique insight into the lives of participants and their perspective of HCV, 
which is missing from current literature. Sample size was small; however the mixed methods 
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approach to in-prison incidence has been conducted for the first time recently with a similar 
number of inmates in a different jurisdiction (not yet published).  
There may have been a level of recall bias. Interviews were conducted in July 2014, where 
participants were asked to recall behaviours and situations as far back as May 2009. It is also 
possible illegal behaviour and repercussions of sharing information could have resulted in 
participants withholding information. Findings from this study are, however, similar to a 
general community based qualitative study in which prior offenders who had injected while in 
prison shared their experiences(33). 
Incident cases were identified due to increased testing as a result of a voluntary HCV 
treatment program. This may have influenced participants’ levels of knowledge and 
understanding of HCV, risk factors, treatment and prevention. It also meant the group included 
in the study was a high risk group. Each participant, however, had an individual story to add a 
different perspective to in-prison incidence.  
No female detainees were included in this study. All female incident cases identified in the 
original 30 cases where not in prison at the time of interviews. Women tend to have shorter 
sentences and therefore in-prison incidence is harder to determine(34). From 2003 to 2013  
incarceration of women in Australia increased by 46.6%(34), yet information on incidence and 
risk factors in the context of female prison facilities is limited and findings from this study may 
not be generalisable to female inmate incidence. 
4.19 Conclusion 
This study provides evidence of in prison HCV incidence, highlighting the extent to which a 
group of high risk prisoners are exposed to blood while residing in prison. Limitations of the 
current national HCV case definition create a barrier to reporting HCV in-prison incidence. This 
study identifies new acquisition of HCV among a group of high risk inmates that is not 
notifiable under the current case definition. True in-prison incidence may be under-reported. 
This prison facility is providing a number of harm minimisation and reduction strategies to 
decrease HCV infection. However, there is evidence of in-prison HCV incidence despite 
availability of these strategies. This finding would imply current harm minimisation and 
reduction strategies are not adequately meeting the needs of a subsection of high risk 
prisoners. The findings of this investigation add to a body of evidence pointing to the need to 
implement NSPs in Australian prisons to complement current strategies. 
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4.20 Recommended control measures 
1. Harm minimisation and reduction activities currently available should be 
continued and continually improved. 
  
2. Sharing of injecting equipment in prison among inmates is a major factor in HCV 
incidence. Introduction of a NSP could reduce sharing of injecting equipment 
among inmates.  
 
3. HCV information should be targeted at the right education level and take into 
consideration other activities in which inmates come into contact with another 
inmate’s blood. Educational tools should include information about how to 
sterilise equipment (injecting, hair clippers, tattoo equipment or anything coming 
into contact with blood) in a way that is considerate of the illegal activity. 
 
4. Targeted education for young non-injecting drug users entering the prison system 
and fast track opiate treatment for individuals withdrawing on entry or risk of 
withdrawal could assist in decreasing isolated instances of sharing injecting 
equipment without cleaning. 
 
5. Taught and learnt behaviour should be taken advantage of through prison peer 
education programs.  
 
6. Inmates should be given the opportunity to do treatment while incarcerated, as 
reducing the circulating HCV prevalence could decrease incidence. However, the 
criteria for treatment should take into consideration inmate concerns around time 
of sentence to undertake treatment, inmate’s perceived mental state and/or 
coping skills. 
 
7. HCV treatment as prevention in an environment that does not offer safe and clean 
injecting alternatives should only be looked at as a combination prevention 
strategy. Treatment as prevention may be appropriate in the general community 
context, where access and the choice to use clean injecting equipment are 
available. Until prisons introduce strategies to decrease sharing of injecting 
equipment, inmates who continue to inject in prison will continue to become 
reinfected during or after treatment. However, those that choose to abstain and 
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those that do not inject should be looked at as optimal candidates for treatment 
programs while in prison.  
 
8. The HCV newly acquired case definition should to be revisited to capture true 
incidence rates in Australia. This is a public health issue not only for prisons, but 
the general Australian population.  
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4.21.1 Appendix 1: Participant Information Sheet  
Incident Hepatitis C cases detected through a custodial HCV treatment program study 
Investigators: Professor Michael Levy, A/Prof Stuart Kinner, Ms Rachel Sacks-Davis, Professor 
Margaret Hellard, Dr Joseph Doyle, Professor Tony Butler and Ms Dina Saulo. 
About the study  
Hepatitis C Virus (Hep C) is a virus that lives in the blood. It is transmitted when there is blood 
to blood contact with a person that is infected with the virus. This can happen through 
Injecting drug use, sharing needles and injecting equipment, tattooing, sharing razors and 
toothbrushes.  
This study aims to identify and describe potential risk factors for Hep C transmission while in 
custody at the Alexander Machonochie Centre (AMC) and to explore if the viruses are linked 
genetically. The study’s results will be used to inform policies that may protect people in 
custody from becoming infected with hepatitis C virus in future.   
Why were you selected? 
You have been invited to be involved in this study due to taking part in testing that was a part 
of the AMC Hep C treatment program.  
What will happen if you consent to be a part of the study? 
There are three parts to the study:  
1. Medical record review  
Your AMC medical records and ACT Pathology records will be reviewed by a research team 
member for history of Hep C testing, the results of any tests, blood samples and other clinical 
information such as receipt of opiate replacement therapy, HCV treatment, HIV testing and 
treatment. No identifying information will be collected.  
 
2. Survey and Interview 
An interviewer will ask you some details about yourself, Hep C, and health behaviours and past 
experiences.  We expect the interview on average to take around 60 minutes depending on 
your responses. Interviews will be recorded for the purpose of the interviewer to write up 
later; recordings will be destroyed once answers have been typed up. No one else will hear the 
recording but the interviewer. 
3. Viral sequencing of stored blood samples 
All hep C viruses are made up of genetic material. The research team want to sequence the 
genetic material of the virus. There are two purposes of this: 1) If you were treated for 
hepatitis C or spontaneously cleared an infection, you might have become reinfected with a 
new hepatitis C virus. It’s also possible that your original virus was not 100% eradicated and 
you had a relapse during or after treatment. Viral sequencing can distinguish between re-
infection and viral relapse.  The reason that the researchers are interested in this is that they 
want to understand whether you might have become infected with a new hepatitis C virus 
while you were at the AMC. 2) The researchers are interested in whether hepatitis C viruses in 
one individual have a link to another at the AMC. This is in order to see whether there is 
evidence of transmission of hepatitis C at the AMC. If you give permission, this will be tested 
by examining stored blood samples. Note, that this does not involve testing of your genes. The 
genetic material of the virus is different to your genes, and it is only the genetic material of the 
virus that the researchers are interested in. 
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Do I have to participate?  
No, it’s your choice whether or not to participate. If you choose to participate but would like 
to pull out at any stage or skip questions, you do not need to explain why you don’t want to 
continue and this will not disadvantage you or the care that you receive in the future in any 
way.  
 
Will anyone else see my information or know my results? 
All your answers and results are confidential and at no point will we reveal any of your answers 
to Corrective Services in ACT or to any other persons outside of this research project.  No one’s 
names will be mentioned in any reports or papers that we might publish from this study after 
the survey.  It will be anonymous.   
 
Will there be a benefit for me?  
There will be no direct benefit to you from your participation in the study although it may have 
an indirect benefit.  The study will help us to develop potential harm reduction measures at 
AMC.  
 
What are the potential risks of doing the survey? 
All answers are confidential but if you feel distressed at any time you can stop the interview or 
skip a question. Simply let the interviewer knows and they will move onto the next question or 
stop the interview. This will not affect your relationship or the health care and support you 
receive from AMC.  Another risk is that if you disclose illegal activities you have been involved 
in the past for which you have not been tried or convicted, we are required to report this 
information by law. 
 
How do I get more information about this study?  
If you would like to know more about the study or if you have any additional questions later, 
Professor Michael Levy will be happy to answer them.  
Name Professor Michael Levy, Director, Justice Health Services 
Phone  (02) 6207 2843 
Email michael.levy@act.gov.au 
 
What if I have a complaint about the research? 
Should you have any problems or queries about the way in which the study was conducted, 
and you do not feel comfortable contacting the study staff, you can contact the ACT Health 
ethics secretariat.  Any complaint you make will be treated in confidence and investigated, and 
you will be informed of the outcome. 
ACT Health Ethics Secretariat 
02 6205 0846  
acthealth-hrec@act.gov.au 
 
What to do now? 
The next step is for you to decide what you would like to do. You can ask any questions about 
the study or you can talk to one of the researchers. You can then sign the consent form if you 
wish to participate. 
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4.21.2 Appendix 2: Survey and Interview Tool 
Incident Hepatitis C cases detected through a custodial HCV treatment program 
study 
Thanks for agree to participating in this survey and interview process. The following survey is 
being conducted to collect information about risk behaviours and exposure to Hepatitis C 
infection in prison. We would like to better understand the risk factors associated with 
transmission of this viral infection. Questions about your background information; date of 
birth, country of birth, followed by possible exposures, questions about tattooing, body 
piercing, drug use and sexual practices. All questions will only be in relation to your current 
period of incarceration.  In particularly the time period between last negative Hepatitis C test 
and first positive test for the particular time period stated for each interviewee.  This will be 
followed by unstructured interview, the whole process may take up to that 1 ½ hours. 
This survey is anonymous and your responses are confidential. Your honest response to 
questions is important. You have the ability to refuse answering any question and to cease the 
interview at any stage.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Interviewer: Please ensure the following have been completed before interview 
Explained the study or given participant the opportunity to read the 
information sheet. 
Participant knows identity and personal details will remain completely 
confidential and anonymous at all times. 
Have you obtained a signed consent form participant? If so please 
attach to survey. 
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                4. What country were you born in? ___________________ 
 
Study ID Number  
Date of Birth D D M M Y Y 
Current Age (in years)  
1. How many times has the 
detainee been in a juvenile 
detention centre? 
 _____________ 
  
   Don’t Know      9 
2. How many times has the detainee 
been in a Adult detention centre? 
 ____________   
    Don’t Know     9   
3. Are you Aboriginal or Torres Strait       
Islander? 
 Yes   1 
  No   2 
  both   3 
  Neither   4 
  Don’t Know   9 
5.  Would you describe yourself as: Straight  1 
  Gay/Lesbian    2 
 Bisexual    3 
Background Information 
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6.    How many years of schooling have you  No formal education   0 
        completed? [Interviewer: for answers like 1-6 years at school   1 
      “intermediate school”, or “junior high”, ask the 7-10 years at school   2 
      number of the years and tick the appropriate 
box] 
11-12 years at school   3  
 CIT   4 
 Tertiary Education   5 
 
7.   Have you ever suffered from any mental Yes   1 
health problem such as depression, anxiety, No   2 
bipolar disorder, psychosis or schizophrenia? Don’t know   9 
 
 
8. In which area(s) of this prison have you been housed during your current stay?  (please 
name all and period of time spent in each specifying month and year and number of people housed in your 
cell) 
Name of housing block 
 Block 
Capacity Time period Number of cell mates 
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In the next section I will be asking questions about possible exposures or risk behaviours such 
as Piercing, tattooing, drugs, Injecting drug use, sexual practices or other activities that could 
have caused blood to blood contact during your current time in prison. You can decline to 
answer questions at anytime or cease the interview.  We ask that you not disclose information 
that might incriminate you.   
Time frame        
                                         
Please only give answers in relation to your current stay in prison between the time frame of 
last  
negative HCV test                                        to first positive HCV test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exposures 
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 Piercing  
10.  How many times have you had your body pierced? ______________ 
[Interviewer: include piercings that do not currently have a ring in them] [Interviewer: if only ears are pierced, write 
the total number of the piercing in both ears, i.e. 1 piercing each ear = 2 in total] 
11. The following questions are to find out more detail about 1) date of piercing 2) description 
of the equipment used 3) if the equipment was used by others.  
 
 
 
9. Have you ever had any part of your Yes (Go to 23)  1 
 body pierced during your current stay in prison? No (Go to 25)  2 
 [Interviewer:  must mention that body  Don’t Recall (Go to 25)  9 
 piercing includes ear piercing as well]    
Piercin
g  No. 
Date of 
piercing 
Type of piercing (where on 
your body)  and Description 
of equipment used  
Was the 
equipment used 
by other inmates 
prior to you? 
Pierced by 
1      Yes   
 No   
 Don’t know  
If yes, how many? 
 
Self  
 cell mate  
 other Inmate 
 
2       Yes   
 No   
 Don’t know  
If yes, how many? 
 
Self  
 cell mate  
 other Inmate 
3       Yes   
 No   
 Don’t know  
If yes, how many? 
 
Self  
 cell mate  
 other Inmate 
4       Yes   
 No   
 Don’t know  
If yes, how many? 
 
Self  
 cell mate  
 other Inmate 
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Tattooing 
12. Have you had a tattoo since you last 
negative HCV test? 
Yes (Go to Q4)  1 
 No (Go to Q7)  2 
 Don’t Recall (Go to Q7)  9 
 
13. How many different times have you been tattooed since your last negative HCV result?
  __________________ 
 [Interviewer: consider each session of tattooing as a separate tattoo] 
[Interviewer: Include tattoos that have been removed 
 
14. The following questions are to find out more detail about 1) date of the tattoo 2) 
description of the equipment used 3) if the equipment was used by others.  
 
 
Tattoo 
No. 
Date of 
tattoo 
Description of equipment 
used (including ink) 
How many were 
tattooed with the 
same device or 
ink? 
Tattooed by 
1      1   2   3-5 
 6-10   11-20  
 more than 20 
 don’t know 
 
Self  
 cell mate  
 other Inmate 
 
2      1   2   3-5 
 6-10   11-20  
 more than 20 
 don’t know  
Self  
 cell mate  
 other Inmate 
3       1   2   3-5 
 6-10   11-20  
 more than 20 
 don’t know  
Self  
 cell mate  
 other Inmate 
4       1   2   3-5 
 6-10   11-20  
 more than 20 
 don’t know  
Self  
 cell mate  
 other Inmate 
5 
    
 1   2   3-5 
 6-10   11-20  
 more than 20 
 don’t know  
Self  
 cell mate  
 other Inmate 
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Injecting drug use and drugs 
This next section is to record the general pattern of IDU since the last HCV negative and first 
positive 
 
 
 
 
 
 
15. Between your last negative and your first 
positive HCV result have you injected 
drugs? 
Yes (go to Q23)  1 
No (go to Q42)  2 
        [Interviewer: this includes injecting either self  
or someone else] 
Don’t recall (go to Q42) 
 9 
16.     If yes, how often have you injected? Less than monthly  1 
Monthly or more often  2 
[Interviewer: check that “daily” and  “more than once a day” 
are distinguished] 
Weekly or more often  3 
  Daily  4 
 More than once a day  5 
 Don’t recall  9 
17. During current  imprisonment this time 
compared to the        
rest of your life, has your injecting frequency  
been…  
[interviewer: assess the lifetime pattern of injecting and code 
yes if frequency, sharing behaviour or drug of choice have 
changed] 
Stable  1 
Increasing  2 
Decreasing  3 
Don’t recall 
 9 
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18. Which drug/s did you injected during your last 
negative and first positive HCV result? 
 [interviewer: read the options and emphasise “injecting”] 
   
Heroin  1 
Buprenorphine (Subutex)  2 
                                                                           Ice (crystal meth/amphetamine)  3 
                                                                                   GHB/GBH/ liquid e/fantasy  4 
                         [Interviewer: Exclude medications prescribed Cocaine/ Coke  5 
                         and administered by health workers, Benzodiazepines/Benzos   6 
                         e.g. Morphine]                                    
Anabolic/Steroids 
 7 
                                                              Other  opiates/codeine/pethidine/opium/omnopon  8 
                                                           Hallucinogens/LSD/    Acid/Magic/Mushies/Daitura  9 
 Ecstacy/ E/MDA/MDMA  10 
 Ketamine/Special K  11 
 Oxycodone 
(e.g. Oxycontin, Endone) 
 12 
 Methadone  13 
 Morphine (e.g. MS Contin)  14 
 Speed/base (or other 
methamphetamine 
 15 
 Other (please specify)  16 
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19. Which one of these was your injecting drug of choice between last negative and first 
positive HCV result? [Interviewer: the most commonly injected drug]
 _________________________________ 
 
 
 
 
 
20. During this time has someone else ever injected 
you with drugs? (Given you a hit?) 
Yes  1 
No  2 
Don’t recall  9 
21. Between last negative and first positive 
HCV test result did you use injecting 
equipment that was not new and sterile? 
                 [Interviewer: include the needle, syringe, spoon, 
swabs, filter, mix] 
Yes   1 
No   2 
Don’t recall  
 9 
    
22. Between last negative and first positive HCV test 
result have you ever shared any part of the injecting 
equipment or used any injecting equipment after 
someone else had used it? That includes the needle, 
syringe, spoon, swabs, filters, mix or tourniquet. 
                       [Interviewer: mention, even onceis a “yes” 
Yes (Go to Q30)  1 
No (Go to Q37  2 
Don’t recall (Go 
to Q37 
 9 
   
23. Between last negative and first positive 
HCV test result how often did you 
share any part of the injecting 
equipment, or use equipment after 
someone else?  
Less than monthly  1 
Monthly or more often 
 2 
  [Interviewer: check that “daily” and “ more  
 than once a day” are distinguished]  
Weekly or more often 
 3 
   Daily  4 
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24. Between last negative and first positive HCV test result which equipment did you 
share? 
 
 Yes No Don’t know 
a. Needle and syringe  1  2  9 
b. Spoon  1  2  9 
c. Mix  1  2  9 
d.  Mix in the spoon  1  2  9 
e.  Mix in the syringe  1  2  9 
f.  Mix in other receptacle  1  2  9 
g. Filter  1  2  9 
h. Swab  1  2  9 
i. Tourniquet  1  2  9 
j. Rinse water  1  2  9 
 
 
 
  More than once a day  5 
 Don’t recall  9 
25. Between last negative and first 
positive HCV test result how  many 
times have you used the same 
needle and  syringe after   
someone else used it 
None  1 
1 time 
 2 
                   (Even if it was cleaned) 2 times  3 
 3 to 5 times  4 
 6 to 10 times  5 
 11 to 20 times  6 
 More than 20 times  7 
 Don’t know 
 99 
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26.  Between last negative and first positive HCV 
test result how many people did you share 
injecting equipment with, both before and 
after injecting? 
None  1 
One 
 2 
 Two  3 
 3-5  4 
 6-10  5 
 11-20  6 
 More than 20   7 
 Don’t recall  9 
 
 
 
 
29. Did you bleach or Fincol the shared equipment 
properly? 
 [Interviewer Explain that 'properly' means 2 flushes of  
Yes, always  1 
Yes, sometimes   2 
Never  3 
 water, 2 flushes of bleach or Fincol, and a 30 second  Don’t recall  9 
 soak of the equipment in bleach or Fincol, and then 2 flushes of 
water 
   
 
 
27. Between last negative and first positive HCV test result 
did you share injecting equipment with someone known 
to have hepatitis C?  
Yes  1 
No  2 
  Don’t recall  9 
28. Between last negative and first positive HCV 
test result did you attempt to bleach or Fincol 
the shared equipment in any way? 
Yes, always (Go to Q35)  1 
Yes, sometimes (Go to Q35)  2 
Never (Go to Q36)  3 
 Don’t recall (Go to Q36)  9 
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Other exposures   
In relation to Last negative and first positive HCV result during current prison stay 
 
 
 
 
 
30. Between last negative and first positive HCV 
test result did someone else help you inject? 
Yes, always  1 
Yes, sometimes  2 
 [Interviewer: do not include medical injections] Never  3 
 Don’t recall  9 
31. Between last negative and first positive HCV 
test result did you help someone else to inject 
drugs? 
 [Interviewer: do not include     medical injections] 
Yes  1 
No  2 
Don’t recall  9 
32. If you were using on the outside 
before this current stay in prison did 
you collect clean fits to use from a 
needle and syringe exchange? 
Never   0 
Some times  1 
Most times I needed  2 
 Every time I needed  3 
33. Have you had sexual contact with another 
inmate during last negative and first positive 
HCV result?  
Yes (go to 55)  1 
[interviewer: if  had anal sex, not including oral sex] No  2 
 Don’t recall  9 
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36. Between  last negative and first positive HCV result 
were you in a fight where blood from another 
person may have come 
Yes  1 
        in contact with your mouth, eyes or an open wound? No  2 
  Don’t Recall  9 
 
 
 
 
34. Did you use a condom?  Never  1 
[interviewer: if  had anal sex, not including oral sex] Sometimes   2 
 Always   
 Don’t recall  9 
35. Have you inserted a penile implant between  last 
negative and first positive HCV result 
Yes  1 
  No  2 
 Don’t recall  9 
37. Between last negative and first positive HCV result 
were you ever stabbed? 
Yes  1 
 [Interviewer: do not include self-stabbing] No  2 
 Don’t recall  9 
38. Between last negative and first positive HCV 
result did you have a haircut where your 
skin or scalp was cut? 
Yes  1 
 No  2 
 Don’t recall  9 
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The end 
We have come to the end of the survey, your input into this study has been important. 
Thank you for your participation! 
 
39. Between last negative and first positive HCV 
result did you ever sharethe same razor as 
someone else? 
Yes  1 
  No  2 
 Don’t recall  9 
40. Between last negative and first positive HCV 
result Have you had someone else’s blood 
Yes  1 
 on you during sport?  (e.g. during a football game) No  2 
 Don’t recall  9 
41. Between last negative and first positive HCV result Have you 
been accidentally pricked 
Yes  1 
           by a needle? (e.g. needle stick injury)  No  2 
 [Interviewer: do not include IDU] Don’t 
recall 
 9 
42. Between last negative and first positive HCV result have 
you ever shared the same toothbrush as someone else? 
Yes  1 
  No  2 
 Don’t recall  9 
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5 Epidemiological Project 
Impact of Australia's HPV vaccination program on the prevalence of HPV 
genotypes among Aboriginal and Torres Strait Islander women  
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5.1 Abbreviation list 
ACCHS  Aboriginal Community Controlled Health Service 
ARIA  Area Remoteness Index of Australia  
CEO  Chief executive officer  
CI  Confidence intervals  
CIN  Cervical intraepithelial neoplasia 
CIN1  Cervical intraepithelial neoplasia grade one 
CIN2  Cervical intraepithelial neoplasia grade two 
CIN3  Cervical intraepithelial neoplasia grade three 
DNA  Deoxyribonucleic acid 
GP  General Practitioner 
HPV  Human papillomavirus 
LBC  Liquid based cytology 
MSM  Men who have sex with men 
NHMD National Hospital Morbidity Database  
NHVPR  National human papillomavirus vaccine program register 
Pap test  Papanicolaou smear or cervical screening  
PCR  Polymerase chain reaction 
VE  Vaccine effectiveness 
VIP  Vaccine impact in the population (post-vaccine genotype prevalence study) 
VIP-I  Vaccine impact in the Indigenous population  
WHINURS  Women’s Human papillomavirus Indigenous Non-indigenous Urban Rural 
Study (pre-vaccine genotype prevalence study)  
WHO  World Health Organization 
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5.2 Prologue 
5.2.1 My role  
On commencement at the Kirby Institute I had a number of discussions with my field 
supervisors about potential projects to meet the requirements of the MAE epidemiological 
project. There were a few possible epidemiological studies mentioned. I steered towards a 
national human papillomavirus (HPV) research project to evaluate the effectiveness of the HPV 
vaccine on circulating genotypes among Indigenous women aged 18 – 26 years in Australia, 
namely the ‘Vaccine impact in the Indigenous population’ (VIP-I) study.  
This project was attractive to me for a number of reasons: the focus on Indigenous women in 
Australia and particularly the post vaccine cohort of 18 – 26 year olds; the ability to engage 
Aboriginal Community Controlled Health Service (ACCHS) and the opportunity to work with 
and learn from experienced investigators who have been instrumental in sexual and 
reproductive medicine and research in Australia.  
VIP-I Investigators include; John Kaldor (Chief investigator, The Kirby Institute, UNSW), Skye 
McGregor (The Kirby Institute, UNSW), Bette Liu (The Kirby Institute & School of Public Health, 
UNSW), Sepehr Tabrizi (Royal Hospital Women, Melbourne), Suzanne Garland (Royal Hospital 
Women, Melbourne), Julia Brotherton (Royal Hospital Women, Melbourne and Victorian 
Cytology Service, Melbourne), Rachel Skinner (University of Sydney) and Mary Stewart (Family 
Planning Australia)  
When I was brought onto this project as an investigator a funding application had been 
submitted. Funding was approved by the Commonwealth Department of Health and Aging 
(now known as the Department of Health) in May 2013 through to December 2014. The 
timeline, although tight, was a good fit for the MAE duration. However, sample collection is 
still currently (November 2014) underway and only preliminary findings are provided in this 
chapter. 
My role as field coordinator was predominantly to engage services, identify a site coordinator, 
sign services onto the study and ensure services understood and followed study procedures. I 
negotiated with VIP-I site coordinators to develop sample procedures to fit each service’s 
internal process and became the main point of contact for most sites. From the beginning of 
my involvement on the project I was tasked with coordinating meetings with investigators and 
sites, and ensuring investigators were up to date. Additionally, I worked closely with Ms Skye 
McGregor (Program manager, Public Health Interventions Research Group, The Kirby Institute) 
in developing study documents for ethics applications including the protocol, questionnaire 
(appendix 1), patient information and consent forms (appendix 2). Skye prepared and 
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submitted six out of seven ethics applications and I applied for approval through the ANU 
Human Research Ethics Committee. I worked with Dr Julia Brotherton (Medical Director, 
National HPV Vaccination Program Register Victorian Cytology Service) to understand the data 
extraction approval process for the HPV vaccine registry. I filled out and circulated the National 
HPV vaccine program register (NHVPR) data request form to other investigators for feedback. I 
then submitted the request to gain access to VIP-I study participant vaccination status and 
dose coverage. 
We adapted the questionnaire for the ‘Vaccine impact in the population’ study (VIP) to be 
culturally sensitive, an improved design based on feedback from use in the VIP study. I did this 
in consultation with other investigators, Dr Bette Lui (Head of Research Assets, The Sax 
Institute), Dr Julia Brotherton, Associate Professor Rachael Skinner (Paediatrics & Child Health, 
Sydney University and Children's Hospital, Westmead) and feedback from service providers.   
Once sites had signed service agreements I organised to conduct training for clinical staff at 
sites, including VIP-I procedures. I developed a VIP-I training manual (appendix 3) along with a 
PowerPoint presentation. The training was to ensure sites were aware of all procedures and 
we had discussions with coordinators and staff about sample storage and transport processes. 
Training sessions included a HPV update covering HPV infection and disease, epidemiology of 
HPV, particularly within the Indigenous population, as well as the vaccine and the vaccination 
program. I provided the HPV update when senior investigators were not available. I provided 
training at three out of five sites (I did not conduct training at other sites due to MAE 
commitments these were undertaken by Skye McGregor). 
 
I met with Sepehr Tabrizi (Senior Research Scientist and Associate Professor) and Samuel 
Phillips (Laboratory assistant) at the Molecular Microbiology Laboratory, The Department of 
Microbiology and Infectious Diseases at the Royal Women’s Hospital in Melbourne. This 
Laboratory is a part of the HPV WHO reference laboratory network. I was taken through the 
laboratory procedures for the VIP-I study and the aliquot procedure. Aliquots were required if 
a site was using liquid based cytology (LBC) rather than conventional methods for 
Papanicolaou smear testing (Pap test). Some sites had indicated they were using liquid based 
cytology. I was taught the aliquot procedure to then train sites to collect samples from the LBC 
solution without having to collect an extra Pap sample from patients. Spending just a day in 
the laboratory trying to understand the VIP-I study processes so I could talk to services about 
them gave me a new appreciation for the time that just one sample takes to process.   
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In 2014 I had the opportunity to attend the International HPV conference. I presented the VIP-I 
project methodology and Australia’s present and future approach to evaluating the impact of 
the HPV vaccine among the Indigenous population. I presented during a morning satellite 
session organised by the International Indigenous HPV alliance (appendix 4. HPV conference 
powerpoint presentation). I have also been asked to present at Preventing Cervical Cancer 
2015: Integrating screening and vaccination conference in February 2015 and I have 
participated in a cancer institute Indigenous specific health promotion campaign in which I was 
interviewed about the importance of screening after vaccination. This is also a print campaign 
which will be sent to all Aboriginal Community Controlled Health Organisations in NSW.  
 
Although this project is not complete at time of thesis submission, the comprehensive nature 
of this study has allowed me to meet MAE competencies of designing and conducting an 
epidemiological study.  
5.2.2 Lessons Learnt 
This was the first ethics application process I was involved in and I was fortunate that Skye 
McGregor was leading the ethics process. Seeing the process of submitting an ethics 
application by someone experienced at the beginning of the MAE led to a quicker, less arduous 
process when time came to submit ethics applications for other MAE projects. After VIP-I I had 
a greater understanding of confidentiality of participants and study sites; understanding of 
ethics implications of collecting biological samples; consent required from participants and 
collection of samples; and laboratory methods.  I was also exposed to the importance of 
algorithms of care and follow up required for studies including testing of biological samples, or 
more so disease outcomes, as a result of testing that required clinical action.   
Prior to this study I had not engaged with laboratories. During VIP-I I had the opportunity to 
observe laboratory processes, methods required to store and test samples to ensure their 
integrity at the WHO HPV reference laboratory in Melbourne. This experience has allowed me 
to appreciate the important role laboratories play in epidemiological investigations.  
I had planned to apply vaccine effectiveness calculations, and although for this preliminary 
analysis I was unable to apply this knowledge, it was a good lesson and brought more clarity to 
exercises undertaken in classes.   
5.2.3 Outcomes and potential public health impact 
VIP-I will demonstrate the effectiveness of the vaccine at a population level among Indigenous 
women who have a higher incidence and mortality rate of cervical cancer compared to non-
Indigenous women(1). The vaccine has the ability to protect against the two most common high 
risk genotypes known to lead to cervical cell abnormalities and in some cases progress to 
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cervical cancer(2, 3). Understanding the impact of the vaccine targeted HPV types within the 
Indigenous and non-Indigenous population is an important indicator of; 1) effectiveness of the 
vaccine program within the population; 2) vaccine coverage and 3) disease outcomes. Accurate 
estimates provide a better understanding of what is actually happening within the population 
and lead to more precise modelling projections for Indigenous and non-Indigenous populations 
evidencing future resource allocation, program focus and gaps.  
 This study will provide the first Indigenous specific genotype prevalence comparisons between 
pre and post-vaccine populations. Additionally, comparisons between post-vaccine vaccinated 
and unvaccinated women will provide vaccine effectiveness among the Indigenous population. 
This will allow for comparison to recent calculated vaccine effectiveness among non-
Indigenous women(4).  Nationally findings will contribute towards future HPV vaccine program 
planning and evaluation, policy and program development, ongoing surveillance initiatives and 
could provide some insight for the national cervical screening program.  
5.2.4 Acknowledgments 
It was fantastic to have an introduction to working in a large research team through the VIP-I 
project and investigators, I have gained many skills from observing and working with such 
experienced investigators. I would like to acknowledge all VIP-I investigators who have 
provided me with support throughout the process, in particular thank you to John Kaldor, Skye 
McGregor, Julia Brotherton, Sepehr Tabrizi, Suzanne Garland, Bette Liu and Sam Phillips. 
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5.3 Abstract  
5.3.1 Background  
The National Human Papilloma Virus (HPV) vaccine program was implemented in 2007 using 
the quadrivalent vaccine which provides coverage for HPV genotypes 6, 11, 16 and 18. As a 
result of the vaccine implementation through school and catch-up programs there have been 
documented reductions in genotype prevalence and disease outcome associated with HPV.  
However no studies have had a sufficient sample to determine if reductions in genotype 
prevalence are equivalent within the Indigenous population. The ‘Vaccine impact in the 
Indigenous population’ (VIP-I) study aims to evaluate the effectiveness of the vaccine program 
on circulating HPV genotypes among Indigenous women.  
5.3.2 Method 
VIP-I is a repeat cross sectional genotype prevalence survey targeted at recruiting Indigenous 
women aged 18-26 years attending participating sites. Samples were collected during a routine 
Pap screen and tested for HPV DNA and genotype. A short demographic and behavioural 
survey was administered and additional consent obtained to access participant information 
from the National HPV vaccination program registry (NHVPR). Using Indigenous specific data 
from a previous pre-vaccine study, genotype prevalence was compared between pre-vaccine 
(2005-2007) and post-vaccine (2013-2014) (VIP-I) cohorts. 
5.3.3 Results 
In this preliminary analysis data from 31 participants from one VIP-I study site were included. 
The prevalence of HPV DNA among Indigenous women aged 18 – 26 years significantly 
decreased from 57.7% among pre-vaccine to 29.3% (p=0.006) post-vaccine. There was also a 
significant decrease in vaccine targeted HPV types 6, 11, 16 and 18 from 25% pre-vaccine 
compared to 2.4% post-vaccine era (p<0.003). Of post-vaccine women, 92.7% had either full or 
partial self reported vaccination. 
5.3.4 Conclusion 
A decrease in HPV vaccine targeted genotypes 16 and 18 in this preliminary analysis indicates l 
promising results for the wider VIP-I study on conclusion.   
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5.4 Introduction 
5.4.1 Epidemiology of HPV   
HPV is a sexually transmissible infection. Transmission occurs through skin to skin contact or 
mucosa to mucosa contact with an infected person. Most people will be infected with one or 
more HPV genotypes within 12 months of first sexual intercourse and throughout their sexual 
life time(5).   
 
There are around 150 HPV types of which 40 are mucosal/genital HPV genotypes categorised 
as high risk or low risk(6). High risk genotypes like 16 and 18 can cause low grade cervical 
abnormalities, cancer precursors and anogenital cancers. Low risk genotypes such as 6 and 11 
cause low grade cervical abnormalities, genital warts and laryngeal papillomas(7). Mediated 
immune cellular response will clear most high risk genotypes within 9.8 months and low risk 
genotypes in 4.3 months of acquisition(8). Additionally, cellular abnormalities as a result of HPV 
can regress after clearance of infection(1). The persistence of high risk genotypes may explain 
the consistently higher prevalence of the most common genotypes 16 and 18 in 
epidemiological studies internationally. 
 
The cause effect relationship between HPV and cervical cancer is strong. HPV DNA is present in 
99.7% of cervical cancers worldwide(2)(3). HPV16 and HPV18 are present in 70% of cervical 
cancers and 50% of cervical intraepithelial neoplasia grade 3 (CIN3)(4). HPV6 and HPV11 
account for >90% of genital warts (7), leading to the assumption that a vaccine for HPV6 and 
HPV11 could almost eliminate new cases of genital warts.  
5.4.2 The national cervical screening program  
Cervical screening programs can detect cervical abnormalities early, monitor changes in 
cytology and lead to appropriate and timely treatment. Cervical screening uses a Papanicolaou 
smear, known as the “Pap test”. A Pap test involves the scraping of cells from the 
transformation zone. The transformation zone is the area where squamous cells from the 
cervix and the glandular cells from the uterus meet. The cells collected by a brush during a Pap 
test are transferred onto a slide. A film is then fixed to the slide and the slide is sent to a 
pathology laboratory for assessment of cells under a microscope for abnormalities(1) . 
 
In Australia, cervical screening from the 1960s onwards was ad hoc until 1991, when Australia 
established an organised approach to screening 18 – 69 year old women. This systematic 
approach included standardisation of: the conventional Pap smear process, interpretation of 
cytology, reporting terminology and laboratory accreditation. Pap smears were, and still are, 
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recommended for women every two years from 18 (or 1 - 2 years after first sexual intercourse) 
to 69 years of age. Cervical screening (Pap test) registers were legislated in each state and 
territory to monitor and evaluate the program. Benefits of this approach are evident from 
1991 onwards with declines in incidence and mortality rates as a result of the cervical 
screening program among Australian women(1).  
5.4.3 HPV Vaccine  
In Australia, since mid-2006 two HPV vaccines have been commercially available. A bivalent 
vaccine (Cervarix® GlaxoSmithKline Inc.), which is a three dose schedule administered at 0, 1 
and 6 months. Cervarix provides coverage against HPV genotypes 16 and 18, the most 
common high risk genotypes found in 70% of cervical cancers worldwide and in Australia(9). 
Currently used (and subsidised) in the national HPV vaccine program is the quadrivalent 
vaccine (Gardasil® CSL Biotherapies), also a three dose schedule administered at 0, 2 and 6 
months. Gardasil provides protection against the above mentioned high risk HPV genotypes 16 
and 18, it also provides protection against low risk HPV genotypes 6 and 11 which cause 90% 
of genital warts(7).     
5.4.4 The National HPV Vaccine Program 
The Australian government implemented a national HPV vaccine program in 2007; the first 
government to fully fund an HPV vaccine program worldwide(10). The program included an 
ongoing school based program targeting 12 - 13 year old girls (girls in first year of high school) 
and from 2007-2009 a catch up program including 14 - 17 year old girls in school. A community 
based program for 12-26 year old girls and women attending primary health clinics and general 
practitioners (GPs) also ran from 2007-2009(10). In 2013 this program was extended to include 
boys 12 - 15 years old in the school based program with an ongoing program of 12 - 13 year 
old boys from 2014 onwards. All eligible people receiving the vaccine as a part of the national 
program receive the vaccine free of charge. People not eligible or those who miss the school 
based program doses will need to attend GP or primary health clinics and pay the price of 
$450(11) plus the cost of attending the clinic to receive the vaccine. 
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Figure 1. Australian national HPV vaccination program rollout timeline 
 
5.4.5 National HPV vaccine program registry 
In 2007 the federal parliament amended the National Health Act to establish a National HPV 
vaccine program registry (NHVPR) to support the national vaccine program. The registry needs 
doctors (namely GPs) or vaccine administers to submit dose information to the registry. It is 
compulsory for school based programs to provide vaccine details to the registry in every state 
and territory of Australia but not compulsory for GPs. During the community based catch-up 
program from 2007-2009 a small monetary incentive was available to GPs to encourage 
completion of records in the registry, however this is no longer available(12). 
In order to understand the current environment post vaccine program implementation in 
Australia, and to meet MAE requirements of producing a literature review, a focused literature 
review was conducted for this project as follows. 
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5.5 Focused literature review 
Question 
What impact has the government funded HPV vaccination program had in the Australian 
population since implementation in 2007? 
Method 
A literature search was carried out in Pub Med, Medline and Web of Science  
Search terms  
In all searches  
 HPV or Human papillomavirus  
 Impact or evaluation or decline or decrease  
Search terms used for different outcomes: 
 Genital warts  
 Cervical abnormalities  
 Cervical cancer  
 Prevalence  
Limits used for some disease outcomes: 
 Australia  
 2007-current 
Papers published in 2014 which are included in the review were received from investigators 
circulating new publications via email to VIP-I investigators. 
5.5.1 Findings of literature review 
In Australia, since the implementation of the vaccine program, 11 population based studies 
have been undertaken to evaluate the effect of the HPV vaccine program on genital warts(11, 13-
17), cervical abnormalities(18-20) and HPV genotype prevalence(4, 21). These eleven studies have 
been reviewed here by different disease outcome. 
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5.5.2 Genital warts 
Genital warts have an incubation period of 3 weeks to 8 months with an average incubation 
period of 2-8 months(22). Due to short disease progression, evaluating the effect of the 
quadrivalent vaccine on the outcome of genital warts commenced early after program 
implementation. Six population based studies on this outcome were identified for review (11, 13-
17); these publications include retrospective clinical data from a number of different sources to 
compare trends over time and binary comparisons of pre and post vaccine populations. All 
study samples have included both females and males, even before the inclusion of boys in the 
school based program.  
One year into the vaccine program, the first impact study documented a rapid decline (25%) in 
genital wart diagnosis among vaccine eligible women (women under 28 years of age) attending 
a large metropolitan sexual health clinic in Melbourne(16). This study also demonstrated early 
signs of herd immunity among heterosexual men less than 28 years of age. This modest 
decline was not seen among men who have sex with men (MSM)(16). A subsequent follow up 
study at the same clinic compared pre vaccine (2004-2007) and post vaccine (2007 -2011) 
cohorts using identical methodology(11). On implementation of the vaccine program, genital 
wart diagnosis among women less than 21 years of age declined from 18.6% to 1.9% in 2010-
2011, a reduction of nearly 90%(11). Declines were also seen in heterosexual men less than 21 
years of age and 21 – 29 year old women and men but not in women or men over 30 years(11). 
These studies report different age ranges, Fairly et al 2009(16)  reporting age groups as women 
under 28 years, women 28 years and over, with no age breakdown of heterosexual men or 
MSM, though this was an early study(16). Read et al 2011 reported age ranges of <21, 21-29 and 
≥30 years for both women and men who have sex with women(11). This age range allowed 
analysis based on vaccine program eligibility. Those aged <21 years of age would have been 
eligible for the school based vaccination program, those aged 21 – 29 years would have been 
eligible for the community based program, while those over 30 years of age would not have 
been eligible for the free vaccine program in 2007. To compare to a non-vaccinated group, 
MSM and female non-residents were reported, but not by age group. Melbourne sexual health 
clinic provides services for the community at large with a focus on those from at risk 
populations such as MSM and lower socioeconomic backgrounds. This study is an indication of 
a well serviced metropolitan community in Victoria. This may not be comparable to rural and 
remote areas of the Australian population outside of metropolitan Victoria, in addition, higher 
vaccine coverage has been reported in Victoria compared to other states and territories(23).  
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The following paragraph deal with a number of studies that report on data from a sentinel 
surveillance program. In 2004, a sentinel surveillance system was established to automatically 
report genital wart diagnosis, demographic and behavioural data from patient information 
systems of eight sexual health clinics across Australia(15). From 2004 - 2009 at surveillance 
clinics, 9% (9867/112083) of all patients had a first diagnosis of genital warts.  Genital wart 
diagnoses were stable from 2004 - 2007 in both men and women, but post-vaccine there were 
significant declines among Australian resident women and heterosexual men aged under 26 
years. No significant changes were seen among those without access to the free vaccine 
program; namely non-resident women, women over 26 years, heterosexual men over 26 years 
or MSM. This study compared Australian women residents less than 26 years old (a vaccine 
eligible group) to a vaccine naive group, Australian non-residents. In the absence of 
vaccination status, comparing vaccine eligible and non-eligible groups would appear to allow 
meaningful comparisons leading to the assumption of vaccine program effectiveness. Ali et al 
2013 published a trend analysis of genital warts surveillance network data adding an extra two 
post-vaccine years(13). From 2004 – 2011 there was a 9% prevalence among new patients 
attending the clinics. This study observed dramatic declines in genital warts prevalence in both 
women (92.6%, p<0.001) and heterosexual men (81.8%, p<0.001) under 21 years of age from 
2007 to 2011.  
To rule out potential influence of decreased risk behaviour during the HPV post vaccine period 
this study reported chlamydia (also a sexually transmissible infection) diagnosis at study 
sites(13). Over the same time period of HPV decline, there were increases in chlamydia 
diagnosis among women, heterosexual men and MSM under 21 years of age. This change 
indicates that HPV decline post-vaccine was not due to a decrease in risk behaviour among this 
age group. Genital warts are not a notifiable disease in Australia therefore sentinel surveillance 
sites from around Australia provide a good source of ongoing impact data.  
Other data sources used to monitor vaccine program impact on clinical burden of genital warts 
included large private and public hospital databases. Ali et al 2013(14) assessed vaccine program 
effectiveness through trends in hospital treatment of warts. This study used the publicly 
available Medicare scheme database, where data were extracted if in-patients were itemised 
as undergoing anaesthetic for genital or anal wart removal. Analysis included procedures 
conducted at all private hospitals in Australia. In-patient treatment of vulval or vaginal warts 
among women aged 15 -24 years declined by 85.3% during the vaccine period from 2007 to 
2011. Between 2000 to 2007 in-patient treatments numbers for penile warts increased by 
200% (17 - 51 treatments) among 15 - 24 year old men. After the vaccine implementation 
targeting women in 2007, in-patient penile wart treatment decreased by 70.6% among men. 
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Likewise, treatment for anal warts among men aged 15 - 24 years was increasing during the 
pre-vaccine period, but decreased by 49.1% in the post-vaccine period suggesting herd 
immunity among young men. 
The most recent study(17) included all private and public hospital admissions with genital warts 
diagnosis (primary or contributing diagnosis) from the National Hospital Morbidity Database 
(NHMD). The NHMD is a comprehensive national database that represents most private and 
public hospital admissions and diagnosis. This study had a large sample size of 39 350 men and 
women and assessed rate of admissions. As found in above mentioned studies, declines in 
genital warts diagnosis were seen at admission; of note this study provided the first indication 
of impact within the Indigenous population. Comparing 2006-2007 to 2010-2011, declines in 
genital warts diagnosis at admission were similar between non-Indigenous (76.1%, CI 71.6%-
79.9%) and Indigenous (86.7%, CI 76.0%-92.7%) women. Indigenous men were not included in 
the analysis due to small sample size. Additionally, two jurisdictions were excluded from the 
subset analysis due to low completion rate of Indigenous status field on medical records. 
No studies evaluating vaccine impact on anogenital warts have linked data with the NHVPR to 
confirm vaccine status of participants. Two studies(11, 15) obtained self-reported vaccine status 
at sexual health clinics, however these were conducted in large metropolitan clinics and 
vaccine coverage may differ by area of remoteness. Most investigators have removed the need 
for vaccine confirmation by comparing vaccine eligible and non-eligible populations, collecting 
self-reported vaccination, referring to vaccine coverage publications, calculating coverage by 
vaccine distribution or correspondence with vaccine registry. These studies would be further 
validated through NHVPR confirmation, but the significant decrease in the clinical burden of 
genital warts is in line with vaccine efficacy against genital warts in clinical trials(2). Researchers 
have provided age breakdowns to determine vaccine eligible age groups and downward trends 
among a vaccine eligible population. However, more consistency of age range analysis among 
published data would allow for improved comparison of results over time. Strengths of genital 
warts impact studies include large sample sizes and the ability to assess whole of population 
data through large ongoing databases. 
5.5.3 Cervical abnormalities  
Cervical abnormalities can occur around 12 months after high risk HPV infection. Disease 
progression to cervical cancer and the true impact of the vaccine on morbidity and mortality 
will not be seen for decades. In 2011 Brotherton et al(18) reported an early decrease in high 
grade abnormalities (HGA) (CIN2 and greater) among young women aged 12 – 17  years using 
Victorian Cervical Cytology Registry (VCCR) population data. In the year before vaccination 
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(2006) HGA among young women aged 12-17 were  0.86% and declined to 0.22% in 2009, 2 
years into the vaccination program(18). This significant decline (0.83%, CI 0.61-0.16, p=0.003) 
was only seen in young women under the age of 18 years(18). Low grade abnormalities were 
declining but considered a part of a long term downward trend and therefore not significant.  
In a retrospective cohort study Gertig et al 2013(20) linked Victorian Cervical Cytology Registry 
(VCCR) data and NHVPR data to determine the effectiveness of the vaccine program on 
outcomes of high-grade or low-grade cervical abnormalities. In this cohort study, vaccinated 
women were compared to those who were unvaccinated (women aged 12-17 years at 
commencement of the vaccine program) and hazard ratios determined in the outcome of high-
grade or low-grade cervical and cytological abnormalities. Outcomes of cervical intraepithelial 
lesions (CIN) low grade 1 (CIN1), high-grade 2 (CIN2) and 3 (CIN3) and adenocarcinoma in situ 
(AIS) were calculated. Rate of histological abnormality was lower among women receiving any 
vaccine dose compared to unvaccinated women. Unvaccinated women compared to 
vaccinated woman were less likely to develop a high grade abnormality (hazard ratio 0.53, CI 
0.36-0.77). Woman with 1-2 vaccine doses compared to unvaccinated women were less likely 
to develop a low grade abnormality (hazard ratio 0.72, CI 0.58 to 0.91). The linkage of a 
screened vaccine eligible population demonstrated the reduced risk of cervical abnormalities 
among vaccinated women who had completed a full vaccine schedule. 
An advantage of registry data is they represent the whole of the screened population; however 
health services access is required for inclusion in these observational studies. Only looking at a 
screened population could bias disease outcome data regardless of vaccination status. One 
group that could be affected by this bias are Indigenous women, who have an 18% lower 
participation rate in the national cervical screening program(24) yet a higher cervical cancer 
incidence and mortality rate than non-Indigenous women(25). Additionally, extracting 
Indigenous specific data from Pap registries is problematic as Indigenous status is not collected 
on pathology forms and therefore the validity of this variable is unreliable; this variable is 
currently being reviewed for quality improvement. Targeted Indigenous specific studies could 
gain consent from participants to retrieve Pap registry data on an ongoing basis for 
longitudinal cohort data. Linking these data with genoprevalence over time would strengthen 
data on the biological effect of the vaccine on cervical abnormalities and cancer outcomes.  
5.5.4 Genotype prevalence  
Genotype data do not exist in large registry or health related databases like the above 
reported genital warts, cervical abnormalities and cancer outcomes because HPV genotype is 
not routinely collected. Samples stored at the Pap registry cannot be used to obtain HPV DNA 
results as the procedure required to assess the cells requires destruction of the Pap registry 
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sample. Therefore, each study using HPV genotype testing requires in-population collection of 
samples. Two HPV genotype prevalence studies have been conducted in Australia; a pre-
vaccine study ‘Women, Human papillomavirus prevalence, Indigenous, Non-indigenous, Urban, 
Rural Study’ (WHINURS)(26) and a follow up post-vaccine study ‘Vaccine impact in the 
population’ (VIP-I)(4, 21). WHINURS aimed to determine the prevalence of circulating HPV 
genotypes among Indigenous and non-Indigenous women in Australia, establishing an 
important pre-vaccine baseline for future genotype prevalence monitoring. From July 2005 to 
February 2008 this study recruited 2156 woman from 43 sites around Australia. Targeted 
recruitment at remote and Indigenous specific clinics contributed to a large Indigenous sample 
size of 655 women. WHINURS found no significant difference in HPV vaccine types 6, 11, 16 
and 18 between Indigenous and non-Indigenous women (table 1), although factors associated 
with HPV detection were higher among Indigenous women including smoking (OR=1.4 p 
=0.010) and abnormal Pap test result. Of women in WHINURS who had a current Pap test 
resulting in a high grade abnormality, 97.8% had detectable HPV. Compared to detection of 
HPV in women with normal results,  women with high grade abnormality  were more likely to 
have detectable HPV (OR=76, p<0.001)  and women with low grade abnormality results were 
also more likely to have detectable HPV  (OR=10, p<0.001)(26). 
Table 1. HPV types in vaccine naive women ≤ 40 by Indigenous status, WHINURS study 
HPV 
types 
Non-Indigenous  
women (n=1494) 
Indigenous 
women (n=655) 
6 47 (3.1%) 13 (2.0%) 
11 9 (0.6%) 6 (0.9%) 
16 141 (9.4%) 69 (10.5%) 
18 62 (4.1%) 25 (3.8%) 
   Source: Garland et al 2011 pg.7 (26) 
There was a significantly higher prevalence of 11 high risk HPV types, other than HPV 16 and 
18, among Indigenous women aged 31-35 and 36-40 years, but younger age groups had no 
significant difference. The disproportionate representation of Indigenous women over the age 
of 30 years with high risk non-vaccine preventable strains is of high importance for future 
monitoring to ensure Indigenous women do not continue to have higher cervical cancer rates 
than non-Indigenous women. WHINURS is the first national prevalence study to assess HPV 
prevalence among Indigenous and non-Indigenous women. Recruitment, sampling and 
laboratory techniques were developed to be repeatable for ongoing monitoring and evaluation 
purposes. To recruit a comparable Indigenous sample again the targeted approach will be 
necessary to ensure ongoing data of a comparable sample. A limitation of this study was the 
CHAPTER 5 EPIDEMILOGICAL PROJECT 
169 
targeted recruitment, where the higher remote recruitment may not be representative of the 
general population as the majority of Indigenous people live in metropolitan areas(27). 
The VIP-I study, repeated the WHINURS cross sectional prevalence methodology. Between 
2010 to 2012, 1058 women aged 18-24 years were recruited from 6 family planning clinics in 
the major metropolitan cities of Melbourne, Sydney and Perth(4, 21). Three clinics from each 
location participated in the WHUNIRS study and one additional clinic located in each city, 
made a comparable post-vaccine cohort. Two papers from this study have been published. The 
first publication presented preliminary findings of vaccine impact on genotype prevalence 
comparing pre and post-vaccine implementation cohorts(21). This paper reported findings from 
data collected from 2010 to 2011 (404 women, the comparable pre-vaccine implementation 
sample was 202 [2005 -2007]). Marked reductions in any HPV genotype, high risk genotypes 
and vaccine preventable types 6, 11, 16 and 18 were seen in post-vaccine women compared to 
pre-vaccine women.  Reduction in vaccine preventable HPV types among post-vaccine 
vaccinated women was larger than reductions seen in non-vaccinated women in the same 
period. Vaccine effectiveness (VE) was calculated using VE=1-RR where rate ratio (RR) = 
adjusted rate ratio between post-vaccine unvaccinated and vaccinated women. VE on HPV 
vaccine types 6, 11, 16 and 18 was 73% (CI 48%-86%, p<0.001). This preliminary report was the 
first genoprevalence study outside of clinical trials.  
The second publication(4) provided genotype prevalence, direct impact, herd immunity, cross 
protection effects of the vaccine program using concluded study data (1058 women). VE 
against 6, 11, 16 and 18 was 86% (CI 71-93, p<0.0001) and VE against genetically related types 
31, 33 and 45 was 58% (CI 26-76, p=0.003) demonstrating significant cross protection on 
closely related HPV types. Herd immunity was demonstrated by the significant decrease of 
vaccine type HPV among unvaccinated women. No genoprevalence studies have linked data 
with the cervical screening registries yet. Linkage of HPV genotype, cervical cytology and 
vaccination status will provide direct biological impact of the vaccine on cervical cancer in the 
future. WHINURS discussed the difficulties in linking genotype and HPV DNA to cervical 
cytology due to sampling processes, however planning and overcoming this barrier may lead to 
more comprehensive understanding of vaccine impact on cervical cancer among Australian 
women in the future. The strength of genoprevalence studies is the ability to further 
demonstrate impact of the HPV vaccine in the population and monitor effects of the vaccine 
on non-vaccine HPV genotypes.  
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5.5.5 Challenges and future work 
Other HPV disease outcomes not included in this analysis and areas of future work could 
include oropharyngeal cancer. One pre-vaccine study(28) could be used as a baseline to 
compare effectiveness of HPV vaccine related types on oropharyngeal cancer outcomes among 
young women and men. 
Australia has established itself as a progressive world leader in HPV vaccine implementation 
and is placed in a good position to adapt to the rapidly changing HPV environment. This 
leadership has vision and is forward planning for foreseeable changes. Targeted populations 
for future focus in surveillance are Indigenous women and men, MSM and people from 
culturally and linguistically diverse backgrounds(10, 29). Considerations for future studies and 
analysis include determining vaccine coverage, dose and vaccine type, dose completion and 
disease outcomes based on dose completion, conformity of age range analysis, disease 
outcomes as a result of vaccination or herd immunity, the demographics of unvaccinated 
populations, monitoring change of circulating HPV genotypes, the prospect of a nonavalent 
vaccine (nine HPV type targeted vaccine) and what complexities its introduction will bring to 
monitoring and reporting.  
5.5.6 Conclusion  
The Australian HPV vaccination program has been evaluated based on common HPV outcomes 
of genital warts, cervical abnormalities and targeted genoprevalence studies. Reproducible 
methodologies and large health databases have been utilised where possible to assess impact. 
Vaccine effectiveness on HPV vaccine genotypes is high at 87% of those women vaccinated(4). 
Both genotype prevalence and genital wart studies have reported herd immunity among 
unvaccinated populations. Decreases in cervical abnormalities and cancer outcomes have 
shown early decline(18-20) although longitudinal studies into the future will demonstrate true 
impact on cervical cancer.  Ongoing surveillance is needed to understand the long term effect 
of the vaccine in the population and type replacement or evolution of the virus as a result of 
vaccination. Genotype prevalence surveillance is essential to the future monitoring of the HPV 
vaccination program impact on the Australian population. 
5.6 VIP-I Study background 
Indigenous women in Australia have higher cervical cancer incidence and mortality rates than 
non-Indigenous women, there is a need to provide evidence of the impact of the HPV vaccine 
program on genotypes among Indigenous women(1). Monitoring is required to ensure any 
changes to vaccine preventable genotypes as a result of the vaccination program benefit both 
Indigenous and non–Indigenous women. If there are inconsistencies in vaccine effectiveness 
on genotypes or vaccine coverage between both groups, steps can be taken to ensure 
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improved delivery of the vaccine program. There has been one study showing comparable 
decreases in genital warts diagnosis at hospital admission among Indigenous and non-
Indigenous women(17). There has also been a documented decrease in HPV vaccine genotypes 
in other studies(4), there has not been a sufficient Indigenous sample size to determine 
whether there has been a comparable decrease in genotype prevalence among the Indigenous 
population(4, 21). Data from the current study (VIP-I) and a pre vaccination genotype prevalence 
study (WHINURS(26)) will be utilised in the attempt to answer the following questions: 
 
1. Does the pre and post-vaccine data show evidence of a decrease in the prevalence of 
vaccine targeted HPV types (16, 18, 6 and 11) circulating in the Indigenous population? 
 
2.  Is a decrease observed in strains not targeted by the vaccine but known to be 
phylogenetically related to the vaccine types (e.g. types 31 and 45), suggesting vaccine 
cross protection? 
 
3. Is there a significant increase in the prevalence of any non‐targeted HPV types which 
may point to potential type replacement? 
5.7 Aims and objectives 
To evaluate the effectiveness of the national HPV vaccination program among Indigenous 
women VIP-I aims to: 
 Estimate the proportion of Indigenous women vaccinated among those aged 18-26 
years attending for Pap testing.  
 
 Estimate the prevalence of HPV types (including vaccine-specific types 6, 11, 16 and18 
and other high risk HPV types) among Indigenous women in the post-vaccine era and 
compare to pre-vaccine era. 
5.8 Methods 
The current ‘Vaccine Impact in the Indigenous Population’ (VIP-I) study is a repeat cross-
sectional genoprevalence study with similar methodology to the pre-vaccine WHINURS 
study(26) and post-vaccine VIP study(4, 21). The VIP-I study data collection consisted of three main 
components; 1) A demographic and behavioural questionnaire, 2) HPV sample collection for 
genotyping and 3) HPV registry data linkage, all discussed in more detail below. 
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5.8.1 VIP-I Study population 
The VIP-I study was focused on recruiting Indigenous women to ensure collection of a sample 
of Indigenous women comparable to a subset of Indigenous women from the pre-vaccine 
WHINURS study.  This was achieved through the following methodology. 
5.8.2 Sample size 
Sample size calculations were based on the estimated HPV prevalence among Indigenous 
women in the prior vaccine impact study ‘WHINURS’. Suspected reduction in prevalence was 
based on the 75% decrease in vaccine targeted HPV genotypes from the post-vaccine study 
‘VIP’ from 28% - 6%. Sample size calculations for the VIP-I study were made using baseline 
(pre-vaccine) vaccine targeted HPV prevalence and using the post vaccine reduction to 6%. 
Using this HPV prevalence and the reduction of HPV vaccine genotypes observed in the VIP 
study, we estimated that 205 women would need to be recruited from the four to six sites to 
give sufficient statistical power (>0.9, alpha=0.05) to detect a difference in HPV prevalence 
between post-vaccine era and pre-vaccine era populations.  
5.8.3 Site recruitment 
Six study sites which had previously recruited larger numbers of Indigenous women during the 
pre-vaccine WHINURS study were approached to take part in the VIP-I study. Initial contact 
was made with site chief executive officer (CEO) and key contacts.  Teleconferences were held 
with services regarding the VIP-I project, service capacity (workforce, ability to take on 
research, numbers of 18 – 26 year olds Indigenous women attending service and number of 
Pap smears conducted per month). Once sites expressed interest to participate in the study, 
site agreements were established and signed by the CEO or board chair. 
5.8.4 Site training  
Site visits were conducted at each participating service (following signed site agreements). Site 
visits included VIP-I study training and HPV update for clinical staff, health workers and 
interested workers from local health organisations. Training materials included: VIP-I 
procedures manual (appendix 2), VIP-I presentation (appendix 3) and an adapted HPV update 
presentation. Where possible, a HPV expert provided the HPV update.  
5.8.5 Participants  
Study sites recruited Indigenous women aged 18-26 years presenting or overdue for cervical 
screening. These were women aged between 11 and 20 years in 2007 when the vaccine 
program started. Age limits were determined according to participant’s eligibility for the 
vaccination program in 2007. Those eligible for vaccine in 2007 were either 11 – 13 years in the 
school based program, or 18-26 years in the community based catch-up program.  
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5.8.6 Inclusion criteria 
 Indigenous women aged 18‐26 years at the time of sample collection 
 Presenting at a participating ACCHS collaborating health service 
 Treatment at clinic to include Pap screening 
 Adequate English and comprehension skills to give informed consent 
5.8.7 Exclusion criteria 
 Males 
 Children and/or young people (i.e. <18 years) 
 Women aged 27 years and over at the time of sample collection 
 People highly dependent on medical care 
 People with a cognitive impairment, an intellectual disability or a mental illness 
 People with insufficient English to allow clear communication of study details 
5.9 VIP-I Study data sources 
5.9.1 Consent  
Identified clinical staff at study sites gained informed consent from participants. A patient 
information and consent form (appendix 2) was provided to participants. Clinical staff also 
verbally conveyed study information to ensure participants could give their informed consent 
to the study. If patients agreed to participate, two consent forms were signed. 
1) VIP-I study consent included: 
a) Questionnaire collection 
b) Use of biological samples from routine Pap smear for HPV DNA and genotype 
testing  
c) Review of medical records for last Pap test date and result plus current Pap result 
 
2) NHVPR data retrieval consent 
5.9.2 Questionnaire  
The VIP-I Questionnaire (appendix 1) was adapted from the post vaccine VIP study. The 
adaption process included the removal and rewording of some questions to be culturally 
appropriate and also took on board feedback from VIP-I study site staff and health 
professionals involved in the VIP study. After the consent process, the VIP-I questionnaire was 
completed by each participant or completed with the assistance of a health professional. 
Variables included: demographics, self-reported vaccination year, vaccine dose, last Pap result, 
age at first sexual intercourse, contraception use and smoking habits.   VIP-I has seen the 
introduction of a survey to gather demographic and behaviour data to be used in subsequent 
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surveillance, but not all variables will have a corresponding variable from the pre-vaccine study 
for the purpose of this analysis. 
5.9.3 HPV sample collection, storage, transport and laboratory genotyping methods 
When a routine Pap smear was conducted on each participant, a conventional Pap slide was 
prepared to be sent to local laboratories as per general clinic procedure at each site. After the 
preparation of a conventional Pap slide an extra step was added for the VIP-I study sample. 
The brush used to collect the conventional Pap was placed into a Thin Prep Preservcyt® jar 
(provided by the study) and rinsed vigorously to allow cervix cells to dislodge from the brush 
and suspend in the Thin Prep Preservcyt®. Jars were labelled with appropriate study labels, 
placed in a zip lock bag and stored in a provided esky. Completed samples in Thin Prep jars 
could be stored at room temperature (any temperature under 38 degrees Celsius). Samples 
could be stored at sites for up to a month before courier transport to the HPV WHO reference 
laboratory at the Department for Microbiology and Infectious Diseases, The Royal Women’s 
Hospital, Melbourne. All sites received VIP-I training along with study procedures for sample 
collection, labelling, storage and transport to ensure quality samples for laboratory testing. 
(See Appendix 3 ‘VIP-I procedures manual’ for detailed descriptions of sample collection, 
labelling and transport procedures). Samples were couriered from study sites each month.  
The methods for HPV genotype detection were the same as those used in the pre‐vaccine 
WHINURS study and post-vaccine VIP study(4, 21). In short, 1 ml of cervical cells in Thin Prep 
Preservcyt® was prepared for DNA extraction. All samples were assessed for the presence of 
HPV DNA and genotype including any of the 13 mucosal HPV types considered “high risk“(16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). HPV genotyping profiles were manually 
interpreted and verified using the HPV reference guide provided with each test kit. Results 
were returned to services for usual results procedures and follow up. A clinical algorithm of 
care for appropriate follow up as per study protocol was provided to services. 
5.9.4 National HPV Vaccine Program Registry data   
Participant consent was obtained to confirm vaccination status by retrieving data from the 
NHVPR. The following variables were collected; participant presence on the registry, current 
vaccination status, vaccination dose date, where dose was received, provider details, 
Indigenous status and required follow-up. 
5.9.5 Pre-vaccine data source  
The pre-vaccine implementation sample included Indigenous women aged 18-26 years 
attending WHINURS sites for routine Pap smears from 2005 to 2007. This cohort of Indigenous 
women was established prior to the implementation of the vaccine program and represents a 
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vaccine naive group. A subset of Indigenous women who attended WHINURS sites are now 
enrolled in the follow up VIP-I study, therefore making a comparable pre-vaccine cohort. A 
questionnaire was not administered during the pre-vaccine study however, general 
demographic information, Pap result, smoking history, contraceptive use and postcode were 
obtained from general medical records with the consent of participants.  
5.10 Data analysis methods 
Preliminary findings are provided here. Due to submission date requirements of the MAE this 
analysis was conducted on data and samples from one VIP-I service available on the 17th 
October 2014. Interpretation of these preliminary data should be done with caution. Full 
analysis of will take place mid next year (2015) on completion of recruitment. Due to the 
power of the preliminary analysis provided here, vaccine effectiveness cannot be calculated. 
Only descriptive analysis and HPV prevalence have been calculated.  
5.10.1 Preliminary analysis 
Using preliminary data, a descriptive analysis of demographic and behavioural characteristics 
of both pre (WHINURS) and post (VIP-I) vaccine cohorts such as age, area remoteness, last Pap 
test, result of last Pap test and cigarette smoking have been conducted. Chi-squared tests have 
been performed to detect any demographic and behavioural variance between the pre and 
post vaccine groups, where numbers were below 5 in any cell Fisher’s exact test was used. The 
Accessibility/Remoteness Index of Australia (ARIA) was used to categorises participants into 
very remote, remote, rural and metropolitan regions based on provided postcode of 
residence(30).  Pre and post vaccine era HPV prevalence by genotype were calculated. HPV 
genotype prevalence comparisons were made between; 1) pre and post-vaccine cohorts and; 
2) vaccinated and unvaccinated women among the post-vaccine cohort. Where appropriate, 
Chi2 test or Fisher’s exact test were used to compare groups. 
Variables of interest included: 
1. Any HPV genotype 
2. HPV vaccine types 6, 11, 16, and 18 
3. Any high risk HPV genotype(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, or 68) 
4. Any high risk HPV genotype excluding 16 and 18 (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 
or 68) 
Additional groupings of HPV types were analysed; HPV types 31, 33, and 45 grouped due to 
their genetic linkage to vaccine targeted HPV types; and HPV 11 and 16 were grouped because 
of their disease outcome of genital warts. 
      INFECTIOUS DISEASES AMONG MARGINALISED POPULATIONS  
 
176 
Vaccine effectiveness (VE) would have been determined using VE=1-PR where PR=ratio of 
prevalence between post vaccine vaccinated and unvaccinated women, but this preliminary 
analysis was not powered to find significance. The required sample size for this calculation was 
57 participants in each group based on reductions in vaccine targeted HPV seen in a previous 
study(4). 
5.10.2 Ethics 
Ethics approval was obtained from 6 relevant Human Research Ethics Committees in all study 
jurisdictions and the Australian National University Human Research Ethics Committee. 
5.11 VIP-I Study update 
On date of reporting these results the VIP-I study had recruited five study sites and around 80 
samples had been collected at 3 of those sites. There were a number of issues in lead time for 
site recruitment and participant recruitment. These included; ethics delays; turnover of staff at 
services (even though services had participated in the previous study staff members who 
coordinated the study were no longer present); new engagement with services; difficulties 
engaging Indigenous women aged 18-26 and Indigenous women’s lower participation in Pap 
screening. All of these factors have resulted in delay and funding agreements have been 
extended to meet the challenges of the project. 
5.12 Results 
Preliminary results reported here represent VIP-I data collected up until 17th October, 2014. A 
total of 57 out of the target 200 Indigenous women aged 18-26 were available for this analysis. 
Results reported are from one VIP-I study site, an ACCHS in the Northern Territory (41 
Indigenous women).  
Fifty-two vaccine naive Indigenous women aged 18-26 years were recruited from the identical 
participating Northern Territory ACCHS during the WHINURS pre-vaccine phase. This cohort 
made up the baseline comparison group for assessing changes in genotype prevalence within 
the post-vaccine VIP-I study population.  
Age among pre and post -vaccine cohorts was similar with a median of 22 years for both 
groups.  
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Table 2. Demographic characteristics of pre and post-vaccine Indigenous women age 18 -26 
  
Pre-vaccine 
(2005-2007) 
n=52 
Post-vaccine 
(2013-2014) 
n=41 
Chi2       
p value 
  n % n %   
Remoteness  
Very remote 12 23 1 2 0.005* 
Remote 40 77 39 95 
Metropolitan 0 0 1 2 
Smoker  
Yes 35 67 21 59 0.191 
No 17 33 17 46 
Pap test 
First Pap 10 23 10 26 0.757 
Had previous Pap 34 77 29 74 
Most recent Pap test 
Normal 47 90 26 87 0.604 
Abnormal 5 10 4 13 
     *Fisher’s exact used 
There was no significant difference in HPV predictors such as tobacco smoking and a recent 
abnormal pap test between the pre and post vaccine cohorts (table 2). Thirty-five (67%) pre-
vaccine participants had ever smoked compared to 21 (59%) participants among the post-
vaccine cohort. Likewise, a similar proportion of abnormal Pap results were present in both 
pre-vaccine (n=5, 10%) and post-vaccine (n=4, 13%) cohorts. Area of remoteness was 
significantly different (p=0.005) as the post-vaccine sample included mostly participants that 
resided in remote areas (95%) and one participant each from a metropolitan and very remote 
area. The pre-vaccine cohort was from remote (77%) and very remote areas (23%) (Table 2). 
The majority of women in both cohorts were returning for a subsequent Pap test. Only 10 
(23%) participants in the pre-vaccine and 10 (26%) in the post-vaccine cohorts were attending 
for their first Pap smear (Table 2). In the post vaccine group, 12 (32%) women had their last 
Pap smear two to three years and three to four years ago; which is greater than the 
recommended two yearly screens. 
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Table 3. HPV genotype prevalence among pre and post-vaccine Indigenous women aged 18 -
26 years 
HPV genotype Overall prevalence 
Pre-vaccine 
n=52 (%) 
Post-vaccine 
n=41 (%) 
Fisher's exact 
p value 
Any HPV type 30 (58) 12 (29) 0.006*** 
Vaccine targeted  HPV 
types 6, 11, 16 & 18 
13 (25) 1 (2) 0.003 
High-risk HPV types* 24 (46) 7 (17) 0.003*** 
High-risk HPV types 
excluding 16 & 18 
13 (25) 6 (15) 0.218 
HPV 16 8 (15) 1 (2) 0.072 
HPV 18 4 (8) 0 0.127 
HPV 6 1 (2) 0 ** 
HPV 11 1 (12) 0 ** 
HPV 6 or 11 2 (4) 0 ** 
HPV 31, 33, or 45  5 (10) 1 (2) 0.224 
HPV 31 2 (4) 0 ** 
HPV 33 2 (4) 1 (2) 1 
HPV 45 1 (2) 0 ** 
HPV 52 3 (6) 3 (7) 1 
HPV 58 5 (10) 1 (2) 0.224 
* High risk types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, or 68 
**statistical comparisons could not be reliably made in these groups 
*** Chi2 used instead of Fisher’s exact 
 
5.12.1 HPV genotype prevalence  
Overall, the prevalence of HPV DNA among Indigenous women aged 18 – 26 years significantly 
decreased from 58% among pre-vaccine to 29% (p=0.006) post-vaccine (Table 3). These 
preliminary findings demonstrates a significant decrease in vaccine targeted HPV types 6, 11, 
16 and 18 from 25% pre-vaccine (2005-2007) compared to 2% in the post-vaccine era (2013-
2014) (p0.003). A significant reduction in 13 high risk HPV genotypes (16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, or 68) (46% down to 17%, p=0.003). However, when HPV genotypes 16 and 
18 were excluded from this analysis the decrease was no longer significant (25% compared to 
15%, p=0.218). Individually, no HPV genotypes significantly decreased between pre-vaccine to 
post-vaccine era. HPV types 6 and 11 were of low prevalence among Indigenous women in the 
pre-vaccine cohort with only one case of each.  
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5.12.2 Self-reported vaccination status  
Self-reported vaccination status from the VIP-I survey has been used for this preliminary 
analysis as registry data was unable to be obtained (only requested) in time for this analysis. 
Of the VIP-I sample (post vaccine era), 27 (66%) self-reported full vaccination, 11 (27%) 
reported only partial vaccination and three (7%) reported no vaccination (Table 4).   
Table 4. Frequency of vaccination among VIP-I women, and by remoteness 
  
Fully vaccinated 
N (%) 
Partial vaccination 
N (%) 
No vaccination 
N (%) 
Self-reported 
vaccination 
27 (66)  11 (27) 3 (7) 
Very remote 0 0 1 
Remote 26 11 2 
Rural 0 0 0 
Metropolitan 1 0 0 
 
Table five presents VIP-I prevalence of HPV genotypes by self-reported vaccination status. The 
full vaccination group included individuals self-reporting full vaccination, and the unvaccinated 
group included those self-reporting no or partial vaccination. Full vaccination was reported by 
66% of participants (27/31).The participant with a positive HPV 16 result in the VIP-I study self-
reported no vaccination and resided in a very remote location.  
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Table 5. HPV genotype prevalence among Indigenous women from the VIP-I study by 
vaccination status 
HPV genotype Post-vaccine  prevalence                                               
(self-reported vaccination) 
 No or partial 
vaccination 
n=25 (%) 
Full 
vaccination 
n=31 (%) 
Fisher’s exact            
p value 
Any HPV type 4(27) 8(30) 0.944*** 
Vaccine HPV types 16, 
18, 6, 11 1(7) 0 0.341 ** 
High-risk HPV types* 3(21) 4(15) 0.673 
High-risk HPV types 
excluding 16 & 18 2(14) 4(15) 1 
HPV 16 1(7) 0 ** 
HPV 18 0 0  - 
HPV 6 0 0  - 
HPV 11 0 0  - 
HPV 6 or 11 0 0  - 
HPV 31, 33, or 45 1 (7) 0 ** 
HPV 31 0 0  - 
HPV 33 1(7) 0 ** 
HPV 45 0 0  - 
HPV 52 2(14) 1(4) 0.265 
HPV 58 1(7) 0 ** 
* HR types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, or 68 
*** chi2 test used 
 
5.13 Discussion  
By returning to services involved in the WHUNIRS pre-vaccine study(26) to run a repeat cross 
sectional prevalence survey, we were able to provide preliminary evidence to demonstrate the 
effectiveness of the HPV vaccine program among Indigenous women. Data used for this 
analysis are from the first site to complete data collection. Significant decreases were seen in 
HPV genotypes covered by the vaccine (6, 11, 16, and 18) among post-vaccine 18-26 year old 
Indigenous women, with only one of 31 study participants reporting any of these genotypes in 
the current VIP-I study. The largest prevalence reductions were seen in HPV 16 and 18, but low 
prevalence of HPV6 and HPV11 were reported among the pre-vaccine era Indigenous women 
so reductions in this type were unlikely to be significant(26). No women in the VIP-I post-vaccine 
cohort tested positive for HPV 6, 11, 18 and only one participant returned a positive HPV 16 
result. Sample size in this preliminary analysis was too small to compare to the dramatic 
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vaccine targeted HPV reduction seen among predominantly non-Indigenous women in the VIP 
study which recorded 86% VE against vaccine targeted HPV types(4). Statistical comparisons of 
individual HPV types with small prevalence and sample size within this preliminary analysis are 
not reliably made and need to be interpreted with caution.  
VIP-I participants self-reported full vaccination at 66%, similar to self-reported three dose 
coverage in a previous study which identified lower vaccine coverage and dose completion 
among Indigenous women, 63% self-reported three dose coverage compared to 83% among 
non-Indigenous responders(31). However, the Northern Territory where women in this 
preliminary analysis reside, has recorded higher coverage rates than other states and 
territories in Australia(23). The VIP-I study (on completion) will validate self-reported 
vaccination against NHPVR vaccine dose confirmation, currently it is too early to draw 
conclusions from these data alone. VIP-I will be the largest sample of Indigenous women 
allowing meaningful analysis of registry notification data against vaccination rates within the 
population, as well as providing an indication of Indigenous status completion on NHPVR 
forms. Obtaining vaccine confirmation through the NHVPR will provide a stronger biological 
link to impact of the vaccine in the Indigenous population. 
Half of VIP-I participants reported cigarette smoking (59%), a predictor for detection of HPV 
DNA. Smoking prevalence was similar to that of the pre-vaccine WHINURS cohort (67%),(26) but 
higher than national prevalence (45%), potentially due to smoking rates increasing with 
remoteness(32). Other HPV DNA predictors identified in WHINURS included younger age (less 
than 21 years of age) and an abnormal Pap result(26). The Indigenous population is younger 
than the non-indigenous population; in 2011 the median age of the Indigenous population was 
21 years compared to 37 years of the non-Indigenous population(33). The Indigenous 
population peaks at the age of highest HPV incidence and the potential burden of disease is, 
therefore, elevated. On completion, the VIP-I study will provide an indication of potential 
disease burden decreases through genotype identification within the population, however 
ongoing genotype surveillance is required to truly understand the impact of the vaccine with in 
all age groups. 
Factors such as low participation in cervical screening(24) and disproportionately high HPV 
predictors(26) among Indigenous women could be the defining difference between disease 
progression and outcomes among Indigenous and non-Indigenous women in the vaccine era. 
Therefore close attention to vaccine coverage, monitoring of HPV genotypes and continued 
campaigns for cervical screens are necessary into the future for Indigenous women. This 
requires a targeted approach as we have seen from post-vaccine studies, sufficient Indigenous 
sample size is not obtainable solely through mainstream health services and medical databases 
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(4, 11, 13-20). It will be imperative to ensure targeted messaging to Indigenous women of the 
importance of continued cervical screening as per national guidelines after vaccination. There 
is evidence to indicate vaccinated women are being screened at a lower rate compared to 
unvaccinated women(34). To ensure maximum impact of the national HPV vaccination program 
Indigenous specific screening program messages should be delivered in a culturally sensitive 
and locally tailored manor.   
5.13.1 Limitations  
As mentioned throughout, sample size was a limitation in this preliminary analysis. Results 
have demonstrated the decrease in all HPV genotypes, high risk genotypes and vaccine 
targeted types when comparing per and post-vaccine cohorts. Analysis beyond this point was 
not possible. This analysis is an indication that VIP-I study objectives will be met on completion 
of recruitment. There are such small numbers in this preliminary analysis that any more cases 
of vaccine targeted HPV could change the results and therefore no definitive conclusions 
should be made until further data is available. 
Preliminary data analysis here consists of participants residing in remote areas of Australia. It is 
acknowledged the Indigenous population is geographically, culturally and linguistically diverse. 
There are also varying levels of access to health services. A finding from WHINURS is that 
Indigenous and non-Indigenous women residing in remote areas were at lower risk for HPV 16 
and 18(26). This sample from the NT is not representative of the wider Indigenous population. 
Caution should be taken in using these data to describe vaccine program effectiveness until 
completion of the full VIP-I sample target is met. In its current state findings should not be 
generalised to the wider Indigenous population. VIP-I service sites have been selected to 
ensure a comparative sample by completion of the study as sites will reflect recruitment from 
a variety of location in a number of jurisdictions. 
5.13.2 Methodological recommendations  
Due to ongoing surveillance of HPV in the population, continued targeted recruitment of 
Indigenous women and the inclusion of men (due to inclusion of boys in the vaccination 
program and monitoring of herd immunity) is required. Below are some methodological 
considerations for future work. 
 Due to lower uptake of cervical screening by Indigenous women compared to non-
indigenous women and the imminent cervical screening guidelines change to genotype 
testing and screening based on risk(35), collecting samples only during routine cervical 
screening may result in long recruitment times. Using self-collected samples in 
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addition to clinician collected samples could reduce recruitment times and research 
burden on services. This method has been successful in other settings(36). 
 The dedication of a full-time/part-time coordinator and the establishment of an 
Indigenous surveillance advisory committee could result in more meaningful 
engagement and longevity of partnerships with services. 
5.14 Conclusion 
This preliminary analysis of the VIP-I study provides some evidence of reductions in circulating  
HPV DNA and vaccine targeted genotypes among Indigenous women of vaccine eligible age. 
This finding implies effectiveness of the national vaccine program among Indigenous women. 
While results here demonstrate promise for the larger VIP-I study objectives, conclusions 
should not be drawn purely from this analysis. Compared to pre-vaccine, predictors for 
presence of HPV DNA did not change among Indigenous women post-vaccine. The known 
burden of HPV related disease outcomes among the Indigenous populations warrant ongoing 
and targeted surveillance initiatives to monitor effect of the HPV vaccine program.  
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PARTICIPANT INFORMATION STATEMENT AND CONSENT FORM 
Has the cervical cancer vaccine made a difference to types of HPV in Indigenous women? (HPV 
stands for ‘human papillomavirus’, sometimes known as the ‘wart virus’, or the virus that can 
cause cervical cancer) 
Principal Investigator 
John Kaldor on behalf of the research team (Suzanne Garland, Sepehr Tabrizi, Bette Liu, Julia 
Brotherton, Dina Saulo, Rachel Skinner, Mary Stewart, Liz Sullivan, Skye McGregor). 
About the study 
HPV (human papillomavirus) is the main cause of cervical cancer worldwide. The vaccine to 
protect against cervical cancer was introduced in Australia in 2007. We are undertaking a 
research study to understand the impact of the vaccine in Indigenous women.  
You are being asked to take part in a study to test for the presence of HPV and type of HPV 
among Aboriginal and Torres Strait Islander woman age 18-26. Information from this study will 
be used to determine if the types of HPV virus in the Aboriginal and Torres Strait Islander 
population have changed since the cervical cancer vaccine was introduced. The study will also 
evaluate if HPV has decreased at the same level among Indigenous woman compared to non 
Indigenous women.  
Do I have to participate? 
No, it is your choice whether or not to participate. If you choose to participate but would like 
to pull out at any stage you can. You do not need to explain why you don’t want to do the 
study and this will not disadvantage you in any way. 
What will happen if I participate? 
If you choose to participate, there are three steps  
1) A health professional will talk to you about the study and you will be asked to sign two  
consent forms. One to consent to the study and a second optional one allowing the 
study group access to your  details on the HPV register. This gives  information about 
the number of doses of HPV vaccine you have had. The personal information you give 
us will only be used to link you to the register, not for any other purposes. Any 
information you provide is confidential.  
 
2) The health professional will ask you questions about health behaviour and past 
experiences from a short confidential survey. Alternatively you can fill out the survey 
yourself. The survey asks some personal questions but please note this is a confidential 
survey: in the survey we will not collect any of your personal contact details such as 
your name, phone number or address.  
 
3) A health professional will collect a Pap test sample during your routine Pap test. This is 
the same type of sample as they would take if you were not in the study. Your sample 
Appendix 2: VIP-I participant information and consent form 
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will be tested for in the normal way to check for changes, as well as an extra test for 
the types of HPV that can cause cervical cancer. 
 
4) The health professional will retrieve from you medical record; information about your 
last Pap test and the result. 
 
5) Once the tests have been done on your Pap sample and when the study is finished, all 
samples will be destroyed. 
 
What about my results? 
The results of your Pap test will be given to you by your doctor or nurse just as if you were not 
in the study. If it is abnormal they will explain to you what this means and what you need to 
do. If the extra test we do for the types of HPV genotypes that can cause cervical cancer is 
positive you will be invited to have a follow-up test a year later. There will be no cost to you for 
this test.  
Will anyone else see my information or know about my results? 
The result of your Pap test will be given to you in the usual way your health service would 
deliver results normally. No one will see your answers to the survey except the researchers, 
and even then there will be no identifying information available. All information about 
individuals that is collected in this study is confidential. You will not be identified in any report 
or publication that results from this survey. We plan to publish the results of the survey in 
reports and in academic papers.  
What if I have a complaint or concern about the research? 
Complaints may be directed to the relevant Ethics Secretariat, details of which are provided 
below. Any complaint you make will be investigated promptly and you will be informed of the 
outcome.  
University of New South Wales HREC  
02 9385 7251 or ethics.gmo@unsw.edu.au   
Application ID: TBA  
 
Central Australian HREC  
08 8951 4700 or cahrec@flinders.edu.au   
Application ID: TBA  
 
Western Australian Aboriginal Health Ethics Committee 
08 9227 1631or ethics@ahcwa.org  
Application ID: TBA  
 
Aboriginal Health and Medical Research Council Ethics Committee 
02 9212 4777 or ethics@ahmrc.org.au  
Application ID: TBA 
 
Townsville Hospital and Health Service Human Research Ethics Committee 
07 4433 1140 or TSV-Ethics-Committee@health.qld.gov.au  
Application ID: TBA 
 
Family Planning NSW Ethics Committee   
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02 8752 4386 or emmap@fpnsw.org.au  
Application ID: TBA 
 
Australian National University  
02 6125 3427or human.ethics.officer@anu.edu.au 
Application ID: 2014/161 
How do I get more information about this study? 
If you would like to know more about the study or if you have any additional questions later, 
Ms Dina Saulo will be happy to answer them. Dina can be contacted on the free call number 
1800 066 141 or by email dsaulo@kirby.unsw.edu.au 
 
You are making a decision whether or not to participate. Your signature on the consent form 
indicates that you have read the information provided above or a health professional has 
gone through the information with you and you have decided to participate.  
You will be given a copy of this form to keep. 
 
Thank you! 
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PARTICIPANT INFORMATION STATEMENT AND CONSENT FORM (continued) 
 
You are making a decision whether or not to participate. Your signature indicates that, 
having read the information provided above, you have decided to participate.  
I,          , voluntarily consent 
to taking part in this study, which has been explained to my by     
  
I have been asked if I would like to have a family member or friend with me while the project 
was explained. I understand that if I do not wish to participate, or if I withdraw from the study 
at any time without explanation, this will not affect my relationship with the health service I 
attend, the researchers involved in or anyone affiliated with the study. 
I understand that I will receive a copy of this consent form. 
            
  
Signature of Research Participant    Signature of Witness  
  
             
  
(Please PRINT name)      (Please PRINT name)  
 
            
  
Date        Nature of Witness  
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REVOCATION OF CONSENT 
 
I hereby wish to WITHDRAW my consent to participate in the research proposal described 
above and understand that such withdrawal WILL NOT jeopardise your relationship with the 
health service nor with any of the organisations affiliated with this research project.  
 
           
Signature       Date  
 
           
Please PRINT Name  
 
The section for Revocation of Consent should be forwarded to: 
Ms Dina Saulo 
The Kirby Institute 
University of New South Wales 
CFI Building 
Corner West and Boundary Streets 
Darlinghurst NSW 2010 
Email: dsaulo@kirby.unsw.edu.au 
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Authorisation for collection of HPV vaccine data from the HPV Register 
The researchers of this study would like to verify your HPV vaccination status by sending your 
details (your name, date of birth and address of residence when vaccinations were received) to 
the National Human Papillomavirus Vaccination Program Register (NHVPR). This is an 
Australian register which records HPV vaccine doses administered to individuals and is owned 
by the Australian Department of Health. We would like to determine whether your vaccine 
history is in the register, the number of doses of the vaccine which you have received and the 
dates of each of the doses. Because some people are not always certain of what vaccines they 
have received and when, we would like to request this data even if you think you may not have 
received the HPV vaccine. It is important to note that if you received the HPV vaccination with 
your General Practitioner it may not be registered with the HPV Vaccination Register yet. In 
this event, with your consent, we would like to verify your vaccination status with your 
General Practitioner. We are more than happy to relay the information that we obtain from 
the register to you for your personal records if you would like us to do so. 
First name: …………………………………… 
Surname: ……………………………………      Previous name (if applicable)………………………………… 
Date of Birth (DD/MM/YY):  __ / __ / ____ 
Current address:                Previous address (if applicable): 
Street …………………………………………                       Street ………………………………………… 
Suburb ………………………………………                         Suburb ……………………………………  
Postcode /State…………………                                         Postcode /State………………… 
Place where vaccinations were received (if applicable):  
 School                 General Practitioner         AMS      remote clinic nurse                 
Other 
Name of school / General Practitioner: …………………………………………………………………… 
Location of school / General Practitioner: ………………………………………………………………… 
Other: ………………………………………………………………………………………………………… 
*If vaccine doses were received at multiple locations, please provide details of each location 
Medicare number: ………………………………… 
(this will help the Register find your record and will not be used for any other purpose) 
I would like to receive confirmation of my HPV vaccination status: 
 Yes             No            Not applicable   
Consent:I have read, or have had this document read to me in a language that I understand, 
and I consent to having my details sent to the National Human Papillomavirus Vaccination 
Program Register for verification of my HPV vaccination status and the dates when I received 
my vaccination doses. I consent to the Register providing my vaccination status and dates of 
doses back to the researchers. I consent to this information being confidentially stored and 
used for the purposes of this research project.  
Signature: ……………………………………………………          Date:  __ / __ / ___ 
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VIP-I Training Manual 
 
 
HPV Vaccine Impact in the  
Australian Indigenous Population  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 VIP-I 
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About VIP-I  
 Background  
During 2005-2008 the Women’s HPV Indigenous Non-Indigenous Urban Rural Study 
(WHINURS) (1) recruited Indigenous and non Indigenous woman throughout Australia 
undergoing cervical cytology screening, in order to estimate the prevalence of human 
papillomavirus (HPV) genotypes in this population. Participants in WHINURS were 
recruited via ACCHS, General practitioner clinics and family planning clinics. As a 
majority of woman were recruited prior to the implementation of Australia’s HPV 
vaccination program, the WHINURS study established an important baseline for post-
vaccine program surveillance of HPV types in this population.  
A second study called VIP compared a post-vaccine sample, recruited through family 
planning clinics, to the pre-vaccine WHINURS sample and found a significant decrease 
in vaccine preventable HPV genotypes (2). The reduction was consistent with what 
would have been expected based on clinical trials that demonstrated vaccine efficacy.  
 
Rationale  
There is a need to evaluate the impact of the HPV vaccine program on the prevalence 
of infection among Indigenous women in Australia. Although there has been a 
documented decrease in HPV vaccine genotypes by other studies they have not had a 
sufficiently large Indigenous sample size to determine whether there has been a 
corresponding decrease in the prevalence of infection among Aboriginal and Torres 
Strait Islander women.  
 
Design  
Six ACCHS which recruited substantial numbers to the WHINURS studies will be 
approached to participate in the VIP-I study to ensure a comparable sample. VIP-I is 
targeting recruitment of 220 Indigenous women aged 18 - 26 who attend ACCHS (or 
other service providers with a high proportion of Indigenous clients) for routine 
cytology screening over the study period.  
 
Aims of VIP-I  
 To estimate the proportion of Indigenous women who have been vaccinated 
among 18-26 years old women attending for cervical cytology screening  
 
 To estimate and compare the prevalence of HPV types (including vaccine-
specific types 6/11/16/18 and other high risk HPV types) among Indigenous 
women in the post-vaccine era compared to pre-vaccine era  
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Time frame  
VIP-I study is funded from May 2013 – December 2014  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
June 2015 
Outputs from research provided to services 
March 2015 
Site report provided to TAIHS 
October 2014 – March 2015 (or until reaching recruitment target ) 
Participant recruitment at TAIHS 
October 2014 
Site training  
June 2013 4 
TAIHS - Site agreement approved  
June 2014  
Ethics committees approval through Townsville HREC 
May 2013  
Study design and development  
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Study Steps 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Fax documentation weekly to investigators -  
participation log, completed questionnaires and 
consent forms 
Transport of samples to RWH, melbourne.                 
via courier once a month or when provided esky is full 
Store sample and Study documents   
Label samples and documentation 
Collect Sample  
Administer Questionnaire 
Gain consent for study & information and signature 
for Pap Registry Consent form 
Use participation log to document declines or 
consents to study 
Provide participant Information Sheet and explain 
study to potential study participants  
 9 
8 
7 
3 
 
VIP-I 
6 
4 
5 
2 
1 
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1. Recruitment 
During the study period any Aboriginal and/or Torres Strait Islander women between 
the ages of 18 – 26 attending the clinic can be asked to participate in the study. The 
following criteria apply to participation in the study. 
 
Who can participate?  
• Aboriginal and Torres Strait Islander women aged 18‐26 years at the time of 
sample collection 
• Adequate English and comprehension skills to give informed consent 
• Presenting at a participating Aboriginal Community Controlled Health Service or 
collaborating health service and are presenting for a Pap or are overdue for a 
Pap and therefore offered the service. 
 
Who cannot participate? 
• Males  
• People less than 18 years of age 
• People aged 27 and over at the time of sample collection  
• People highly dependent on medical care  
• People with a cognitive impairment, an intellectual disability or a mental illness  
• People with insufficient English to allow clear communication of study details, 
which would prevent informed consent  
Participant Information  
Every potential participant must be provided with a participant information sheet 
and/or the participant information sheet verbally communicated to potential 
participant.  
It’s essential to ensure a clear understanding of the study to allow potential 
participants ability to provide informed consent.  
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2. Participation Log 
Logging refusals and participation in the VIP-I participation log will allow understanding of the 
following; 
 Number of 18-26 year old Aboriginal and Torres Strait Islander women attending the 
service 
 Number being offered participation in VIP-I  
 Uptake of the study among attending  18-26 year old women 
Regardless of reason for attending clinic log 18-26 year old Aboriginal and Torres Strait Islander 
patients in the participation log documenting the following; 
1. Current Date 
2. Date of birth 
3. If the patient has been approached to participate  
4. If the patient declines or participates  
Logging participation will allow investigators to gauge the representativeness of the samples 
provided by your service.  Additionally if numbers are low it will allow for understanding of 
how to engage participants in the study, for example, wether a community based drive to 
increase numbers of women in the age range to attend the clinic would assist  or if Pap 
providers need particular prompts in clinic rooms to remember to ask patients during consults.  
 All Pap providers should have a participation log 
 Fax participation log each month to Dina  on 02 9385 0891  
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3. Consent Process 
 All participants must have receives PIS  
 All participants must sign consent forms before participating in the study  
 There are 2 consent forms both are a part of the Participant information  
and consent form. 
3.1       Study Consent form  
Consenting to participate in the study which includes access to information in patient 
records such as vaccine dose dates, participation in the questionnaire and sample 
collection  
3.2 Pap register consent form 
This consent form gives investigators permission to access the participants HPV 
vaccine information on the national HPV vaccine registry, this information will only be 
provided to the research group.  
 Please ensure patients although there is identifying information being collected 
on the Pap register consent form only the research group will have access to it 
and once researchers receive information from the registry all information will 
de-identify.  No identifying information will be published in study outputs.  
3.1 Consent process flow chart 
 
*see section 9 for transport and courier information 
 
5. File consent forms in central VIP-I Study folder 
consent forms should be couriered along with other study documents and samples to Melbourne* 
4. Label consent forms  
attach an allocated piggy-back label so the consent forms corrollate with sample  and questionnaire   
3. Pap registry consent 
We would like to gain access to participants Pap registry information such as dose and where dose was 
administered. This requires an extra consent form with extra information 
2. Study consent 
If Participants understand the study and would like to participate gain written consent This requires a 
signature from the participant, once signed provide the participant with the PIS to take home 
1. Participant Information Sheet (PIS) provided  
Run through the Participant information sheet with patients to ensure they have a full understanding 
of the study 
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4.  Questionnaire 
Questionnaires can be self administered or administered by health staff. This is up to the 
services and the participant.  
 
After Consent forms are completed administer the questionnaire or allow the patient to 
complete the questionnaire. 
While we would like the questionnaire to be complete as possible we understand that some 
participants may not be comfortable in answering certain questions. It is optimal that the 
participant if comfortable  
 
 
*see section 9 for transport and courier information
3. File Questionnare in central VIP-I Study folder 
Questionnare should be couriered along with other study documents and samples to 
Melbourne* 
2. Label Questionnaire 
Attach corrolating VIP-I piggy-back label to front of Questionnaire 
1. Administer Questionnaire 
Administered by health staff or allow the participant to complete the 
questionnaire  
Participants can consent to the study but decline pap 
register consent and still be a part of the study 
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5. Sample collection 
Participating services will be provided ThinPrep sample jars by study coordinators. Sample jars 
will be sent in 2 batches 25. 
Sample target: 50 
 PAP PRACTITIONER COLLECTION DOCUMENT 
- Obtaining the Thin Prep sample - Labelling the VIP-I request slip 
-  
 
To obtain an adequate sample from the 
cervix; 
 
 Insert central bristles of the BRUSH 
into the endocervical canal 
 Apply enough pressure to bend 
lateral bristles against the 
ectocervix and,  
 ROTATE BRUSH 5 TIMES 
 
 
Prepare the conventional smear by; 
 
 ‘SMEARING’ first one side of the 
brush on the glass slide, and then 
the other 
 
 Apply fixative 
 
 RINSE the brush in the Thin Prep jar by 
pushing it into the bottom of the vial 10 
times, forcing the bristles apart 
 SWIRL the BRUSH vigorously to release 
more material 
 Discard all collection devices. DO NOT 
leave them in the solution 
 Re-cap the vial and tighten so that the 
small black mark passes the 
corresponding line on the vial 
 
 VIP-I 
Obtain and adequate sample from the cervix 
 
 
 
 
 
 
 
 
 
 
1 
2 
Prepare the conventional smear 
3 Prepare Thin Prep jar 
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 RECORD clients name as per usual clinic 
procedure 
 Place a ‘VIP-I’ pink label on Preservecyt  
lid 
 ADD a ‘VIP-I’ piggy back label to the 
vial, filling in D.O.B, and initials (first 
name initial and surname) 
 Place Preservcyt labelled bottled into 
the Biohazard Bag and place in the 
shipping box for couriering to the RWH 
Laboratory. 
 Place a ‘VIP-I’ piggy back label on your 
patient records, as well as on consents 
and questionnaire. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 VIP-I 
4 Label study documents and sample 
 
For women with previous history of cone 
biopsy/cervical ablation use the endocervical 
canal brush (with the spatula) and the cervix 
brush as in these patients the broom may not be 
able to reach the transformation zone, which in 
these patients may recede up the endocervical 
canal 
 
CHAPTER 5 EPIDEMILOGICAL PROJECT 
207 
5 Labelling 
 Labelling of samples and study documents will ensure all study components correlate.  
 
 
 
  
5. Label information and consent form with 1 piggy back label  
Place label on first page 
4. Label Questionnaire with 1 piggy back label 
place label on fron page of questionnaire 
3. Place 2 pink VIP-I study sticker on Thin Prep sample jar 
Place the 1 Pink VIP-I stickers on the lid and 1on the side of the sample Jar  
2. Place 2 piggy back labels on ThinPrep sample jar 
place piggy back labels around the thinPrep jar 
1. Clearly write participants details on 4 piggy back Labels  
patient initials, patient DOB and date of sample collection on  four sample labels 
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Labelling for VIP-I HPV Study Samples 
 
1. Clearly write sample details – patient initials, 
patient DOB and date of sample collection on 
four sample labels (generally an additional two 
spare labels have been provided for each 
participant ID –total of 6 labels). 
 
 
2. If the ThinPrep sample jars do not already have 
 pink VIP study identification stickers, please 
 label as shown (left) 
 
 
 
3. Place one pair of patient ID 
stickers – still on their double 
backing – onto the appropriate 
sample jar as shown. 
 
4. The second pair of stickers is separated – one for the patient’s questionnaire 
and one for the consent form. This ensures full traceability between the 
patient’s sample, documentation and receipt logs when the sample reaches the 
lab.
 VIP-I 
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6. Storing samples and study documents 
Samples can be stored in less than 30oC, in most cases storing at room temperature is 
acceptable. Services will be provided with an esky for storing and transporting samples. 
Additionally service will be provided a study folder including all study documents. 
For efficiency allocate a location for the esky and folder so health service staff have one central 
place to store study samples and completed documents.  Samples and completed document 
should be stored after each collection.  
The sample esky is located............................................................................................ 
The study folder is located............................................................................................ 
7. Sending samples by Courier   
Samples can be transported when esky is full or every 4 weeks depending which is more 
frequent.  
The preferred courier for sample transport to the Royal Women’s Hospital laboratory in 
Melbourne is PDP Couriers (http://www.pdpcouriers.com).   
 
Contact Dina or Skye when samples are ready, they will organise pickup of esky and send 
through a consignment note to be attached to esky box.  
 
Dina Saulo    Sky e McGregor 
The Kirby Institute    The Kirby Institute  
University of New South Wales    University of New South Wales 
Wallace Wurth Building, Sydney NSW 2052   Wallace Wurth Building, Sydney 
NSW 2052 
Email: dsaulo@kirby.unsw.edu.au    Email: 
smcgregor@kirby.unsw.edu.au  
Ph: 02 9385 9002     Ph: 02 9385 0958  
Fax: +612 9385 0891     M: 014 0231 8891  
Fax: +61 (0)2 9385 0891 
 
 
Testing Laboratory Address 
 
Molecular Microbiology Laboratory   
Royal Women’s Hospital – Department of Microbiology and Infectious Diseases  
Delivery Entrance C, Business Incubator Building (Bldg 404)  
Rear of Bio21 Institute, 30 Flemington Road  
Parkville, 3052 
 Contact Dina or Skye if you require more information 
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8. Results and follow up 
 
 Reports will be sent to clinics in the form of a letter addressed to Pap providers. 
The letter will contain a HPV positive or negative result.  
 
 A further report will be sent to clinics on completion of sample collection after 
all information has been processed. 
 
 Clinics should continue their conventional pap smear, abnormal and normal 
results should be fed back to clients as per usual. Along with usual follow up 
and recall procedures.  
 
 A recommended algorithm of care for HPV testing has been provided by the 
research team.  
 
 If a Colposcopy is required as per recommended algorithm, costs for 
Colposcopy testing will be covered by the research institutes.  
9.  Study outputs 
The following research out puts will be produced: 
 Patient results sent to Pap providers to feed back to participants 
 Clinic report 
 Paper for publication 
 Conference presentations  
No mention of service names or participants identified in outputs.  
All outputs will be sent to services for approval in sufficient time before 
publication, or presentation. 
Due to the type of research, there may be media interest in findings. No services 
will be mentioned in any media communication.  
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Recommended algorithm of care for HPV testing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
No follow-up. Recommend 
routine Pap in 2 years Normal 
High risk HPV 
DNA detected? 
Pap 
Abnormal 
No 
Persistent (i.e. same 
genotype detected at both 
test points) infection with 
high-risk type(s) other than 
16 or 18 
Persistent infection with 
HPV 16 or 18 
No follow-up. Recommend 
routine Pap in 2 years 
Abnormal 
Yes 
Treat as per standard 
algorithm for abnormal 
Pap 
Invite for repeat Pap and 
HPV test in 12 months 
Pap 
Infection with different 
high-risk genotypes at 
each test point 
If Pap at 24 months is normal but same high-risk HPV type 
infection persists, recommend colposcopy 
Recommend colposcopy Repeat Pap and HPV in 12 
months 
No follow-up. Recommend 
routine Pap in 2 years 
Normal 
No 
High risk HPV 
DNA detected? 
Yes 
Refer genotype report from laboratory 
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Study pack 
At the commencement of the study services will be provided with the following items. If 
services require more please contact the VIP-I coordinator. 
 1 folder containing study documents 
 50 Precervcyt ThinPrep sample jars – sent in two batches of 25 
 50 snap lock bags 
 300 piggy back VIP-I study labels 
 150 round pink VIP-I study stickers 
 60 questionnaires 
 60 participant information and consent forms 
 1 Sample storage and transport Esky, more to be provided as needed 
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VIP-I
Evaluating the effectiveness of the 
HPV vaccine among Indigenous 
women in Australia
Dina Saulo1, Skye McGregor1, John Kaldor1, Bette Liu1,2, Sepehr Tabrizi3, 
Suzanne Garland3, Julia Brotherton4,3, Rachel Skinner5 & Mary Stewart6
1.The Kirby Institute , UNSW  2.School of Public Health, UNSW 3.Royal Hospital Women, Melbourne  
4. Victorian Cytology Service, Melbourne 5. University of Sydney 6. Family Planning Australia
 
Community-based 
program targeting women 
≤26
Introduction of 12-15 
year old boys to 
school based 
program 
School-based program continued, targeting 12 – 13 year old 
women in first year high school 
School-based program 
targeting 12-17 year 
old women
National Human Papillomavirus (HPV) vaccination program 
2007    2008     2009     2010     2011     2012     2013     2014
April 2007 - Dec 2008
July 2007 - Dec 2009
2009 - Ongoing
2013 - 2014
 
Community-based 
program targeting women 
≤26
Introduction of 12-15 
year old boys to 
school based 
program 
School-based program continued, targeting 12 – 13 year old 
women in first year high school 
School-based program 
targeting 12-17 year 
old women
Approaches to evaluating HPV vaccine program in Australia
2007    2008     2009     2010     2011     2012     2013     2014
April 2007 - Dec 2008
July 2007 - Dec 2009
2009 - Ongoing
2013 - 2014
Genital Warts
Histological Abnormalities
Genotype Prevalence 
Gertig et al 2013Brotherton et al 2011
Donovan et al 2011Fairley et al 2009
Crowe et al 2014
Ali al 2013
Ali al 2013
Tabrizi et al 2012
Pre vaccine era -
Garland et al 2011
 
The importance of evaluating vaccination 
program impact on HPV genotypes among 
Indigenous women 
 
Greater burden of 
cervical cancer in 
Indigenous vs non-
Indigenous women
Cervical cancer 
incidence and mortality 
is disproportionately 
higher (AIHW 2010)
Cervical cancer 
screening participation 
estimated to be ~18% 
lower (Binns 2006)
Incidence 
2004-2008
22 vs 8.5
Mortality 
2006-2010
10.6 vs 1.9
AIHW 2010
 
Overall 3 dose 
70% coverage in 
women
Limited estimates 
of vaccine 
coverage in 
Indigenous girls 
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HPV vaccine 
coverage
Brotherton MJA 2013
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Appendix 4: VIP-I international HPV conference presentation  
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2152 women, 
655 Indigenous
BMC Med 2011
 
JID 2012
75%
 
Vaccine Impact in Indigenous Population (VIP-I)
Objective
Evaluation of the impact of the Australian Vaccination Program on
the prevalence of circulating HPV genotypes among Aboriginal and
Torres Strait Islander women.
Aim
• To estimate the proportion of Aboriginal and Torres Strait
Islander women who have been vaccinated
• To estimate and compare the prevalence of HPV types among
demographically similar post-vaccine era and pre-vaccine era
(WHINURS participants) cohorts .
Target
• Aboriginal & Torres Strait Islander woman aged 18 – 26 years
• Attending study sites for Pap testing
 
VIP-I study sites
Sample size = 200
 
Methods
1. Demographic and behavioural questionnaire
2.   Laboratory confirmation of HPV DNA and genotype
3.   Linking participant dose coverage data from the 
National HPV vaccination program register  
(NHVPR)
 
Methods
• Service led 
– Site coordinator 
– Collaborative team – Aboriginal health workers, 
doctors, nursing and midwifery/ mothers & babies 
staff and health promotion workers
• Capacity building 
– HPV update
– VIP-I training 
– Pap provider training available for health staff
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Conclusion
• There is potential the HPV vaccine program could  
reduce cervical cancer rates in the Indigenous 
population if ;
• Indigenous and non-Indigenous women have 
similar HPV prevalence profiles, as was found 
in the baseline survey 
• Vaccine coverage does not differ by Indigenous 
status
 
Future work
• Indigenous HPV Surveillance network
• Inclusion of Indigenous boys and men
• Possibility of self collected samples 
• Novel methodologies such as utilising social media 
networks to recruit and using new technologies
 
Acknowledgement
• Participating women
• Participating Services
• Site coordinators
• WHINURS and VIP investigators
Funding: Commonwealth 
Department of Health
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6 Teaching Experience 
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6.1 Lessons from the field 
Lessons from the field (LFF) are a teaching exercise created by each MAE student focusing on 
an issue, learning or strength from their field placement. Each student develops guided 
learning exercises for fellow students to complete. Students are required to attend a 
teleconference to discuss and reflect on the LFF responses. I developed a LFF on project 
management with a focus on principles, qualities and transfer of knowledge in research. 
Although I had project managed in the past, I had not explored project management theory. 
The principles of project management I developed over time evolved through previous work 
and personal experiences. I believe strong project management skills are needed in the field of 
epidemiology. I began by gathering project management resources, I then collected 
publications and resources focused on areas I thought would benefit other MAE students.  
Students completed the exercises (Appendix 1) and I held a teleconference to discuss 
responses on 22nd May 2014. 
6.2 MAE teaching experience 
A half day teaching session ran by the entire 2013 MAE cohort was conducted in March 2014. 
This year, our cohort taught first year MAE students over a half day. We divided into small 
groups, running four different lessons, each team created lesson plans, teaching resources and 
presentations. 
I formed a group with colleagues Pip Chidzgey and Jason Agostino. Our MAE data analysis 
projects shared two similarities, a focus on the Indigenous population and analysis of trends 
over time. We came together on teleconferences to discuss our own data sets and develop a 
lesson plan with set learning objectives, the lesson plan evolved as we narrowed our focus 
(Appendix 2). As a team and in consultation with our academic supervisors we develop a 
session entitled “interpreting rate change in time series data”. We went about creating a 
systematic framework for assessing change using each team member’s data analysis as a case 
study. 
To create a frame work we documented our own process for interpreting rate change in time 
series data. As a team we brought our own processes together to develop a stream lined 
framework (Appendix 3). We identified common steps and discussed order and we soon 
realised steps set out in our framework could be used interchangeably.   
CHAPTER 6 TEACHING EXPERIENCE 
219 
We structured a lesson flow using our case studies to demonstrate steps of the frame work 
(see lesson PowerPoint Appendix 4). We worked well together contributing to all aspects of 
the exercise.  
Students evaluated the lesson very highly with one student commenting “Excellent session – 
well presented and interesting case studies”. 
The LFF was an individual effort so working in a team for the teaching exercise was fantastic. 
We worked well together to produce a well thought out simplistic approach to teaching on 
what could have been a complex topic. Frameworks when teaching provide a lasting structure 
for students to use in the future.  
6.3 Lessons learnt 
While the LFF is a learning experience for fellow MAE students, I also learnt more about 
project management and the work invested into producing teaching resources. This LFF has 
given me the opportunity to validate some of the processes I use but mostly it has equipped 
me with new tools, language and understanding of project management fundamentals and 
opened my eyes to an entirely new application of these skills.   
I explored the process of learning through reading literature and discussed with others Blooms 
taxonomy domains and Robert Gagné's Nine Steps of Instruction to improve the objectives, 
structure and delivery(3, 4).   
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6.3.1 Appendix 1: Lessons from the field 4: Project management 
 
 
 
 
 
 
 
 
 
 
Lessons from the field 4: Project Management 
Please save your answers in this word document 
Send answers back by: Thursday 15th May 2014 
Teleconference: Wednesday 21st May, 2014 
 
Learning Objectives  
 Understand what project management, a project and activities are  
 Understand the advantages of a trans-disciplinary team and the qualities needed to 
successful project manager a trans-disciplinary team 
 Apply project management principles and qualities to case study and own practice  
 Understand the vital role of knowledge transfer in research 
 Understand the fluidity and interactions of project activities and how they impact planning 
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Background 
 
During 2005-2008 the Women’s HPV Indigenous Non-Indigenous Urban Rural Study 
(WHINURS)(1) recruited Indigenous and non Indigenous woman throughout Australia 
undergoing cervical cytology screening in order to estimate the prevalence of human 
papillomavirus (HPV) genotypes in this population. Participants in WHINURS were recruited via 
Aboriginal Community Controlled Health Services (ACCHS), General Practitioner clinics and 
family planning clinics.  As a majority of woman were recruited prior to the implementation of 
Australia’s HPV vaccination program, the WHINURS study established an important baseline 
for post-vaccine program surveillance of HPV types in this population.  
 
A second study called Vaccine Impact in the Population (VIP)compared a post-vaccine sample, 
recruited through family planning clinics, to the pre-vaccine WHINURS sample and found a 
significant decrease in vaccine preventable HPV genotypes(2). The reduction was consistent 
with what would have been expected based on clinical trials that demonstrated vaccine 
efficacy. 
 
There is a need to evaluate the impact of the HPV vaccine program on the prevalence of 
infection among Indigenous women in Australia. Although there has been a documented 
decrease in HPV vaccine genotypes by other studies they have not had a sufficiently large 
Indigenous sample size to determine whether there has been a corresponding decrease in the 
prevalence of infection among Aboriginal and Torres Strait Islander women. 
 
The HPV Vaccine Impact in the Australian Indigenous Population (VIP-I) project will evaluate 
HPV vaccine program effectiveness in Indigenous women by comparing HPV genotype 
prevalence in cervical samples collected at Pap testing in post-vaccine populations to that in a 
comparable population tested in the WHINURS study (pre-vaccine) 
 
Aims of VIP-I  
 
 To estimate the proportion of Indigenous women who have been vaccinated among 
18-26 years old women attending for cervical cytology screening 
 
 To estimate and compare the prevalence of HPV types (including vaccine-specific types 
6/11/16/18 and other high risk HPV types) among Indigenous women in the post-
vaccine era compared to pre-vaccine era 
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Design 
 
VIP-I is a cross sectional prevalence survey. Six ACCHS which recruited substantial numbers to 
the WHINURS study will be approached to participate in the VIP-I study to ensure a 
comparable sample. VIP-I is targeting recruitment of 220 Indigenous women aged 18 - 26 who 
attend ACCHS (or other service providers with a high proportion of Indigenous clients) for 
routine cytology screening over the study period. 
 
Methods 
 
1. Demographic and behavioural questionnaire 
After gaining consent participating studies will collect the following questionnaire 
information; age, postcode of residence, education, number of past partners , age of first 
intercourse, use of hormonal contraception, smoking, receipt of HPV vaccine and the 
number of doses and Pap test history 
 
2. Laboratory confirmation of HPV DNA and genotype  
Pap test samples collected by participating sites transported to Royal Woman's Hospital, 
Melbourne for laboratory testing  
 
3.   Accessing participant HPV vaccination register records  
Consent gained from participants to access vaccination status and dose coverage 
information from the register 
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Scenario 
 
When you start the MAE you are asked to be the field coordinator of the VIP-I project. You are 
essentially a project officer for the project from start to finish.  
 
You will work with a small team at your research centre to complete study activities but also 
link into utilise the resources, skills and knowledge of other investigators. The team of 
investigators on the project are from six different organisations. The investigators have 
established relationships, working together on past research projects and publications. 
Investigators have different professional backgrounds including; epidemiology microbiology, 
biostatistics, medical, policy and research.   
 
You have been brought on as a project officer to coordinate study activities, recruit services to 
the study, developing study procedures and processes and ensuring participating sites are 
trained in study processes. You work with a smaller core group at you research centre to 
advance the project. 
 
Your first task is to organise a face to face meeting with investigators. From this meeting a 
number of activities are established; writing the study  protocol, study documents and 
submitting ethics applications to eight different ethics committees as a starting point and 
starting to contact potential sites to gauge interest in taking part in the study.  
 
The project will only run over a 24month period. It is vital to ensure project activities are 
completed on time and there is progression at all stages. This is a team effort and at some 
stages different investigators take on a projects management role depending on the activities.  
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Task 1: Project management  
 
There are many different frameworks and tools created for project management. These 
frameworks and tools have been developed mainly for engineering, construction and business 
purposes. The concepts are transferable across all fields in which projects are undertaken. 
Apply the concepts from the following resources to your work as an epidemiologist and 
answer the following questions about project management: 
 
Resources: 
 
a) PM@UTS PROGRAM: Guide to project managment pg 4(3) 
b) A Guide To The Project Managment Body of Knowledge pg 4-6(4)  
c) Applying project management principles to research projects in a health setting(5) 
 
1. What is a project? 
 
ANNA: 
A project is a temporary endeavour to create a unique product or service. 
Projects can be conducted by one or many people or organisations, and is 
defined by a specific time frame or lifecycle. Unlike operational activities 
projects must eventually come to a conclusion. 
 
2. What is project management? 
.  
ANNA: 
Project management is using knowledge, skills, tools and techniques to 
complete project activities that meet the projects requirements. In other words 
project management ensures that the outcome of the project is clearly defined, 
objectives are aligned to the desired outcomes and there is a means to monitor 
and control the projects progress and its ability to meet defined deadlines. 
 
TIM: 
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Project management is a systematic approach to do what it says, manage a 
project. Ensuring milestones, timelines, deliverables are met to achieve 
successful completion of the project. 
 
3. What key project management principles/stages are identified in “Applying project 
management principles to research projects in a health setting”(5)?   
 
PIP: 
Plan (initiating and planning), monitoring and control (executing and 
controlling), implementation (closing) 
 
 
ANNA: 
Planning  
a. Initiate- establish a research question, provide background, study 
design, identify study population, define desired outcomes, determine 
how to report findings and plan analyses. Scope of the project should 
be defined in this stage and a study proposal provided. 
b. Plan – define the number of participants in your study population, 
develop a sampling framework, recruit participants, identify data 
systems, plan for how funding should be used, determine how to 
manage stakeholders and identify the number of staff required for the 
project.- This stage defines the components required to meet the 
projects objectives. 
Monitoring and control 
c. Execute-ethical and regulatory requirements are complete, study 
participants are approached, data is collected, stakeholder 
consultations and management of these relationship continue and the 
education of site staff occurs- This stage activates the project proposal 
or plan. 
d. Control- oversight of deadlines, controls and adjusts for changes in 
timeframes, manages the risk of the project, conducts on-site 
monitoring, verifies source data, stakeholder consultations and 
management of these relationships continue and audits the project.  
This stage provides quality assurance of project activities. 
Implement 
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Close-analyses of the data, write up the results, close the study sites 
formally, present results to stakeholders and participants, produce a 
manuscript, refine the research question and if required start the 
project life cycle again.  This stage provides the impact the project has 
on the area of study and should outline the lessons learnt along the 
way. 
 
 
4. There is limited literature on the application of project management 
principles/stages in epidemiological research. List other principles or stages you 
would include for the management of the VIP-I project and why.  
 
Community consultation 
COURTNEY: 
There is some talk of ‘stakeholder management’, however, I think stakeholder 
consultation could be another stage for this project since there are many 
different organisations involved and perhaps also community consultation, 
which while always important, is particularly needed in this project as the 
research is focussed around Indigenous health and increasing community 
engagement might help ensure that the research is relevant and acceptable to 
the community and help increase participation and enthusiasm for the 
research amongst both sites and individuals.  
 
TOVE:  
Consultation with Aboriginal communities- This would be the very first stage 
for me to explain the proposed study and how it will benefit the communities 
to ensure that the study is culturally safe and appropriate. I think consultation 
at the end is also crucial to ensure that the interpretations of the results are 
correct. 
 
Evaluation  
ANNA: 
I would add in an evaluation stage. Whilst that is mentioned in the close, I 
think it’s really important to have a separate stage for this and in a lot of 
projects it’s not done at all. In the evaluations stage I would look at how the 
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project went, whether it achieved its objectives and what could be done better 
in the future for similar studies. 
PIP: 
I would include an explicit step on its own, “evaluate”.  I know this could be 
part of “monitoring” but when you read the definition provided by Vachan, it is 
monitoring of the project, not the actual monitoring of the outcomes of the 
project. Evaluation would allow us to monitor the effect and success of the 
project, so lessons could be learnt, and the project could be developed into an 
ongoing program if it achieves its objectives. 
 
Task 3: Trans-disciplinary teams 
As a project officer of the VIP-I project you have submitted an abstract at a conference to 
ensure knowledge of the project is being disseminated during the research project.  
You attend a couple of presentations about the importance of partnerships and collaboration 
in the development of research. At the conference a number of people talk about translation 
of research by the inclusion of investigators from across different sectors. The inclusion of 
investigators from other sectors including policy makers can enhance the application of 
research outcomes. For example, the inclusion of policy makers as investigators could assist in 
framing research communication to lead to the development of evidence based policy. 
 
The VIP-I project has a trans-disciplinary team consisting of investigators from six different 
organisations with backgrounds in; epidemiology microbiology, biostatistics, medicine, policy 
and research.   
 
Reading: Enhancing Trans-disciplinary Research Through Collaborative Leadership(6) 
 
1. Using the literature provided and your own experience, discuss the advantages and 
disadvantages of building and/or working in a trans-disciplinary research team. 
Included in the table are responses from Courtney, Kerryn, Anna, Tim and Tove categorised 
into common themes. 
 
 
 
      INFECTIOUS DISEASES AMONG MARGINALISED POPULATIONS  
 
228 
Advantages Disadvantages 
Methodology re-orientation 
 Creation of new methodologies and science 
 Promotes theoretical, conceptual and 
methodological re-orientation. 
 Emergence of new data and interactions 
Integration of knowledge 
 Improves communication between 
disciplines 
 Can ensure a more comprehensive response 
to a question. 
 Able to tackle ‘more’ aspects of the problem 
 Provides a more complete answer to a 
problem as it provides insight and 
knowledge from different disciplines. 
Comprehensive research and outcomes  
 Improved legitimacy of work 
 More holistic objectives 
 Appealing to multiple stakeholders 
Creation 
 Increased opportunity for creative problem 
solving  and innovation 
 Members of a trans-disciplinary team may 
challenge each other about the research 
which can encourage researchers to re-think 
the research and improve on the original 
plans. 
 
Ego  
 Power differences  
 Need to accommodate egos 
Conflict  
 Misunderstanding and “groupthink”- 
disagreements and differences. 
 Personal conflicts between members of 
the project team can delay or prevent 
project activities 
Lack of respect or other disciplinary 
methodologies and concepts 
 Lack of acceptance of the validity of 
methodologies of other disciplines 
 Differences in reward and therefore 
aims and priorities 
 Disagreements between collaborators 
on the validity of others work and type 
of framework to be used for the project 
 Mismatches between rewards stressing 
disciplinary competence over innovation 
 Crucial information is not collected due 
to misunderstanding of its importance 
or relevance to the overall project 
 Might be difficult to respond to 
stakeholders needs.   
Communication breakdown  
 Lack common problem focus 
 Multiple agendas/ideas/egos 
 Greater communication and people 
management needed 
Multiple Institution interaction 
 Institutional disincentives 
 Multiple bureaucratic clearance 
processes 
 Lack of common goals across sectors 
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2. Using your assigned quality required to successfully project manages a research 
team, answer questions a) and  b)   
 
Resources: 
 Anita – Influencing, Anna – Problem solving, Pip – Negotiating, Tove - Leading 
Tim – Communicating: Refer to Pg 20, 23 & 24, A Guide To The Project 
Managment Body of Knowledge pg 4-6 (4)  
 Courtney – Conflict management & Kerryn – Self monitoring: Refer to: How 
Personality traits and Dimensions of Project Managers Can Conceptually affect 
Project Success(7) 
 Feel free to use other literature including the above Enhancing Trans-
disciplinary Research Through Collaborative Leadership(6).  
 
a) Define the quality  
b) How can this quality be applied to managing of the VIP-I project?  
Give an example 
 
COURTNEY: CONFLICT MANAGMENT 
 
a) Creasy and Anatatmula state that conflict arises when there are incompatible 
goals, thoughts or emotions between individuals that are the result of 
differences in opinion, perception or belief. They posit that conflict can be 
dysfunctional (negative and disruptive), particularly when people-focussed, but 
that task and process orientated conflict can be beneficial and lead to 
improvements, problem solving and innovation where communication is clear.  
The text defines three different approaches to conflict management by project 
managers. The traditional approach is to view conflict as negative and focuses 
on avoidance of problems. The behavioural view also views conflict as negative 
but natural and inevitable, this view focuses on managing rather than 
eliminating conflict. The final, interactionist, view believes that a certain level 
of conflict should be encouraged to increase performance. The authors propose 
that behavioural or interactionist approaches to conflict management in 
project management will have more success than traditional approaches.  
 
b) As the VIP-I is a trans disciplinary team, conflict about the validity and 
appropriateness of selected methods may be encountered due to differences in 
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training and prior beliefs. By taking non-avoidance focussed approach to 
conflict management you can prepare for this conflict by implementing good 
communication channels. In doing this you may be able to not only ensure 
everyone is happy with the new arrangements but may be able to innovate and 
find ways to incorporate multiple methods into the project, strengthening the 
project output and increasing the application of its findings (due to 
acceptability across multiple disciplines).  
 
KERRYN: SELF-MONITORING  
a) The ability for a person to adapt their behaviour in a situation to achieve the 
outcomes they want. A high self-monitoring personality is good at this. A low 
self-monitoring personality is more concerned with maintaining a consistent 
approach to everything, regardless of the effect on other people, the team or 
the outcome.  
b) This would be an extremely important ability when engaging ACCHS as there is 
a need to recognise what the ACCHS is trying to achieve, their priorities, 
resources and training. ACCHS’s operate differently than general GP services 
and understanding the environment and community that they are operating in 
and engaging with that would be essential to recruiting ACCHS’s and 
participants. 
 
ANNA: INFLUENCING 
a) Influencing is defined as the ability to get things done. This quality requires an 
understanding of both the formal and informal structures of all the 
organisations involved in the project and a comprehensive knowledge of the 
internal and external politics and positions of power. This include 
understanding the organisations itself, its customers, contractors and 
numerous other people or areas that influence or are affected by the 
organisations. 
b) This quality can be applied the VIP-I study by engaging with local communities 
in the planning phases of the project to obtain participant and ensure the 
project does not disadvantage or marginalise the study population. These 
initial consultations need to include engagement with the health services, 
elders of the community and potential participants.  In addition, a member 
from each of the communities involved in the study should be appointed as a 
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member of the research team. This member should be a representative of the 
community and is someone who is nominated by the community. When 
managing this project it is essential to ensure all stakeholders are provided 
with regular information about the projects progress, the benefits this study 
will have towards the community and informed about the use of the collected 
information.   
PIP: NEGOTIATING 
a) Conferring with others in order to come to terms or reach an agreement (Duncan, 
1996). 
b) I think it would be a good idea at the first team meeting to ask every team member 
what their goals are for the project and what they would like to get out of the 
project. I think this would be better than coming in with project objectives and 
telling everyone it’s your way or the highway. Then, negotiations can take place to 
come to agreement on team goals and objectives. I think this sort of negotiation 
would be beneficial, it means everyone will be on the same page and there is a 
clear focus. 
 
TIM: COMMUNICATING 
a) Clear and concise exchange of information and ensuring it is understood by all 
parties. 
b) Ensuring all members on the project understand what is going on possibly through 
regular updates or team meetings. At these meetings each member could feedback 
as to what they have been doing, any issues they have faced and how they were 
resolved or ideas from other on how to resolve them. 
 
TOVE: LEADING 
a) Leading people involves establishing direction for a project, aligning people who 
work within the project and motivating and inspiring those involved in the project 
b) At the first meeting you could talk about where the project originated from and 
what is expected out of the study and how this will make a difference in the lives of 
Indigenous women. You could then talk with the people who are conducting each 
of the activities and explain how what they are doing individually contributes to the 
study as a whole and how that fits with the “big picture” 
c)  
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Task 3: Knowledge brokers  
As epidemiologists, we will at some stage lead or be a part of a trans-disciplinary team. Let’s 
look at our own roles within a trans-disciplinary team as knowledge brokers to ensure 
knowledge dissemination is optimised within the team, is shared with stakeholders as well as 
the appropriate dissemination of research outcomes/findings. 
Use the provided resources on knowledge brokers and reflect on your role in the VIP-I project 
team and how a project manager takes on a knowledge broker role.  
Readings  
“Know–Do” Gap: Knowledge brokering to improve child wellbeing: Chapters 6(8)  
Reflections on Knowledge Brokering Within a Multidisciplinary Research Team(9) 
Source: http://projectcartoon.com 
 
 
This cartoon is a great example of how communication can affect a project. Even 
though this example is in the context of a business solution, the interpretation and 
communication of concepts between team members and stakeholders in a large 
research project has a similar impact on outcomes. 
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1. What is a knowledge broker? 
 
COURNTEY:  
A knowledge broker is someone who facilitates ongoing communication 
between team members in an interdisciplinary team and develops and 
maintains relationships and communication with stakeholders groups and 
decision makers, with a view to developing an interactive communication 
process between decision makers and researchers.  
ANNA: 
A knowledge broker is a person within a research team who understands both 
the policy and research perspectives of a project and acts as an intermediary 
between the two worlds. This role requires the person to be a driver change, 
communicate across professional paradigms, understand different contexts, 
utilise opportunistic change as it arises and be able to persuade and develop a 
compromise between disciplines.  
 
2. What does a knowledge broker do to ensure translation of knowledge across a 
research team and stakeholders? Dot point 
 
Answer reflects combined common themes from responses provided by Courtney, 
Kerryn, Anna, Tim and Tove.  
Communication 
 Sustaining team member engagement 
 Communicate effectively with people from these different areas to persuade 
them to put research into policy action or direct research into areas policy 
needs more evidence  
 Developing and maintaining communication skills/strategies  
 Medicate conflicts 
 Develop communication tools for the project – internal and external 
Networking/ harnessing relationships  
 Seek out and communicate well with all stakeholders  
 Build relationships 
 Obtain feedback and suggestions from stakeholders 
 Facilitating communication (establishing lines of communication if necessary) 
 Connecting with all stakeholders 
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Vision  
 Understand both sides of the policy and research worlds 
 Understand the broader context and work within this to achieve the best 
research and policy outcomes. 
Facilitate  
 Work closely with research team members to develop appropriate research 
questions and decide upon the most appropriate format for collection and 
analysis. 
Provide the big picture 
 Team coordination and building 
 Have a clear understanding of all disciplines involved in the project 
 Harnessing and sharing team member’s skills and expertise 
 Establishing relationships within and between team members and stakeholders 
 Sustaining participation and ensuring active involvement by team members 
 Harnessing expertise and ensuring it is shared across the project 
 
3. In a couple of sentences, discuss the similarities of a knowledge broker and a project 
manager. 
PIP: 
Essentially, a good project manager should be a knowledge broker for their 
team. Project managers should facilitate communication and meetings and 
engage with key stakeholders. Knowledge brokers focus on development, 
which would be a good focus for project managers, as aiding knowledge 
sharing and education is a good way to build personal skills and team 
functioning. 
TIM: 
I’d argue that the roles are almost identical and depending on the size of the 
project could be done by the same person. For large projects the role may be 
spilt, so that the project manager can focus on the project as a whole with 
someone else ensuring communication happens 
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Task 4: Defining and scheduling activities  
Activity sequencing is the identification of interactive dependencies to create a realistic time 
frame on activities and later developments. The ability to sequence activities in a logical way, 
understand which activities can be undertaken simultaneously and ability to be flexible with 
activity timeframes within a larger set project time line are important skills for a project 
manager. 
Readings 
 PMBOK resource, pg 62(4) 
 Also see PM@UTS PROGRAM: Giude to project managment Pg 38(3) 
 
1. The following project activities have been identified; your task is to sequence these 
activities. Use the PMBOK resource, pg 62(4)  to categorise the below identified 
project activities into one of the following 3 categories.  
 
a. Mandatory dependent activities 
b. Externally dependent activities  
c. Discretionary dependent activities – preferred logic 
 
 
 
 
 
 
 
All responses and teleconference discussion combined below 
This exercise was mostly discussed on teleconference. Every response was different for similar 
reasons. Colleagues identified each activity can be in different categories at different phases of 
the project. The objective of this exercise was to encourage discussion about planning and the 
fluidity of activities within a project. There were different ideas of what discretionary 
dependents meant. Ideas were valid in that they were centred around the unpredicted time 
impact of activities, based on difference of concept, process understanding of best practise 
arising among team members and or stakeholders. 
Ethics approvals 
 
Service Agreement 
 
Service training 
 
Site recruitment 
 
Site support for ethics 
Apply for data from national HP 
register 
 
Reporting back to services 
 
Adaption of a demographic and behavioural questionnaire 
 
Study site training 
 
Investigator meetings  
 
Development of study protocol and study document 
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2. What scheduling and timeline tools or tasks do you use in your own work?  
 List two and how you use them.  
Collectively the following tools were discussed: 
□ To-do lists 
□ Gantt charts 
□ Calendar lists 
□ Smart chart 
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6.3.2 Appendix 2: Lesson Outline 
 
Description of the Training 
A systematic framework for assessing a change in the rate of a health condition using three 
examples from studies on predominately Aboriginal and Torres Strait Islander populations. 
Time: 50 minutes 
Learning Objectives:  At the end of the lesson, students will be able to: 
1. Describe steps for systematically interpreting time series trends 
2. Apply the principles of the epidemiological triad in offering alternative explanations of 
trends in time series data 
3. Describe how selection and measurement bias may contribute to artifactual change in 
time series data 
4. Identify issues to consider when interpreting data on vulnerable populations. 
Training Techniques: Content on key epidemiological concepts will be delivered alongside 
three case studies from current MAE scholars.   
Content: 
Introduction: Introduction to three speakers and MAE placements.  Outline of how lesson will 
run and learning objectives. (<5 mins) 
Key concepts (PPT): Introduce framework for interpreting time series data. Describe key 
concepts such as agent, host, and environment in relation to interpretation of time series 
trends.  Build on earlier teaching principles of selection and measurement bias in determining 
whether a change is real or artifactual. (15 mins) 
Practical activity: Apply framework to case study examples in order to illustrate key concepts 
and points. (25 minutes) Given the limited timeframe, the group will have key questions to 
answer in relation to the framework. i.e: 
- Is the change real or artifactual? 
- What factors relating to the population may have impacted on rates? 
- What factors relating to the agent (or disease) may impact on rates? 
- What factors relating to the environment may have impacted on rates? 
- Could there have been a change in how subjects were included in the study 
population? 
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- Could there have been a change in measurement of the outcome? 
- What are the ethical and cultural issues to consider in interpreting the results from this 
study? 
Assessment: Students will demonstrate achievement of the learning objectives by 
participating in the group session and by a short pop quiz (5 mins).  
Materials and Equipment 
Materials For the Instructor: 
1. PowerPoint file for the presentation 
2. Instructor Guide with notes for 
presentation and course 
3. Handouts (sample questionnaire) 
 
For the Participants: 
1. Participant guide 
Equipment  
1. Projector 
2. Whiteboard 
 
Prerequisites:  None 
Readings: None 
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6.3.3 Appendix 3: Time Series Interpretation Framework 
Interpretation of Time series data 
1. Context  
Literature review, talk with local experts, know your topic, background, 
purpose of analysis. 
2. Question 
Determine if rate change is real or artefact? This will determine the next step.  
If real continue to steps 3, 4 and 5. If artefact concluded by identifying why it’s 
false, take learning’s and remember for future application. 
 
3. Epidemiological Triad 
Consider how the time trend may have been impacted by each component of 
the triad 
- Agent  
- Population   
- Environment    
 
4. Describing your data 
Describe data by person and place: by sex, age, location etc exposure, 
outcome variables. Cross tabulation to explore risk factors by outcome. 
Stratification to assess confounding and effect modification  
 
5. Validity  
Consider the potential impact of selection or measurement bias on the time 
series 
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6.3.4  
  
 
 
 
 
  
 
 
Validity 
 
5 
 Population 
 Environment 
Question   
 
2 
Real  Artefact 
Context  
 
1 
Is rate change 
real or artefact? 
 
 
Time Series Data Interpretation 
Framework 
 
3 
 
3  Identify 
 Remember 
 Learn 
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6.3.5 Appendix 4: “Interpreting rate change in time series data” Lesson PowerPoint  
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